ORIGINAL_ARTICLE
Molecular mechanisms regulating immune responses in thromboangiitis obliterans: a comprehensive review
Thromboangiitis obliterans (TAO) is a thrombotic-occlusive as well as an inflammatory peripheral vascular disease with unknown etiology. Recent evidence has supported the immunopathogenesis of the disease, however, the factors contributing to the altered immune function and vascular tissue inflammation are still unclear. This review was intended to collate the more current knowledge on the regulatory molecules involved in TAO from an immunoreactive perspective. The homeostasis of the immune system as well as a variety of progenitor cell populations appear to be affected during TAO and these alterations are associated with intrinsic signaling defects that are directing to an improved understanding of the crosstalk between angiogenesis and the immune system, as well as the potential of new co-targeting strategies applying both immunotherapy and angiogenic therapy.
https://ijbms.mums.ac.ir/article_12193_b6d3067617aa0df7c74858b0c2cd44cb.pdf
2019-03-01
215
224
10.22038/ijbms.2019.31119.7513
Angiogenesis
Immune system
Molecular biology
Signal pathways
Thromboangiitis obliterans
Abbas
Shapouri-Moghaddam
shapourima@mums.ac.ir
1
Immunology Research Group, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mohamad Hadi
Saeed modaghegh
modagheghmh@mums.ac.ir
2
Vascular and Endovascular Surgery Research Center, Alavi Hospital, Mashhad University of Medical Sciences, Iran
AUTHOR
Hamid reza
Rahimi
hamid.r.rahimi@gmail.com
3
Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Seyyed-Morteza
Ehteshamfar
ehteshamfarsm@mums.ac.ir
4
Immunology Research Group, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Jalil
Tavakolafshari
shapouri9153152927@gmail.com
5
Immunology Research Group, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Lie JT, Mann RJ, Ludwig J. The brothers von Winiwarter, Alexander (1848-1917) and Felix (1852-1931), and thromboangiitis obliterans. Mayo Clin Proc 1979; 54:802-807.
1
2. Fazeli B, Modaghegh H, Ravrai H, Kazemzadeh G. Thrombophlebitis migrans as a footprint of Buerger’s disease: a prospective–descriptive study in north-east of Iran. Clin Rheumatol 2008; 27:55-57.
2
3. Hafezi S, Modaghegh MS. Sympathetic denervation using endovascular radiofrequency ablation in patients with thromboangiitis obliterans (Buerger’s disease). Ann Vasc Surg 2017; 45:336.
3
4. Modaghegh MH, Ravari H, Haghighi MZ, Rajabnejad A. Effect of folic acid therapy on homocysteine level in patients with atherosclerosis or Buerger’s disease and in healthy individuals: a clinical trial. Electron Physician 2016; 8:3138-3143.
4
5. Modaghegh MH, Kazemzadeh GH, Ravari H, Johari HG, Barzanuni A. Buerger’s disease in the northeast of Iran: Epidemiology and clinical features. Vascular 2015; 23:519-524.
5
6. Kobayashi M, Ito M, Nakagawa A, Nishikimi N, Nimura Y. Immunohistochemical analysis of arterial wall cellular infiltration in Buerger’s disease (endarteritis obliterans). J Vasc Surg 1999; 29:451-458.
6
7. Adar R, Papa MZ, Halpern Z, Mozes M, Shoshan S, Sofer B, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 1983; 308:1113-1116.
7
8. Eichhorn J, Sima D, Llndschau C, Turowski A, Schmidt H, Schneider W, et al. Antiendothelial cell antibodies thromboangiitis obiiterans. Am J Med Sci 1998; 315:17-23.
8
9. Arslan C, Altan H, Beşirli K, Aydemir B, Kiziler AR, Denli Ş. The role of oxidative stress and antioxidant defenses in Buerger disease and atherosclerotic peripheral arterial occlusive disease. Ann Vasc Surg 2010; 24:455-460.
9
10. He J, Liu XY, Wang YP, Liu LB. Effects of oxidative stress on NF-κB, iNOS and NO in endothelial cells. J Fujian Med Univ 2010; 44:186-189.
10
11. Fazeli B, Rezaee SA. A review on thromboangiitis obliterans pathophysiology: thrombosis and angiitis, which is to blame? Vascular 2011; 19:141-153.
11
12. Hus I, Sokolowska B, Walter-Croneck A, Chrapko M, Nowaczynska A, Dmoszynska A. Assessment of plasma prothrombotic factors in patients with Buerger’s disease. Blood Coagul Fibrinolysis 2013; 24:133-139.
12
13. Csiszar A, Podlutsky A, Wolin MS, Losonczy G, Pacher P, Ungvari Z. Oxidative stress and accelerated vascular aging: implications for cigarette smoking. Front Biosci 2009; 14:3128-3144.
13
14. Nagata M. Inflammatory cells and oxygen radicals. Curr Drug Targets Inflamm Allergy 2005; 4:503-504.
14
15. Alamdari DH, Paletas K, Pegiou T, Sarigianni M, Befani C, Koliakos G. A novel assay for the evaluation of the prooxidant–antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem 2007; 40:248-254.
15
16. Glueck CJ, Haque M, Winarska M, Dharashivkar S, Fontaine RN, Zhu B, et al. Stromelysin-1 5A/6A and eNOS T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: a pilot, hypothesis-generating study of gene-environment pathophysiological associations with Buerger’s disease. Clin Appl Thromb Hemost 2006; 12:427-439.
16
17. Stammler F, Diehm C, Hsu E, Stockinger K, Amendt K. [The prevalence of hyperhomocysteinemia in thromboangiitis obliterans. Does homocysteine play a role pathogenetically?]. Dtsch Med Wochenschr 1996; 121:1417-1423.
17
18. Akgul A, Bilgic A, Sezer S, Arat Z, Ozdemir FN, Haberal M. Low total plasma homocysteine level in relation to malnutrition, inflammation, and outcome in hemodialysis patients. J Ren Nutr 2008; 18:338-346.
18
19. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol 2005; 289:H2649-H2656.
19
20. Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase. Circulation 2003; 107:2342-2347.
20
21. Brodmann M, Hafner F, Gary T, Seinost G, Pilger E. Impaired endothelial-dependent and endothelium-independent vasodilatation in patients with thromboangiitis obliterans. Clin Appl Thromb Hemost 2013; 19:33-36.
21
22. Ketha SS, Cooper LT. The role of autoimmunity in thromboangiitis obliterans (Buerger’s disease). Ann N Y Acad Sci 2013; 1285:15-25.
22
23. Kobayashi M, Sugimoto M, Komori K. Endarteritis obliterans in the pathogenesis of Buerger’s disease from the pathological and immunohistochemical points of view. Circ J 2014; 78:2819-2826.
23
24. Guo Y, Dai Y, Lai J, Fan Y. Study about correlation of anti-neutrophil cytoplasmic antibodies and anticardiolipin antibodies with thromboangiitis obliterans. Vascular 2013; 21:363-368.
24
25. Maslowski L, McBane R, Alexewicz P, Wysokinski WE. Antiphospholipid antibodies in thromboangiitis obliterans. Vasc Med 2002; 7:259-264.
25
26. Schenkein H, Berry C, Burmeister J, Brooks C, Barbour S, Best A, et al. Anti-cardiolipin antibodies in sera from patients with periodontitis. J Dent Res 2003; 82:919-922.
26
27. Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006; 2:661-670.
27
28. Noel LH, Antineutrophil cytoplasm antibodies (ANCA): description and immunopathological role. Ann Med Interne; 2000; 151:178-183.
28
29. Savage CO. Pathogenesis of anti‐neutrophil cytoplasmic autoantibody (ANCA)‐associated vasculitis. Clin Exp Immunol 2011; 164:23-26.
29
30. Schultz DR, Diego JM, editors. Antineutrophil cytoplasmic antibodies (ANCA) and systemicvasculitis: update of assays, immunopathogenesis, controversies, and report of a novel de novo ANCA-associated vasculitis after kidney transplantation. Semin Arthritis Rheum 2000; 29:267-285.
30
31. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med 2002; 126:1424-1429.
31
32. Mulligan A, McAuley C. Thrombosis and psychosis--possible association with the antiphospholipid syndrome and anticardiolipin antibodies. Ir Med J 2009; 102:61.
32
33. Dragun D, Philippe A, Catar R, Hegner B. Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. Thromb Haemost 2009; 101:643-648.
33
34. Luft FC. Activating autoantibodies and cardiovascular disease. Physiology 2013; 28:254-261.
34
35. Walther T, Stepan H. Agonist autoantibodies against the angiotensin AT1 receptor in renal and hypertensive disorders. Curr Hypertens Rep 2007; 9:128-132.
35
36. Xia Y, Kellems RE. Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev Clin Immunol 2011; 7:659-674.
36
37. Karczewski P, Haase H, Hempel P, Bimmler M. Agonistic antibody to the α1-adrenergic receptor mobilizes intracellular calcium and induces phosphorylation of a cardiac 15-kDa protein. Mol Cell Biochem 2010; 333:233-242.
37
38. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation 1994; 89:2760-2767.
38
39. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, et al. Direct evidence for a β1-adrenergic receptor–directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004; 113:1419-1429.
39
40. Wenzel K, Haase H, Wallukat G, Derer W, Bartel S, Homuth V, et al. Potential relevance of α1-adrenergic receptor autoantibodies in refractory hypertension. PloS One 2008; 3:e3742.
40
41. Zhou Z, Liao Y, Li L, Wei F, Wang B, Wei Y, et al. Vascular damages in rats immunized by α1-adrenoceptor peptides. Cell Mol Immunol 2008; 5:349-356.
41
42. Zhou Z, Liao Y-H, Wei Y, Wei F, Wang B, Li L, et al. Cardiac remodeling after long-term stimulation by antibodies against the α 1-adrenergic receptor in rats. Clin Immunol 2005; 114:164-173.
42
43. Klein-Weigel PF, Bimmler M, Hempel P, Schopp S, Dreusicke S, Valerius J, et al. G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger’s disease) and their removal by immunoadsorption. Vasa 2014; 43:347-352.
43
44. Baumann G, Stangl V, Klein-Weigel P, Stangl K, Laule M, Enke-Melzer K. Successful treatment of thromboangiitis obliterans (Buerger’s disease) with immunoadsorption: results of a pilot study. Clin Res Cardiol 2011; 100:683-690.
44
45. Klein-Weigel P, Köning C, Härtwig A, Krüger K, Gutsche-Petrak B, Dreusicke S, et al. Immunoadsorption in thrombangiitis obliterans: a promising therapeutic option: results of a consecutive patient cohort treated in clinical routine care. Zentralbl Chir 2012; 137:460-465.
45
46. Chen YW, Iwai T, Umeda M, Nagasawa T, Huang Y, Takeuchi Y, et al. Elevated IgG titers to periodontal pathogens related to Buerger disease. Int J Cardiol 2007; 122:79-81.
46
47. Slavov E, Stanilova S, Petkov D, Dobreva Z. Cytokine production in thromboangiitis obliterans patients: new evidence for an immune-mediated inflammatory disorder. Clin Exp Rheumatol 2005; 23:219-226.
47
48. Czarnacki M, Zdrojowy K, Adamiec R. Review of current etiopathogenic data of Buerger disease. Pol Merkur Lekarski 2002; 13:263-265.
48
49. Kröger K, Kreuzfelder E, Moser C, Santosa F, Buss C, Grosse-Wilde H. Thrombangitis obliterans: subpopulationen der leukozyten und zirkulierende immunkomplexe. Vasa 2001; 30:189-194.
49
50. Zdrojowy K, Adamiec R, Czarnacki M. New aspects of prostaglandin E1 therapeutic influence in thrombo-angiitis obliterans. Pol Arch Med Wewn 2002; 108:1071-1077.
50
51. Halacheva K, Gulubova MV, Manolova I, Petkov D. Expression of ICAM-1, VCAM-1, E-selectin and TNF-α on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem 2002; 104:177-184.
51
52. Fazeli B, Rafatpanah H, Ravari H, Farid Hosseini R, Tavakol Afshari J, Valizadeh N, et al. Sera of patients with thromboangiitis obliterans activated cultured human umbilical vein endothelial cells (HUVECs) and changed their adhesive properties. Int J Rheum Dis 2014; 17:106-112.
52
53. Fazeli B, Rafatpanah H, Ravari H, Hosseini RF, Rezaee SR. Investigation of the expression of mediators of neovascularization from mononuclear leukocytes in thromboangiitis obliterans. Vascular 2014; 22:174-180.
53
54. Gulati S, Agarwal V, Sharma V, Saha K. C3 complement components & their breakdown product (C3d) in patients of thromboangiitis obliterans. Indian J Med Res 1986; 84:607-611.
54
55. Kim EJ, Cho BS, Lee TS, Kim SJ, Seo JW. Morphologic change of the lnternal elastic lamina in Buerger’s. J Korean Med Sci 2000; 15:44-48.
55
56. Lee T, Seo JW, Sumpio B, Kim S. Immunobiologic analysis of arterial tissue in Buerger’s disease. Eur J Vasc Endovasc Surg 2003; 25:451-457.
56
57. Buerger L. Landmark publication from the american journal of the medical sciences,’ thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene’. 1999. Am J Med Sci 2009; 337:274-284.
57
58. Brodmann M, Renner W, Seinost G, Pabst E. Genetic evaluation of the common variant of the endothelial nitric oxide synthase (Glu (298)-> Asp) in patients with thrombangiitis obliterans. Int Angiol 2002; 21:169-172.
58
59. Czarnacki M, Gacka M, Adamiec R. [A role of endothelin 1 in the pathogenesis of thromboangiitis obliterans (initital news)]. Przegl Lek 2004; 61:1346-1350.
59
60. Hoeft D, Kroger K, Grabbe S, Dissemond J. [Thrombangiitis obliterans: an overview]. J Dtsch Dermatol Ges 2004; 2:827-832.
60
61. Deng J, De S, He S, Chen B. [Correlation of expressions of ER and CD59 in Buerger disease]. Sichuan Da Xue Xue Bao Yi Xue Ban 2006; 37:427-429, 483.
61
62. Cui XM, Pan L, Cui L, Li Y, Zhao WG, Li ZB. Electron microscopic observation of immune complexes deposited in tunica media vasorum in patients with thromboangiitis obliterans. J Norman Bethune Univ Med Sci 2001; 27:379-381.
62
63. Dellalibera‐Joviliano R, Joviliano EE, Silva JSd, Evora PR. Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients. Clin Exp Immunol 2012; 170:28-35.
63
64. Moussion C, Ortega N, Girard J-P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PloS One 2008; 3:e3331.
64
65. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479-490.
65
66. Chinese Clinical Trial Registry. Clinical Trial Registration NO. ChiCTR-CRC-17011428 (preliminary and unpublished data). ND.
66
67. Shoda T, Futamura K, Orihara K, Emi-Sugie M, Saito H, Matsumoto K, et al. Recent advances in understanding the roles of vascular endothelial cells in allergic inflammation. Allergol Int 2016; 65:21-29.
67
68. Azizi M, Boutouyrie P, Bura-Riviere A, Peyrard S, Laurent S, Fiessinger JN. Thromboangiitis obliterans and endothelial function. Eur J Clin Investig 2010; 40:518-526.
68
69. Joras M, Poredoš P, Fras Z. Endothelial dysfunction in Buerger’s disease and its relation to markers of inflammation. Eur J Clin Invest 2006; 36:376-382.
69
70. Makita S, Nakamura M, Murakami H, Komoda K, Kawazoe K, Hiramori K. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger’s disease). Circulation 1996; 94:(9 Suppl):211-215.
70
71. Stojkovic S, Kaun C, Basilio J, Rauscher S, Hell L, Krychtiuk KA, et al. Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation. Sci Rep 2016; 6:25171-25182.
71
72. Komai‐Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL‐33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007; 37:2779-2786.
72
73. Chalubinski M, Wojdan K, Luczak E, Gorzelak P, Borowiec M, Gajewski A, et al. IL-33 and IL-4 impair barrier functions of human vascular endothelium via different mechanisms. Vasc Pharmacol 2015; 73:57-63.
73
74. McLaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, Miller AM, et al. IL-33 reduces macrophage foam cell formation. J Immunol 2010; 185:1222-1229.
74
75. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205:339-346.
75
76. Ashlin TG, Buckley ML, Salter RC, Johnson JL, Kwan AP, Ramji DP. The anti-atherogenic cytokine interleukin-33 inhibits the expression of a disintegrin and metalloproteinase with thrombospondin motifs-1,-4 and-5 in human macrophages: requirement of extracellular signal-regulated kinase, c-Jun N-terminal kinase and phosphoinositide 3-kinase signaling pathways. Int J Biochem Cell Biol 2014; 46:113-123.
76
77. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci 2007; 104:18660-18665.
77
78. Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011; 7:321-329.
78
79. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13:816-825.
79
80. Chen Z, Nakajima T, Inoue Y, Kudo T, Jibiki M, Iwai T, et al. A single nucleotide polymorphism in the 3′-untranslated region of MyD88 gene is associated with Buerger disease but not with Takayasu arteritis in Japanese. J Hum Genet 2011; 56:545-547.
80
81. Pahwa R, Nallasamy P, Jialal I. Toll-like receptors 2 and 4 mediate hyperglycemia induced macrovascular aortic endothelial cell inflammation and perturbation of the endothelial glycocalyx. J Diabetes Complications 2016; 30:563-572.
81
82. Echavarria R, Mayaki D, Neel JC, Harel S, Sanchez V, Hussain SN. Angiopoietin-1 inhibits toll-like receptor 4 signalling in cultured endothelial cells: role of miR-146b-5p. Cardiovasc Res 2015; 106:465-477.
82
83. Aplin AC, Ligresti G, Fogel E, Zorzi P, Smith K, Nicosia RF. Regulation of angiogenesis, mural cell recruitment and adventitial macrophage behavior by Toll-like receptors. Angiogenesis 2014; 17:147-161.
83
84. Farzadnia M, Ravari H, Masoudian M, Valizadeh N, Fazeli B. Unexpected inflammation in the sympathetic ganglia in thromboangiitis obliterans. Int J Angiol 2017; 26:212-217.
84
85. McLachlan EM, Hu P. Inflammation in dorsal root ganglia after peripheral nerve injury: effects of the sympathetic innervation. Auton Neurosci 2014; 182:108-117.
85
86. Bradl M, Bauer J, Flügel A, Wekerle H, Lassmann H. Complementary contribution of CD4 and CD8 T lymphocytes to T-cell infiltration of the intact and the degenerative spinal cord. Am J Pathol 2005; 166:1441-1450.
86
87. Fehervari Z. Healing the CNS. Nat Immunol 2015; 16:228.
87
88. Yamada T, Harber P, Pettit GW, Wing DA, Oster CN. Activation of the kallikrein-kinin system in Rocky Mountain spotted fever. Ann Intern Med 1978; 88:764-768.
88
89. Dellalibera‐Joviliano R, Joviliano E, Évora P. Determination of kininogens levels and kallikrein/kininase II activities in patients with thromboangiitis obliterans. Scand J Immunol 2010; 72:128-133.
89
90. Hamza M, Wang XM, Adam A, Brahim JS, Rowan JS, Carmona GN, et al. Kinin B 1 receptors contributes to acute pain following minor surgery in humans. Mol Pain 2010; 6:12.
90
91. Mansueto P, Vitale G, Cascio A, Seidita A, Pepe I, Carroccio A, et al. New insight into immunity and immunopathology of Rickettsial diseases. Clin Dev Immunol 2012; 2012:967852.
91
92. Rathore MH. Rickettsial infection [Internet]. 2016 [cited 12 January 2018]. Available from: https://reference.medscape.com/article/968385-overview.
92
93. Puechal X, Fiessinger JN. Thromboangiitis obliterans or Buerger’s disease: challenges for the rheumatologist. Rheumatology 2007; 46:192-199.
93
94. Ashida S, Ishihara M, Ogawa H, Abiko Y. Protective effect of ticlopidine on experimentally induced peripheral arterial occlusive disease in rats. Thromb Res 1980; 18:55-67.
94
95. Nakata Y, Ban I, Hirai M, Shionoya S. Onset and clinicopathological course in Buerger’s disease. Angiology 1976; 27:509-517.
95
96. Nielubowicz J, Rosnowski A, Pruszynski B, Przetakiewicz Z, Potemkowski A. Natural history of Buerger’s disease. J Cardiovasc Surg 1980; 21:529-540.
96
97. Norregaard R, Kwon TH, Frokiaer J. Physiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidney. Kidney Res Clin Pract 2015; 34:194-200.
97
98. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31:986-1000.
98
99. Fiessinger J, Schäfer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet 1990; 335:555-557.
99
100. Niźankowski R, Krolikowski W, Bielatowicz J, Szczeklik A. Prostacyclin for ischemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study. Thromb Res 1985; 37:21-28.
100
101. Xu Y, Zhang R, Chen J, Zhang Q, Wang J, Hu J, et al. Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin‐releasing factor type 1 receptors. Br J Pharmacol 2009; 157:1368-1379.
101
102. Zhang R, Xu Y, Fu H, Wang J, Jin L, Li S. Urocortin induced expression of COX‐2 and ICAM‐1 via corticotrophin‐releasing factor type 2 receptor in rat aortic endothelial cells. Br J Pharmacol 2009; 158:819-829.
102
103. Sahni SK, Rydkina E. Host-cell interactions with pathogenic Rickettsia species. Future Microbiol 2009; 4:323-339.
103
104. Reinold H, Ahmadi S, Depner UB, Layh B, Heindl C, Hamza M, et al. Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest 2005; 115:673-679.
104
105. Shireman PK. The chemokine system in arteriogenesis and hind limb ischemia. J Vasc Surg 2007; 45:A48-A56.
105
106. Funahashi Y, Shawber CJ, Vorontchikhina M, Sharma A, Outtz HH, Kitajewski J. Notch regulates the angiogenic response via induction of VEGFR-1. J Angiogenes Res 2010; 2:3.
106
107. Kimura T, Kohno H, Matsuoka Y, Murakami M, Nakatsuka R, Hase M, et al. CXCL8 enhances the angiogenic activity of umbilical cord blood‐derived outgrowth endothelial cells in vitro. Cell Biol Int 2011; 35:201-208.
107
108. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996; 184:981-992.
108
109. Furuta S, Vadiveloo P, Romeo-Meeuw R, Morrison W, Stewart A, Mitchell G. Early inducible nitric oxide synthase 2 (NOS 2) activity enhances ischaemic skin flap survival. Angiogenesis 2004; 7:33-43.
109
110. Hristov M, Zernecke A, Liehn EA, Weber C. Regulation of endothelial progenitor cell homing after arterial injury. Thromb Haemost 2007; 98:274-277.
110
111. Ringe J, Strassburg S, Neumann K, Endres M, Notter M, Burmester GR, et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 2007; 101:135-146.
111
112. Meyer M, Schreck R, Baeuerle PA. H2O2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J 1993; 12:2005-2015.
112
113. Park HS, Cho KH, Kim KL, Kim DK, Lee T. Reduced circulating endothelial progenitor cells in thromboangiitis obliterans (Buerger’s disease). Vasc Med 2013; 18:331-339.
113
114. Steer SA, Scarim AL, Chambers KT, Corbett JA. Interleukin-1 stimulates β-cell necrosis and release of the immunological adjuvant HMGB1. PLoS Med 2005; 3:e17.
114
115. Moscatelli D, Rifkin DB. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 1988; 948:67-85.
115
116. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493-2503.
116
117. Matrisian LM. The matrix‐degrading metalloproteinases. Bioessays 1992; 14:455-463.
117
118. Dellalibera-Joviliano R, Jacob-Ferreira AL, Joviliano EE, Tanus-Santos JE, Évora PR. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans. Vasc Med 2012; 17:73-78.
118
119. Yongxin S, Wenjun D, Qiang W, Yunqing S, Liming Z, Chunsheng W. Heavy smoking before coronary surgical procedures affects the native matrix metalloproteinase-2 and matrix metalloproteinase-9 gene expression in saphenous vein conduits. Ann Thorac Surg 2013; 95:55-61.
119
120. De Caridi G, Bitto A, Massara M, Pallio G, Pizzino G, Serra R, et al. Increased serum HMGB-1, ICAM-1 and metalloproteinase-9 levels in Buerger’s patients. Curr Vasc Pharmacol 2016; 14:382-387.
120
121. Sun W, Jiao Y, Cui B, Gao X, Xia Y, Zhao Y. Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis. Lab Invest 2013; 93:626-638.
121
122. Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NF-κB reduces matrix metalloproteinase-1,-3 and-9 production by vascular smooth muscle cells. Cardiovasc Res 2001; 50:556-565.
122
123. Hou CH, Fong YC, Tang CH. HMGB‐1 induces IL‐6 production in human synovial fibroblasts through c‐Src, Akt and NF‐κB pathways. J Cell Physiol 2011; 226:2006-2015.
123
ORIGINAL_ARTICLE
Pharmacological effects of gallic acid in health and disease: A mechanistic review
Objective(s): Gallic acid is a natural phenolic compound found in several fruits and medicinal plants. It is reported to have several health-promoting effects. This review aims to summarize the pharmacological and biological activities of gallic acid in vitro and animal models to depict the pharmacological status of this compound for future studies.Materials and Methods: All relevant papers in the English language were collected up to June 2018. The keywords of gallic acid, antioxidant, anticancer, antimicrobial, gastrointestinal-, cardiovascular-, metabolic-, neuropsychological-, and miscellaneous- diseases were searched in Google Scholar, PubMed, and Scopus.Results: Several beneficial effects are reported for gallic acid, including antioxidant, anti-inflammatory, and antineoplastic properties. This compound has been reported to have therapeutic activities in gastrointestinal, neuropsychological, metabolic, and cardiovascular disorders. Conclusion: Current evidence confirms the pharmacological and therapeutic interventions of gallic acid in multiple health complications; however, available data are limited to just cellular and animal studies. Future investigations are essential to further define the safety and therapeutic efficacy of gallic acid in humans.
https://ijbms.mums.ac.ir/article_12251_1e2b9a1363690fd784d6b16a6d3a5d5a.pdf
2019-03-01
225
237
10.22038/ijbms.2019.32806.7897
Anticancer
Antioxidant
Gallic acid
Health benefits
Pharmacological effects
Niloofar
Kahkeshani
niloofar6767@gmail.com
1
Department of Pharmacognosy, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
AUTHOR
Fatemeh
Farzaei
f.farzaei@gmail.com
2
Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
AUTHOR
Maryam
Fotouhi
medicalmaryam@gmail.com
3
Student Research Committee, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Seyedeh Shaghayegh
Alavi
n.sh.alavi@gmail.com
4
Department of Food Science, Engineering and Technology, Faculty of Agricultural Engineering and Technology, University of Tehran, Karaj, Iran
AUTHOR
Roodabeh
Bahramsoltani
roodabeh.b.s.88@hotmail.co.uk
5
Department of Pharmacy in Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Rozita
Naseri
rnasseri.75@gmail.com
6
Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
AUTHOR
Saeideh
Momtaz
saeideh58_momtaz@yahoo.com
7
Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran
AUTHOR
Zahra
Abbasabadi
zahra_abasabadi@yahoo.com
8
Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
AUTHOR
Roja
Rahimi
rojarahimi@gmail.com
9
Department of Pharmacy in Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mohammad Hosein
Farzaei
mh.farzaei@gmail.com
10
Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
LEAD_AUTHOR
Anupam
Bishayee
abishayee@gmail.com
11
Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA
AUTHOR
1. Pengelly A. The Constituents of Medicinal Plants: An Introduction to the Chemistry and Therapeutics of Herbal Medicine. 2nd ed, CABI, 2004.
1
2. Siah M, Farzaei M, Ashrafi-Kooshk M, Adibi H, Arab S, Rashidi M, Khodarahmi R. Inhibition of guinea pig aldehyde oxidase activity by different flavonoid compounds: an in vitro study. Bioorg Chem 2016; 64:74-84.
2
3. Fernandes F, Salgado H. Gallic acid: review of the methods of determination and quantification. Crit Rev Anal Chem 2016; 46:257-265.
3
4.Choubey S, Varughese L, Kumar V, Beniwal V. Medicinal importance of gallic acid and its ester derivatives: a patent review. Pharm Pat Anal 2015; 4:305-315.
4
5. Borges A, Ferreira C, Saavedra M, Simoes M. Antibacterial activity and mode of action of ferulic and gallic acids against pathogenic bacteria. Microb Drug Resist 2013; 19:256-265.
5
6. Cueva C, Moreno-Arribas M, Martin-Alvarez P, Bills G, Francisca Vicente M, Basilio A, et al. Antimicrobial activity of phenolic acids against commensal, probiotic and pathogenic bacteria. Res Microbiol 2010; 161:372-382.
6
7. Farag M, Al‐Mahdy D, Salah El Dine R, Fahmy S, Yassin A, Porzel A, et al. Structure activity relationships of antimicrobial gallic acid derivatives from pomegranate and acacia fruit extracts against potato bacterial wilt pathogen. Chem Biodivers 2015; 12:955-962.
7
8. Rivero-Buceta E, Carrero P, Doyagüez E, Madrona A, Quesada E, Camarasa M, et al. Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors. Eur J Med Chem 2015; 92:656-671.
8
9. Sanchez-Maldonado A, Schieber A, Ganzle M. Structure–function relationships of the antibacterial activity of phenolic acids and their metabolism by lactic acid bacteria. J Appl Microbiol 2011; 111:1176-1184.
9
10. Shao D, Li J, Li J, Tang R, Liu L, Shi J, et al. Inhibition of gallic acid on the growth and biofilm formation of Escherichia coli and Streptococcus mutans. J Food Sci 2015; 80: 1299-1305.
10
11. Borges A, Saavedra MJ, Simoes M. The activity of ferulic and gallic acids in biofilm prevention and control of pathogenic bacteria. Biofouling 2012; 28:755-767.
11
12. Kang M, Oh J, Kang I, Hong S, Choi C. Inhibitory effect of methyl gallate and gallic acid on oral bacteria. J Microbiol 2008; 46:744-750.
12
13. Teodoro G, Ellepola K, Seneviratne C. potential use of phenolic acids as anti-candida agents-a review. Front Microbiol 2015; 6:1420. doi: 10.3389/fmicb.2015.01420. eCollection 2015.
13
14. Oh B, Jeon E. Synergistic anti-Campylobacter jejuni activity of fluoroquinolone and macrolide antibiotics with phenolic compounds. Front Microbiol 2015; 13:1129. doi: 10.3389/fmicb.2015.01129. eCollection 2015.
14
15. Nohynek L, Alakomi H, Kahkonen M, Heinonen M, Helander I, Oksman-Caldentey K, et al. Berry phenolics: antimicrobial properties and mechanisms of action against severe human pathogens. Nutr Cancer 2006; 54:18-32.
15
16. Godstime C, Felix O, Augustina O, Christopher O. Mechanisms of antimicrobial actions of phytochemicals against enteric pathogens, J Pharm Chem Biol Sci 2014; 2:77-85.
16
17. Kubo I, Fujita K, Nihei K, Masuoka N. Non-antibiotic antibacterial activity of dodecyl gallate. Bioorg Med Chem 2003; 11:573-580.
17
18. Modi M, Goel T, Das T, Malik S, Suri S, Rawat AK, et al. Ellagic acid & gallic acid from Lagerstroemia speciosa L. inhibit HIV-1 infection through inhibition of HIV-1 protease & reverse transcriptase activity. Indian J Med Res 2013; 137:540-548.
18
19. Singh A, Pal T. Docking analysis of gallic acid derivatives as HIV-1 protease inhibitors. Int J Bioinform Res Appl 2015; 11:540-546.
19
20. Ahn C, Jung W, Park S, Kim Y, Kim W, Je J. Gallic acid-g-chitosan modulates inflammatory responses in LPS-stimulated RAW264.7 cells via NF-kappaB, AP-1, and MAPK pathways. Inflammation 2016; 39:366-374.
20
21. Flausino O, Dufau L, Regasini L, Petronio M, Silva D, Rose T, et al. Alkyl hydroxybenzoic acid derivatives that inhibit HIV-1 protease dimerization. Curr Med Chem 2012; 19:4534-4540.
21
22. Kratz J, Andrighetti-Frohner C, Kolling D, Leal P, Cirne-Santos C, Yunes R, et al. Anti-HSV-1 and anti-HIV-1 activity of gallic acid and pentyl gallate. Mem Inst Oswaldo Cruz 2008; 103:437-442.
22
23. Zuo G, Li Z, Chen L, Xu X. In vitro anti-HCV activities of Saxifraga melanocentra and its related polyphenolic compounds. Antivir Chem Chemother 2005; 16:393-398.
23
24. Govea Salas M, Rivas Estilla A, Morlett Chávez J, Lozano Sepúlveda S, Rodríguez Herrera R, Aguilar González C. P420 gallic acid has antiviral effect against hepatitis C virus (HCV), which is mediated by its antioxidant activity. J Hepatol 2014; 60:S208.
24
25. Govea-Salas M, Rivas-Estilla A, Rodriguez-Herrera R, Lozano-Sepulveda S, Aguilar-Gonzalez C, Zugasti-Cruz A, et al. Gallic acid decreases hepatitis C virus expression through its antioxidant capacity. Exp Ther Med 2016; 11:619-624.
25
26. Hsu W, Chang S, Lin L, Li C, Richardson C, Lin C, et al. Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry. Antiviral Res 2015; 118:139-147.
26
27. Lee J, Oh M, Seok J, Kim S, Lee D, Bae G, et al. Antiviral effects of black raspberry (Rubus coreanus) seed and its gallic acid against influenza virus infection. Viruses 2016; 6. pii: E157. doi: 10.3390/v8060157.
27
28. Ndjonka D, Abladam E, Djafsia B, Ajonina-Ekoti I, Achukwi M, Liebau E. Anthelmintic activity of phenolic acids from the axlewood tree Anogeissus leiocarpus on the filarial nematode Onchocerca ochengi and drug-resistant strains of the free-living nematode Caenorhabditis elegans. J Helminthol 2014; 88:481-488.
28
29. Abouelhassan Y, Garrison A, Bai F, Norwood V, Nguyen M, Jin S, et al. A Phytochemical-halogenated quinoline combination therapy strategy for the treatment of pathogenic bacteria. Chem Med Chem 2015; 10:1157-1162.
29
30. Li D, Liu Z, Yuan Y, Liu Y, Niu F. Green synthesis of gallic acid-coated silver nanoparticles with high antimicrobial activity and low cytotoxicity to normal cells. Process Biochem 2015; 50:357-366.
30
31. Lima V, Oliveira-Tintino C, Santos E, Morais L, Tintino S, Freitas T, et al. Antimicrobial and enhancement of the antibiotic activity by phenolic compounds: gallic acid, caffeic acid and pyrogallol. Microb Pathog 2016; 99:56-61.
31
32. Lee D, Eom S, Kim Y, Kim H, Yim M, Lee S, et al. Antibacterial and synergic effects of gallic acid-grafted-chitosan with beta-lactams against methicillin-resistant Staphylococcus aureus (MRSA). Can J Microbiol 2014; 60:629-638.
32
33. Choi J, Kang O, Lee Y, Oh Y, Chae H, Jang H, et al. In vitro activity of methyl gallate isolated from galla rhois alone and in combination with ciprofloxacin against clinical isolates of salmonella. J microbiol biotechnol 2008; 18:1848-1852.
33
34. Shibata H, Kondo K, Katsuyama R, Kawazoe K, Sato Y, Murakami K, et al. Alkyl gallates, intensifiers of β-lactam susceptibility in methicillin-resistant Staphylococcus aureus. Antimicrob agents chemother 2005; 49:549-555.
34
35. Kasper D, Hauser S, Jameson J, Fauci A, Longo D, Loscalzo J. Harrison’s Principles of Internal Medicine, 19th ed. Mc Graw Hill, 2015.
35
36. Farzaei M, Bahramsoltani R, Rahimi R. Phytochemicals as adjunctive with conventional anticancer therapies. Curr Pharm Des 2016; 22:4201-4218.
36
37. Shokoohinia Y, Jafari F, Mohammadi Z, Bazvandi L, Hosseinzadeh L, Chow N, et al. Potential anticancer properties of osthol: a comprehensive mechanistic review. Nutrients 2018; 10:36.
37
38. Ahmedin J, Freddie B, Melissa M, Jacques F, Elizabeth W, David F. Global cancer statistics. Cancer J Clin 2011; 61:69-90.
38
39. Giftson J, Jayanthi S, Nalini N. Chemopreventive efficacy of gallic acid, an antioxidant and anticarcinogenic polyphenol, against 1, 2-dimethyl hydrazine induced rat colon carcinogenesis. Invest New Drugs 2010; 28:251-259.
39
40. Subramanian V, Venkatesan B, Tumala A, Vellaichamy E. Topical application of gallic acid suppresses the 7, 12-DMBA/croton oil induced two-step skin carcinogenesis by modulating anti-oxidants and MMP-2/MMP-9 in Swiss albino mice. Food Chem Toxicol 2014; 66:44-55.
40
41. Balch C, Gershenwald J, Soong S, Thompson J, Atkins M, Byrd D, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
41
42. Liao C, Lai K, Huang A, Yang J, Lin J, Wu S, et al. Gallic acid inhibits migration and invasion in human osteosarcoma U-2 OS cells through suppressing the matrix metalloproteinase-2/-9, protein kinase B (PKB) and PKC signaling pathways. Food Chem Toxicol 2012; 50:1734-1740.
42
43. Nemec M, Kim H, Marciante A, Barnes R, Talcott S, Mertens-Talcott S. Pyrogallol, an absorbable microbial gallotannins-metabolite and mango polyphenols (Mangifera Indica L.) suppress breast cancer ductal carcinoma in situ proliferation in vitro. Food Funct 2016; 7:3825-3833.
43
44. Da Silva S, Chaar J, Yano T. Chemotherapeutic potential of two gallic acid derivative compounds from leaves of Casearia sylvestris Sw (Flacourtiaceae). Eur J Pharmacol 2009; 608:76-83.
44
45. Huang P, Hseu Y, Lee M, Kumar K, Wu C, Hsu L, et al. In vitro and in vivo activity of gallic acid and Toona sinensis leaf extracts against HL-60 human premyelocytic leukemia. Food Chem Toxicol 2012; 50:3489-3497.
45
46. Jagan S, Ramakrishnan G, Anandakumar P, Kamaraj S, Devaki T. Antiproliferative potential of gallic acid against diethylnitrosamine-induced rat hepatocellular carcinoma. Mol Cell Biochem 2008; 319:51-59.
46
47. Mard S, Mojadami S, Farbood Y, Gharib Naseri M. The anti-inflammatory and anti-apoptotic effects of gallic acid against mucosal inflammation- and erosions-induced by gastric ischemia-reperfusion in rats. Vet Res Forum 2015; 6:305-311.
47
48. Pal C, Bindu S, Dey S, Alam A, Goyal M, Iqbal MS, et al. Gallic acid prevents nonsteroidal anti-inflammatory drug-induced gastropathy in rat by blocking oxidative stress and apoptosis. Free Radicals Biol Med 2010; 49:258-267.
48
49. Chatterjee A, Chatterjee S, Biswas A, Bhattacharya S, Chattopadhyay S, Bandyopadhyay SK. Gallic acid enriched fraction of Phyllanthus emblica potentiates indomethacin-induced gastric ulcer healing via e-NOS-dependent pathway. Evid Based Complement Alternat Med 2012; 2012:487380.
49
50. Pandurangan A, Mohebali N, Norhaizan M, Looi C. Gallic acid attenuates dextran sulfate sodium-induced experimental colitis in BALB/c mice. Drug Des Devel Ther 2015b; 9:3923-3934.
50
51. Pandurangan A, Mohebali N, Mohd. Esa N, Looi C, Ismail S, Saadatdoust Z. Gallic acid suppresses inflammation in dextran sodium sulfate-induced colitis in mice: possible mechanisms. Int Immunopharmacol 2015a; 28:1034-1043.
51
52. Park J, Han W, Park J, Choi S, Choi J. Changes in hepatic drug metabolizing enzymes and lipid peroxidation by methanol extract and major compound of Orostachys japonicus. J Ethnopharmacol 2005; 102:313-318.
52
53. Anand K, Singh B, Saxena A, Chandan B, Gupta V, Bhardwaj V. 3,4,5-trihydroxy benzoic acid (gallic acid), the hepatoprotective principle in the fruits ofterminalia belerica-bioassay guided activity. Pharmacol Res 1997; 36:315-321.
53
54. Kartkaya K, Oglakci A, Senturk H, Bayramoglu G, Canbek M, Kanbak G. Investigation of the possible protective role of gallic acid on paraoxanase and arylesterase activities in livers of rats with acute alcohol intoxication. Cell Biochem Funct 2013; 31:208-213.
54
55. Oyagbemi A, Omobowale O, Asenuga E, Akinleye A, Ogunsanwo R, Saba A. Cyclophosphamide-induced hepatotoxicity in wistar rats: the modulatory role of gallic acid as a hepatoprotective and chemopreventive phytochemical. Int J Prev Med 2016; 7:51. doi:[10.4103/2008-7802.177898].
55
56. Reckziegel P, Dias V, Benvegnú D, Boufleur N, Barcelos R, Segat H, et al. Antioxidant protection of gallic acid against toxicity induced by Pb in blood, liver and kidney of rats. Toxicol Rep 2016; 3:351-356.
56
57. Bayramoglu G, Kurt H, Bayramoglu A, Gunes H, Degirmenci I, Colak S. Preventive role of gallic acid on hepatic ischemia and reperfusion injury in rats. Cytotechnology 2015; 67:845-849.
57
58. Priscilla D, Prince P. Cardioprotective effect of gallic acid on cardiac troponin-T, cardiac marker enzymes, lipid peroxidation products and antioxidants in experimentally induced myocardial infarction in wistar rats. Chem Biol Interact 2009; 179:118-124.
58
59. Gandhi G, Jothi G, Antony PJ, Balakrishna K, Paulraj M, Ignacimuthu S, et al. Gallic acid attenuates high-fat diet fed-streptozotocin-induced insulin resistance via partial agonism of PPARgamma in experimental type 2 diabetic rats and enhances glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway. Eur J Pharmacol 2014; 745:201-216.
59
60. Kade I, Ogunbolude Y, Kamdem J, Rocha J. Influence of gallic acid on oxidative stress-linked streptozotocin-induced pancreatic dysfunction in diabetic rats. J Basic Clin Physiol Pharmacol 2014; 25:35-45.
60
61. Bak E, Kim J, Jang S, Woo G, Yoon H, Yoo Y, et al. Gallic acid improves glucose tolerance and triglyceride concentration in diet-induced obesity mice. Scand J Clin Lab Invest 2013; 73:607-614.
61
62. Hsu C, Yen G. Effect of gallic acid on high fat diet-induced dyslipidaemia, hepatosteatosis and oxidative stress in rats. Br J Nutr 2007; 98:727-735.
62
63. Huang D, Chang W, Wu J, Shih R, Shen S. Gallic acid ameliorates hyperglycemia and improves hepatic carbohydrate metabolism in rats fed a high-fructose diet. Nutr Res 2016; 36:150-160.
63
64. Ban J, Nguyen H, Lee H, Cho S, Ju H, Kim J. Neuroprotective properties of gallic acid from Sanguisorbae radix on amyloid beta protein (25-35)-induced toxicity in cultured rat cortical neurons. Biol Pharm Bull 2008; 31:149-153.
64
65. Mansouri M, Farbood Y, Sameri M, Sarkaki A, Naghizadeh B, Rafeirad M. Neuroprotective effects of oral gallic acid against oxidative stress induced by 6-hydroxydopamine in rats. Food chem 2013; 138:1028-1033.
65
66. Nagpal K, Singh S, Mishra D. Nanoparticle mediated brain targeted delivery of gallic acid: in vivo behavioral and biochemical studies for protection against scopolamine-induced amnesia. Drug Deliv 2013; 20:112-119.
66
67. Kang M, Kang N, Jang Y, Lee K, Lee H. Gallic acid induces neuronal cell death through activation of c-Jun N-terminal kinase and downregulation of Bcl-2. Ann N Y Acad Sci 2009; 1171:514-520.
67
68. Crispo J, Piché M, Ansell D, Eibl J, Tai I, Kumar A. Protective effects of methyl gallate on H2O2-induced apoptosis in PC12 cells. Biochem Biophys Res Commun 2010; 393:773-778.
68
69. Nazir N, Koul S, Qurishi M, Taneja S, Ahmad S, Bani S, et al. Immunomodulatory effect of bergenin and norbergenin against adjuvant-induced arthritis—a flowcytometric study. J Ethnopharmacol 2007; 112:401-405.
69
70. Santos A, De Campos R, Miguel O, Cechinel-Filho V, Yunes R, Calixto J. The involvement of K+ channels and Gi/o protein in the antinociceptive action of the gallic acid ethyl ester. Eur J Pharmacol 1999; 379:7-17.
70
71. Kroes B, van den Berg A, Quarles van Ufford H, van Dijk H, Labadie R. Anti-inflammatory activity of gallic acid. Planta Med 1992; 58:499-504.
71
72. Choi K, Lee Y, Jung M, Kwon S, Kim M, Jun W, et al. Gallic acid suppresses lipopolysaccharide-induced nuclear factor-κB signaling by preventing RelA acetylation in A549 lung cancer cells. Mol Cancer Res 2009; 7:2011-2021.
72
73. Wen L, Qu T, Zhai K, Ding J, Hai Y, Zhou J. Gallic acid can play a chondroprotective role against AGE-induced osteoarthritis progression. J Orthop Sci 2015; 20:734-741.
73
74. Canbek M, Bayramoglu G, Senturk H, Oztopcu Vatan A, Uyanoglu M, Ceyhan E, et al. The examination of protective effects of gallic acid against damage of oxidative stress during induced-experimental renal ischemia-reperfusion in experiment. Bratisl Lek Listy 2014; 115:557-562.
74
75. Akomolafe S, Akinyemi A, Anadozie S. Phenolic acids (gallic and tannic acids) modulate antioxidant status and cisplatin induced nephrotoxicity in rats. Int Sch Res Notices 2014; 2014:984709.
75
76. Olusoji M, Oyeyemi O, Asenuga E, Omobowale T, Ajayi O, Oyagbemi A. Protective effect of Gallic acid on doxorubicin-induced testicular and epididymal toxicity. Andrologia 2016;49. doi: 10.1111/and.12635.
76
77. Prasad L, Khan T, Jahangir T, Sultana S. Effect of gallic acid on renal biochemical alterations in male Wistar rats induced by ferric nitriloacetic acid. Hum Exp Toxicol 2006; 25:523-529.
77
78. Yousuf M, Vellaichamy E. Protective activity of gallic acid against glyoxal -induced renal fibrosis in experimental rats. Toxicol Rep 2015; 2:1246-1254.
78
79. Peng C, Hsieh C, Wang H, Chung J, Chen K, Peng R. Ferulic acid is nephrodamaging while gallic acid is renal protective in long term treatment of chronic kidney disease. Clin Nutr 2012; 31:405-414.
79
80. Nikbakht J, Hemmati A, Arzi A, Mansouri M, Rezaie A, Ghafourian M. Protective effect of gallic acid against bleomycin-induced pulmonary fibrosis in rats. Pharmacol Rep 2015; 67:1061-1067.
80
81. Gandhi N, Nair C. Protection of DNA and membrane from gamma radiation induced damage by gallic acid. Mol Cell Biochem 2005; 278:111-117.
81
82. Nair G, Nair C. Radioprotective effects of gallic acid in mice. Biomed Res Int 2013; 2013:953079. doi: 10.1155/2013/953079.
82
83. Kumar K, Vani M, Wang S, Liao J, Hsu L, Yang H, et al. In vitro and in vivo studies disclosed the depigmenting effects of gallic acid: a novel skin lightening agent for hyperpigmentary skin diseases. Biofactors 2013; 39:259-270.
83
84. Hwang E, Park S, Lee H, Lee T, Sun Z, Yi T. Gallic acid regulates skin photoaging in UVB-exposed fibroblast and hairless mice. Phytother Res 2014; 28:1778-1788.
84
85. Shaik A, Rasool S, Reddy A, Kareem M, Saayi Krushna G, Lakshmi Devi K. Cardioprotective effect of HPLC standardized ethanolic extract of Terminalia pallida fruits against isoproterenol-induced myocardial infarction in albino rats. J Ethnopharmacol 2012; 141:33-40.
85
86. Prince P, Priscilla H, Devika P. Gallic acid prevents lysosomal damage in isoproterenol induced cardiotoxicity in wistar rats. Eur J Pharmacol 2009; 615:139-143.
86
87. Padma V, Poornima P, Prakash C, Bhavani R. Oral treatment with gallic acid and quercetin alleviates lindane-induced cardiotoxicity in rats. Can J Physiol Pharmacol 2013; 91:134-140.
87
88. Yeh C, Ching L, Yen G. Inducing gene expression of cardiac antioxidant enzymes by dietary phenolic acids in rats. J Nutr Biochem 2009; 20:163-171.
88
89. Umadevi S, Gopi V, Elangovan V. Regulatory mechanism of gallic acid against advanced glycation end products induced cardiac remodeling in experimental rats. Chem Biol Interact 2014; 208:28-36.
89
90. Patel S, Goyal R. Cardioprotective effects of gallic acid in diabetes-induced myocardial dysfunction in rats. Pharmacognosy Res 2011; 3:239-245.
90
91. Sutra T, Oiry C, Azay-Milhau J, Youl E, Magous R, Teissedre PL, et al. Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress. J Agric Food Chem 2008; 56:11683-11687.
91
92. El-Hussainy E, Hussein A, Abdel-Aziz A, El-Mehasseb I. Effects of aluminum oxide (Al2O3) nanoparticles on ECG, myocardial inflammatory cytokines, redox state, and connexin 43 and lipid profile in rats: possible cardioprotective effect of gallic acid. Can J Physiol Pharmacol 2016; 94:868-878.
92
93. Badavi M, Sadeghi N, Dianat M, Samarbafzadeh A. Effects of gallic Acid and cyclosporine a on antioxidant capacity and cardiac markers of rat isolated heart after ischemia/reperfusion. Iran Red Crescent Med J 2014; 16:e16424. doi:[10.5812/ircmj.16424].
93
94. Jin L, Lin M, Piao Z, Cho J, Kim G, Choi S, et al. Gallic acid attenuates hypertension, cardiac remodeling, and fibrosis in mice with NG-nitro-L-arginine methyl ester-induced hypertension via regulation of histone deacetylase 1 or histone deacetylase 2. J Hypertens 2017; 35: 1502-1512.
94
95. Ogunsanwo O, Oyagbemi A, Omobowale T, Asenuga E, Saba A. Biochemical and electrocardiographic studies on the beneficial effects of gallic acid in cyclophosphamide-induced cardiorenal dysfunction. J Complement Integr Med 2017; 144. doi: 10.1515/jcim-2016-0161.
95
96. Eler G, Peralta R, Bracht A. The action of n-propyl gallate on gluconeogenesis and oxygen uptake in the rat liver. Chem Bio Interact 2009; 181:390-399.
96
97. Gupta N, Gupta S, Mahmood A. Gallic acid inhibits brush border disaccharidases in mammalian intestine. Nutr Res 2007; 27:230-235.
97
98. Hsieh S, Wu C, Wu C, Yen J, Liu M, Hsueh C. Gallic acid selectively induces the necrosis of activated hepatic stellate cells via a calcium-dependent calpain I activation pathway. Life Sci 2014; 102: 55-64.
98
99. Kanbak G, Canbek M, Oglakci A, Kartkaya K, Senturk H, Bayramoglu G, et al. Preventive role of gallic acid on alcohol dependent and cysteine protease-mediated pancreas injury. Mol Biol Rep 2012; 39:10249-10255.
99
100. Pal C, Bindu S, Dey S, Alam A, Goyal M, Iqbal M, et al. Tryptamine-gallic acid hybrid prevents non-steroidal anti-inflammatory drug-induced gastropathy: correction of mitochondrial dysfunction and inhibition of apoptosis in gastric mucosal cells. J Biol Chem 2012; 287:3495-3509.
100
101. Rasool M, Sabina E, Ramya S, Preety P, Patel S, Mandal N, et al. Hepatoprotective and antioxidant effects of gallic acid in paracetamol-induced liver damage in mice. J Pharm Pharmacol 2010; 62:638-643.
101
102. Sachdeva M, Chadha R, Kumar A, Karan M, Singh T, Dhingra S. Hepatoprotective effect of trimethylgallic acid esters against carbon tetrachloride-induced liver injury in rats. Indian J Exp Biol 2015; 53:803-809.
102
103. Sen S, De B, Devanna N, Chakraborty R. Total phenolic, total flavonoid content, and antioxidant capacity of the leaves of Meyna spinosa Roxb., an Indian medicinal plant. Chin J Nat Med 2013; 11:149-157.
103
104. Wang Y, Chung F, Lee S, Dykes G. Inhibition of attachment of oral bacteria to immortalized human gingival fibroblasts (HGF-1) by tea extracts and tea components. BMC Res Notes 2013; 6:143. https://doi.org/10.1186/1756-0500-6-143.
104
105. Zhao X, Wang Y, Sun Y. Quantitative and qualitative determination of Liuwei Dihuang tablets by HPLC-UV-MS-MS. J Chromatogr Sci 2007; 45:549-552.
105
106. Sugimoto K, Sakamoto S, Nakagawa K, Hayashi S, Harada N, Yamaji R, et al. Suppression of inducible nitric oxide synthase expression and amelioration of lipopolysaccharide-induced liver injury by polyphenolic compounds in Eucalyptus globulus leaf extract. Food Chem 2011; 125:442-446.
106
107. Tung Y, Wu J, Hsieh C, Chen P, Chang S. Free radical-scavenging phytochemicals of hot water extracts of Acacia confusa leaves detected by an on-line screening method. Food Chem 2009; 115:1019-1024.
107
108. Padma V, Sowmya P, Felix T, Baskaran R, Poornima P. Protective effect of gallic acid against lindane induced toxicity in experimental rats. Food Chem Toxicol 2011; 49:991-998.
108
109. Nirala S, Li P, Bhadauria M, Guo G. Combined effects of gallic acid and propolis on beryllium-induced hepatorenal toxicity. Integr Zool 2008; 3:194-207.
109
110. Latha R, Daisy P. Insulin-secretagogue, antihyperlipidemic and other protective effects of gallic acid isolated from Terminalia bellerica Roxb. in streptozotocin-induced diabetic rats. Chem Biol Interac 2011; 189: 112-118.
110
111. Oi Y, Hou I, Fujita H, Yazawa K. Antiobesity effects of Chinese black tea (Pu-erh tea) extract and gallic acid. Phytother Res 2012; 26:475-481.
111
112. Punithavathi V, Prince P, Kumar R, Selvakumari J. Antihyperglycaemic, antilipid peroxidative and antioxidant effects of gallic acid on streptozotocin induced diabetic wistar rats. Eur J Pharmacol 2011; 650:465-471.
112
113. Punithavathi V, Prince P, Kumar M, Selvakumari C. Protective effects of gallic acid on hepatic lipid peroxide metabolism, glycoprotein components and lipids in streptozotocin-induced type II diabetic wistar rats. J Biochem Mol Toxicol 2011; 25:68-76.
113
114. Ramkumar K, Vijayakumar R, Vanitha P, Suganya N, Manjula C, Rajaguru P, et al. Protective effect of gallic acid on alloxan-induced oxidative stress and osmotic fragility in rats. Hum Exp Toxicol 2014; 33:638-649.
114
115. Mohammed A, Koorbanally N, Islam M. Phytochemistry, antioxidative activity and inhibition of key enzymes linked to type 2 diabetes by various parts of Aframomum melegueta in vitro. Acta Pol Pharm 2016; 73:403-417.
115
116. Ahad A, Ahsan H, Mujeeb M, Siddiqui W. Gallic acid ameliorates renal functions by inhibiting the activation of p38 MAPK in experimentally induced type 2 diabetic rats and cultured rat proximal tubular epithelial cells. Chem Bio Interact 2015; 240:292-303.
116
117. de Oliveira L, de Oliveira T, da Costa R, de Souza Gil E, Costa E, Passaglia C, et al. The vasorelaxant effect of gallic acid involves endothelium-dependent and -independent mechanisms. Vascul Pharmacol 2016; 81:69-74.
117
118. Mansouri M, Naghizadeh B, Ghorbanzadeh B, Farbood Y, Sarkaki A, Bavarsad K. Gallic acid prevents memory deficits and oxidative stress induced by intracerebroventricular injection of streptozotocin in rats. Pharmacol Biochem Behav 2013; 111:90-96.
118
119. Mansouri M, Soltani M, Naghizadeh B, Farbood Y, Mashak A, Sarkaki A. A possible mechanism for the anxiolytic-like effect of gallic acid in the rat elevated plus maze. Pharmacol Biochem Behav 2014; 117:40-46.
119
120. Nabavi S, Habtemariam S, Jafari M, Sureda A, Nabavi S. Protective role of gallic acid on sodium fluoride induced oxidative stress in rat brain. Bull Environ Contam Toxicol 2012; 89:73-77.
120
121. Naghizadeh B, Mansouri M. Protective effects of gallic acid against streptozotocin-induced oxidative damage in rat striatum. Drug Res (Stuttg) 2015; 65:515-520.
121
122. Yang Y, Wang Z, Zheng J, Wang R. Protective effects of gallic acid against spinal cord injury-induced oxidative stress. Mol Med Rep 2015; 12:3017-3024.
122
123. Ortega-Arellano H, Jimenez-Del-Rio M, Velez-Pardo C. Dmp53, basket and drICE gene knockdown and polyphenol gallic acid increase life span and locomotor activity in a Drosophila Parkinson’s disease model. Genet Mol Biol 2013; 36:608-615.
123
124. Reckziegel P, Peroza L, Schaffer LF, Ferrari M, de Freitas C, Burger M, et al. Gallic acid decreases vacuous chewing movements induced by reserpine in rats. Pharmacol Biochem Behav 2013; 104:132-137.
124
125. Reckziegel P, Dias VT, Benvegnu D, Boufleur N, Barcelos R, Segat H, et al. Locomotor damage and brain oxidative stress induced by lead exposure are attenuated by gallic acid treatment. Toxicol Lett 2011; 203:74-81.
125
126. Parihar P, Jat D, Ghafourifar P, Parihar M. Efficiency of mitochondrially targeted gallic acid in reducing brain mitochondrial oxidative damage. Cell Mol Biol 2014; 60:35-41.
126
127. Sun H, Zhang Y, Xie X, Che Y. Biochemical studies for improved antioxidant and antidepressant-like activity. Drug Deliv 2012; 19:378-391.
127
129. Dhingra D, Chhillar R, Gupta A. Antianxiety-like activity of gallic acid in unstressed and stressed mice: possible involvement of nitriergic system. Neurochem Res 2012; 37:487-494.
128
130. Farbood Y, Sarkaki A, Hashemi S, Mansouri M, Dianat M. The effects of gallic acid on pain and memory following transient global ischemia/reperfusion in wistar rats. Avicenna J Phytomed 2013; 3:329-340.
129
131. Hajimoradi M, Fazilati M, Gharib-Naseri M, Sarkaki A. Gallic acid and exercise training improve motor function, nerve conduction velocity but not pain sense reflex after experimental sciatic nerve crush in male rats. Avicenna J Phytomed 2015; 5:288-297.
130
132. Hajipour S, Sarkaki A, Farbood Y, Eidi A, Mortazavi P, Valizadeh Z. Effect of gallic acid on dementia type of Alzheimer disease in rats: electrophysiological and histological studies. Basic Clin Neurosci 2016; 7:97-106.
131
133. Kade I, Rocha J. Gallic acid modulates cerebral oxidative stress conditions and activities of enzyme-dependent signaling systems in streptozotocin-treated rats. Neurochem Res 2013; 38:761-771.
132
134. Kim M, Seong A, Yoo J, Jin C, Lee Y, Kim Y, et al. Gallic acid, a histone acetyltransferase inhibitor, suppresses beta-amyloid neurotoxicity by inhibiting microglial-mediated neuroinflammation. Mol Nutr Food Res 2011; 55:1798-1808.
133
135. Korani M, Farbood Y, Sarkaki A, Fathi Moghaddam H, Mansouri M. Protective effects of gallic acid against chronic cerebral hypoperfusion-induced cognitive deficit and brain oxidative damage in rats. Eur J Pharmacol 2014; 733:62-67.
134
136. Lu Z, Nie G, Belton P, Tang H, Zhao B. Structure–activity relationship analysis of antioxidant ability and neuroprotective effect of gallic acid derivatives. Neurochem Int 2006; 48:263-274.
135
137. Zhang Q, Chen W, Zhao J, Xi W. Functional constituents and antioxidant activities of eight Chinese native goji genotypes. Food Chem 2016; 200:230-236.
136
138. Yigitturk G, Acara A, Erbas O, Oltulu F, Yavasoglu N, Uysal A, et al. The antioxidant role of agomelatine and gallic acid on oxidative stress in STZ induced type I diabetic rat testes. Biomed Pharmacother 2017; 87:240-246.
137
139. Giftson Senapathy J, Jayanthi S, Viswanathan P, Umadevi P, Nalini N. Effect of gallic acid on xenobiotic metabolizing enzymes in 1,2-dimethyl hydrazine induced colon carcinogenesis in Wistar rats – a chemopreventive approach. Food Chem Toxicol 2011; 49:887-892.
138
140. Ji B, Hsu W, Yang J, Hsia T, Lu C, Chiang J, et al. Gallic acid induces apoptosis via caspase-3 and mitochondrion-dependent pathways in vitro and suppresses lung xenograft tumor growth in vivo. J Agric Food Chem 2009; 57:7596-7604.
139
141. Kawada M, Ohno Y, Ri Y, Ikoma T, Yuugetu H, Asai T, et al. Anti-tumor effect of gallic acid on LL-2 lung cancer cells transplanted in mice. Anticancer Drugs 2001; 12:847-852.
140
142. Nakamura E, Kurosaki F, Arisawa M, Mukainaka T, Takayasu J, Okuda M, et al. Cancer chemopreventive effects of a Brazilian folk medicine, Juca, on in vivo two-stage skin carcinogenesis. J Ethnopharmacol 2002; 81:135-137.
141
143. Thiele W, Rothley M, Teller N, Jung N, Bulat B, Plaumann D, et al. Delphinidin is a novel inhibitor of lymphangiogenesis but promotes mammary tumor growth and metastasis formation in syngeneic experimental rats. Carcinogenesis 2013; 34:2804-2813.
142
ORIGINAL_ARTICLE
Clonal dissemination of Staphylococcus aureus isolates causing nosocomial infections, Tehran, Iran
Objective(s): In the current research, the prevalence of Staphylococcus aureus clones and genes encoding antimicrobial resistance and toxins were examined among 120 S. aureus strains from nosocomial infections in tehran, Iran.Materials and Methods: Antimicrobial susceptibility was examined, based on disk diffusion and PCR method to identify resistance and toxin-encoding genes. Based on the polymorphisms in SCCmec, agr, spa, and MLST, the isolates were typed. Results: Among 120 S. aureus isolates, 85 (70.8%) were methicilin resistant S. aureus (MRSA), and 35 (29.2%) were methicilin sensetive S. aureus (MSSA). The tested isolates contained resistance genes, including ant(4΄)-Ia (90%), aac(6΄)-Ie/aph(2˝) (80%), aph(3΄)-IIIa (30%), erm(A) (26.7%), erm(B) (10.8%), erm(C) (11.7%), msr(A) (40.8%), msr(B) (14.2%), tet(M) (45.8%), and mupA (8.3%). The MRSA strains were clustered into six different clones. The most common genotypes included ST239-SCCmec III/t037 (23.3%), ST239-SCCmec III/t388 (22.5%), ST22-SCCmec IV/t790 (8.3%), ST15-SCCmec IV/t084 (7.5%), ST585-SCCmec III/t713 (5%), and ST239-SCCmec III/t924 (4.2%), respectively. ST182/t196 (8.3%) and ST123/t171 (5%) belonged exclusively to MSSA strains. Overall, 10 (66.7%) and 5 (33.3%) out of 15 isolates with pvl genes were attributed to clones ST22-SCCmec IV/t790 and ST15-SCCmec IV/t084, respectively. ST22-SCCmec IV/t790, ST239-SCCmec III/t037, and ST15-SCCmec IV/t084, were related to high-level mupirocin-resistant phenotypes. Conclusion: The genetic diversity of S. aureus was confirmed in our hospitals, and ST239-SCCmec III/t037 showed a relatively high prevalence in our study. It seems that assessment of resistance and virulence genes in different S. aureus molecular types is necessary for proper antibiotic consumption.
https://ijbms.mums.ac.ir/article_12031_b31d72e5fe0d98edb3165a3a9a42d777.pdf
2019-03-01
238
245
10.22038/ijbms.2018.30067.7245
Staphylococcus aureus
SCCmec
agr
MLST
MRSA
spa
Mehdi
Goudarzi
m.goudarzi@sbmu.ac.ir
1
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Gita
Eslami
gita_eslami@yahoo.com
2
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Razieh
Rezaee
rominarezaee@yahoo.com
3
Microbiology Department, Faculty of Biological Sciences, Shahid Beheshti University, Tehran, Iran
AUTHOR
Mohsen
Heidary
mohsenheidary40@gmail.com
4
Department of Medical Microbiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
saeed
khoshnood
saeed.khoshnood22@gmail.com
5
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Raheleh
Sajadi Nia
rahelehsajadinia@yahoo.com
6
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
1. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015;28:603-661.
1
2. Dulon M, Haamann F, Peters C, Schablon A, Nienhaus A. MRSA prevalence in European healthcare settings: a review. BMC Infect Dis 2011;11:138-151.
2
3. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-182.
3
4. Boye K, Bartels MD, Andersen IS, Moeller JA, Westh H. A new multiplex PCR for easy screening of methicillin-resistant Staphylococcus aureus SCCmec types I–V. Clin Microbiol Infect 2007;13:725-727.
4
5. Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, et al. Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents 2012;39:273-282.
5
6. Seyedi Marghaki F, Kalantar-Neyestanaki D, Safaari F, Fasihi Y, Moradi M. Frequency of aminoglycoside-resistance genes in methicillin resistant Staphylococcus aureus isolated from clinical specimens. J Mazandaran Univ Med Sci 2017;27:112-117.
6
7. Houghton JL, Green KD, Chen W, Garneau‐Tsodikova S. The future of aminoglycosides: the end or renaissance? ChemBioChem 2010;11:880-902.
7
8. Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother 2003;51:613-617.
8
9. Steward CD, Raney PM, Morrell AK, Williams PP, McDougal LK, Jevitt L, et al. Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J Clin Microbiol 2005;43:1716-1721.
9
10. Japoni-Nejad A, Rezazadeh M, Kazemian H, Fardmousavi N, van Belkum A, Ghaznavi-Rad E. Molecular characterization of the first community-acquired methicillin-resistant Staphylococcus aureus strains from Central Iran. I International J Infect Dis 2013;17:949-954.
10
11. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 27th Informational Supplement. 2017 CLSI document M100-S27 (ISBN 1-56238-805-3).
11
12. Goudarzi M, Seyedjavadi SS, Nasiri MJ, Goudarzi H, Nia RS, Dabiri H. Molecular characteristics of methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from patients with bacteremia based on MLST, SCCmec, spa, and agr locus types analysis. Microb Pathog 2017;104:328-335.
12
13. Alfatemi SMH, Motamedifar M, Hadi N, Saraie HSE. Analysis of virulence genes among methicillin resistant Staphylococcus aureus (MRSA) strains. Jundishapur J Microbiol 2014;7:e10741.
13
14. Ardic N, Sareyyupoglu B, Ozyurt M, Haznedaroglu T, Ilga U. Investigation of aminoglycoside modifying enzyme genes in methicillin-resistant staphylococci. Microbiol Res 2006;161:49-54.
14
15. Martineau F, Picard FJ, Lansac N, Ménard C, Roy PH, Ouellette M, et al. Correlation between the resistance genotype determined by multiplex PCR assays and the antibiotic susceptibility patterns of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 2000;44:231-238.
15
16. Lina G, Quaglia A, Reverdy M-E, Leclercq R, Vandenesch F, Etienne J. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999;43:1062-1066.
16
17. Udo E, Jacob L, Mathew B. Genetic analysis of methicillin-resistant Staphylococcus aureus expressing high-and low-level mupirocin resistance. J Med Microbiol 2001;50:909-915.
17
18. Gilot P, Lina G, Cochard T, Poutrel B. Analysis of the genetic variability of genes encoding the RNA III-activating components Agr and TRAP in a population of Staphylococcus aureus strains isolated from cows with mastitis. J Clin Microbiol 2002;40:4060-4067.
18
19. Harmsen D, Claus H, Witte W, Rothgänger J, Claus H, Turnwald D, et al. Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 2003;41:5442-5448.
19
20. Ko KS, Lee J-Y, Suh JY, Oh WS, Peck KR, Lee NY, et al. Distribution of major genotypes among methicillin-resistant Staphylococcus aureus clones in Asian countries. J Clin Microbiol 2005;43:421-426.
20
21. Ida T, Okamoto R, Shimauchi C, Okubo T, Kuga A, Inoue M. Identification of aminoglycoside-modifying enzymes by susceptibility testing: epidemiology of methicillin-resistant Staphylococcus aureus in Japan. J Clin Microbiol 2001;39:3115-3121.
21
22. Shahsavan S, Emaneini M, Khoshgnab BN, Khoramian B, Asadollahi P, Aligholi M, et al. A high prevalence of mupirocin and macrolide resistance determinant among Staphylococcus aureus strains isolated from burnt patients. Burns 2012;38:378-382.
22
23. Gadepalli R, Dhawan B, Mohanty S, Kapil A, Das BK, Chaudhry R, et al. Mupirocin resistance in Staphylococcus aureus in an Indian hospital. Diagn Microbiol Infect Dis 2007;58:125-127.
23
24. Aqel A, Ibrahim A, Shehabi A. Rare occurrence of mupirocin resistance among clinical Staphylococcus isolates in Jordan. Acta Microbiol Immunol Hung 2012;59:239-247.
24
25. Nezhad RR, Meybodi SM, Rezaee R, Goudarzi M, Fazeli M. Molecular characterization and resistance profile of methicillin resistant Staphylococcus aureus strains isolated from hospitalized patients in intensive care unit, Tehran-Iran. Jundishapur J Microbiol 2017;10:e41666.
25
26. Schreckenberger PC, Ilendo E, Ristow KL. Incidence of constitutive and inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci in a community and a tertiary care hospital. J Clin Microbiol 2004;42:2777-2779.
26
27. Fiebelkorn K, Crawford S, McElmeel M, Jorgensen J. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 2003;41:4740-4744.
27
28. Lavallée C, Rouleau D, Gaudreau C, Roger M, Tsimiklis C, Locas M-C, et al. Performance of an agar dilution method and a Vitek 2 card for detection of inducible clindamycin resistance in Staphylococcus spp. J Clin Microbiol 2010;48:1354-1357.
28
29. Monecke S, Coombs G, Shore AC, Coleman DC, Akpaka P, Borg M, et al. A field guide to pandemic, epidemic and sporadic clones of methicillin-resistant Staphylococcus aureus. PloS one 2011;6:e17936.
29
30. Monecke S, Skakni L, Hasan R, Ruppelt A, Ghazal SS, Hakawi A, et al. Characterisation of MRSA strains isolated from patients in a hospital in Riyadh, Kingdom of Saudi Arabia. BMC Microbiol 2012;12:146-155.
30
31. Ohadian Moghadam S, Pourmand MR, Mahmoudi M, Sadighian H. Molecular characterization of methicillin-resistant Staphylococcus aureus: characterization of major clones and emergence of epidemic clones of sequence type (ST) 36 and ST 121 in Tehran, Iran. FEMS Microbiol Lett 2015;362: fnv043.
31
32. Ho C-M, Ho M-W, Li C-Y, Lu J-J. Fine typing of methicillin-resistant Staphylococcus aureus isolates using direct repeat unit and staphylococcal interspersed repeat unit typing methods. J Microbiol Immunol Infect 2015;48:370-375.
32
33. Ellington MJ, Ganner M, Warner M, Cookson BD, Kearns AM. Polyclonal multiply antibiotic-resistant methicillin-resistant Staphylococcus aureus with Panton–Valentine leucocidin in England. J Antimicrob Chemother 2009;65:46-50.
33
34. Udo E, O’brien F, Al-Sweih N, Noronha B, Matthew B, Grubb W. Genetic lineages of community-associated methicillin-resistant Staphylococcus aureus in Kuwait hospitals. J Clin Microbiol 2008; 46:3514-3516.
34
35. Nadig S, Raju SR, Arakere G. Epidemic meticillin-resistant Staphylococcus aureus (EMRSA-15) variants detected in healthy and diseased individuals in India. J Med Microbiol 2010;59:815-821.
35
36. Rolo J, Miragaia M, Turlej-Rogacka A, Empel J, Bouchami O, Faria NA, et al. High genetic diversity among community-associated Staphylococcus aureus in Europe: results from a multicenter study. PloS one 2012;7:e34768.
36
37. Rasigade J-P, Laurent F, Lina G, Meugnier H, Bes M, Vandenesch F, et al. Global distribution and evolution of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus, 1981–2007. J Infect Dis 2010;201:1589-1597.
37
ORIGINAL_ARTICLE
Effect of intracerebroventricular injection of GABA receptors antagonists on morphine-induced changes in GABA and GLU transmission within the mPFC: an in vivo microdialysis study
Objective(s): Many studies have focused on ventral tegmental area than of other mesocorticolimbic areas, and implicated a key role for the medial prefrontal cortex (mPFC) in the development of addictive behaviors. So far, the role of gamma-aminobutyric acid (GABA) receptors in the discriminative properties of morphine has received little attention and few studies evaluated the role of these receptors in drug dependence. Hence, we investigated the role of this receptor on morphine- induced GABA/ glutamate (GLU) changes in the mPFC following morphine administration using in vivo microdialysis.Materials and Methods: In this study, 60 rats weighing 270-300 g were divided into six groups. First, microdialysis probe was inserted into the mPFC and was perfused with artificial cerebrospinal fluid and collected the baseline samples in all groups. In saline and morphine groups, the saline, in phaclophen and (phaclofen+morphine) groups, phaclofen (100 nmol), and in bicuculline and (bicuculline+morphine) groups, bicuculline (20 nmol) was injected intracerebroventricular. In saline, phaclofen and bicuculline groups 20 min later, animals received saline (0.2 ml, IP) and others groups received morphine (20 mg/kg, IP).Results: Our results showed that morphine increased the average concentration of GABA and decreased the concentration of GLU within mPFC. Pretreatment with phaclofen and bicuculline 20 min before morphine administration had no effect on GABA and GLU release for 100 min.Conclusion: The present study indicated that morphine influence the GABA and GLU transmission in mPFC. Therefore evaluation of neurochemistry changes of this neural circuitry may provide further insight into the mechanisms underlying drug dependence.
https://ijbms.mums.ac.ir/article_12168_9216e0819cbea524bcf4a2a96021792b.pdf
2019-03-01
246
250
10.22038/ijbms.2019.28478.6925
Addiction
GABA-A receptor antagonists GABA-B receptor antagonists Morphine Prefrontal cortex
Effat
Ramshini
effat.ramshini@yahoo.com
1
Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Hojjat allah
Alaei
alaei@med.mui.ac.ir
2
Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Parham
Reisi
reisi@yahoo.com
3
Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
naser
Naghdi
naghdi@yahoo.com
4
Department of Physiology, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Hossein
Afrozi
afrozi@yahoo.com
5
Drug Research Center of Daropakhsh, Tehran, Iran
AUTHOR
Samaneh
Alaei
samaneh_alaei@yahoo.com
6
Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Maryam
Alehashem
maryamalehashem@yahoo.com
7
Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Shahrzad
Eftekharvaghefi
shahrzad.eftekharvaghefi@yahoo.com
8
Department of Physiology, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
1. Gao H, Xiang Y, Sun N, Zhu H, Wang Y, Liu M, et al. Metabolic changes in rat prefrontal cortex and hippocampus induced by chronic morphine treatment studied ex vivo by high resolution 1H NMR spectroscopy. Neurochem Int 2007; 50: 386-394.
1
2. De Vries TJ, Shippenberg TS. Neural systems underlying opiate addiction. J Neurosci 2002; 22: 3321-3325.
2
3. Van den Oever MC, Spijker S, Smit AB, De Vries TJ. Prefrontal cortex plasticity mechanisms in drug seeking and relapse. Neurosci. Biobehav. Rev 2010; 35: 276-284.
3
4. Xi Z-X, Gardner EL. Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Current drug abuse reviews 2008; 1: 303-327.
4
5. Fattore L, Fadda P, Spano M, Pistis M, Fratta W. Neurobiological mechanisms of cannabinoid addiction. Mol Cell Endocrinol 2008; 286: 97-107.
5
6. Diaz SL, Barros VG, Antonelli MC, Rubio MC, Balerio GN. Morphine withdrawal syndrome and its prevention with baclofen: Autoradiographic study of μ‐opioid receptors in prepubertal male and female mice. SYNAPSE 2006; 60: 132-140.
6
7. Bartoletti M, Colantoni A, De Luca V, Gaiardi M. Single and repeated baclofen treatment attenuates the discriminative stimulus effects of morphine in rats. Pharmacol Biochem Behav 2010; 97: 279-283.
7
8. Nakagawa T, Kaneko S. Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3, 4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N, N-diisopropyltryptamine (foxy). Pharmacol Biochem Behav 2008; 106: 2-8.
8
9. Giacchino J, Henriksen S. Systemic morphine and local opioid effects on neuronal activity in the medial prefrontal cortex. Neuroscience 1996; 70: 941-949.
9
10. Huang C-C, Lin H-J, Hsu K-S. Repeated cocaine administration promotes long-term potentiation induction in rat medial prefrontal cortex. Cereb Cortex 2006; 17: 1877-1888.
10
11. Li Y, Fang F, Wang X, Lei H. Neuronal projections from ventral tegmental area to forebrain structures in rat studied by manganese-enhanced magnetic resonance imaging. Magn Reson Imaging 2009; 27: 293-299.
11
12. Rozeske RR, Der-Avakian A, Bland ST, Beckley JT, Watkins LR, Maier SF. The medial prefrontal cortex regulates the differential expression of morphine-conditioned place preference following a single exposure to controllable or uncontrollable stress. Neuropsychopharmacology 2009; 34: 834-843.
12
13. Harte M, O’Connor W. Evidence for a selective prefrontal cortical GABA B receptor-mediated inhibition of glutamate release in the ventral tegmental area: a dual probe microdialysis study in the awake rat. Neuroscience 2005; 130: 215-222.
13
14. Zarrindast M-R, Hoghooghi V, Rezayof A. Inhibition of morphine-induced amnesia in morphine-sensitized mice: involvement of dorsal hippocampal GABAergic receptors. Neuropharmacology 2008; 54: 569-576.
14
15. Padgett CL, Lalive AL, Tan KR, Terunuma M, Munoz MB, Pangalos MN, et al. Methamphetamine-evoked depression of GABA B receptor signaling in GABA neurons of the VTA. Neuron 2012; 73: 978-989.
15
16. Ridderinkhof KR, Nieuwenhuis S, Braver TS. Medial frontal cortex function: An introduction and overview. Cogn Affect Behav Neurosci 2007; 7: 261-265.
16
17. Jinno S. Structural organization of long-range GABAergic projection system of the hippocampus. Front Neurosci 2009; 3: 13-21.
17
18. Heinrichs S, Leite-Morris K, Carey R, Kaplan G. Baclofen enhances extinction of opiate conditioned place preference. Behav Brain Res 2010; 207: 353-359.
18
19. Nasif FJ, Hu X-T, White FJ. Repeated cocaine administration increases voltage-sensitive calcium currents in response to membrane depolarization in medial prefrontal cortex pyramidal neurons. J Neurosci 2005; 25: 3674-3679.
19
20. Torregrossa MM, Kalivas PW. Microdialysis and the neurochemistry of addiction. Pharmacol Biochem Behav 2008; 90: 261-272.
20
21. Talkhooncheh M, Alaei HA, Ramshini E, Shahidani S. The effect of vitamin C on morphine self-administration in rats. Adv Biomed Res 2014; 3: 178-186.
21
22. Radahmadi M, Ramshini E, Hosseini N, Karimi S, Alaei H. Effect of electrical stimulation of nucleus accumbens with low, median and high currents intensities on conditioned place preference induced by morphine in rats. Adv Biomed Res 2014; 3: 14-22.
22
23. Giuliani S, Lecci A, Santicioli P, Del Bianco E, Maggi C. Effect of the GABAB antagonist, phaclofen, on baclofen-induced inhibition of micturition reflex in urethane-anesthetized rats. Neuroscience 1992; 48: 217-223.
23
24. Rodrigues MCA, de Oliveira Beleboni R, Coutinho-Netto J, dos Santos WF, Garcia-Cairasco N. Behavioral effects of bicuculline microinjection in the dorsal versus ventral hippocampal formation of rats, and control of seizures by nigral muscimol. J Epilepsy Res 2004; 58: 155-165.
24
25. Paxinos G, Watson C. The rat brain in stereotaxic coordinates: Elsevier Academic Press. San Diego, CA. 2005.
25
26. Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 2011; 31: 13110-13117.
26
27. De Freitas Silva DM, Ferraz VP, Ribeiro ÂM. Improved high-performance liquid chromatographic method for GABA and glutamate determination in regions of the rodent brain. J Neurosci Methods 2009; 177: 289-293.
27
28. Kim HJ, Baburin I, Zaugg J, Ebrahimi SN, Hering S, Hamburger M. HPLC-based activity profiling–discovery of sanggenons as GABAA receptor modulators in the traditional Chinese drug sang bai pi (Morus alba root bark). Planta Med 2012; 78: 440-447.
28
29. Kang L, Dai Z-Z, Li H-H, Ma L. Environmental cues associated with morphine modulate release of glutamate and gamma-aminobutyric acid in ventral subiculum. Neurosci Bull 2006; 22: 255-260.
29
30. Sun JY, Yang JY, Wang F, Wang JY, Song W, Su GY, et al. Lesions of nucleus accumbens affect morphine‐induced release of ascorbic acid and GABA but not of glutamate in rats. Addict Biol 2011; 16: 540-550.
30
31. Caillé S, Parsons LH. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology 2006; 31: 804-813.
31
32. Hoshi K, Yamamoto A, Ishizuki S, Fujihira E, Ichihara K. Excitatory amino acid release in the locus coeruleus during naloxone-precipitated morphine withdrawal in adjuvant arthritic rats. Inflamm Res 2000; 49: 36-41.
32
33. Jayaram P, Steketee JD. Effects of cocaine‐induced behavioural sensitization on GABA transmission within rat medial prefrontal cortex. Eur J Neurosci 2005; 21: 2035-2039.
33
34. Lelevich V, Lelevich S, Doroshenko E. Neuromediator changes in different rat brain regions after acute morphine intoxication. J Neurochem 2009; 3: 49-53.
34
ORIGINAL_ARTICLE
Therapeutic effect of valsartan against doxorubicin-induced renal toxicity in rats
Objective(s): Doxorubicin (DXR)-induces glomerular atrophy and fibrosis in rat kidneys. The objective of the current study was to investigate the protective effects of valsartan on DXR-induced glomerular toxicity and its mechanisms of actions in rats. Materials and Methods: Male Sprague-Dawley (SD) rats were divided into four groups, and each group contains ten rats. First group was control and was treated with saline only. Treatment groups were injected with DXR (6.5 mg/kg) alone, or intragastric gavage with 10 mg/kg or 20 mg/kg of valsartan after DXR treatment.Results: Rats treated with DXR only showed significant changes in concentrations of urinary protein, serum creatinine (SCr), and blood urea nitrogen (BUN). Moreover, glomerular structural damages were observed in rats treated with DXR. Valsartan significantly alleviated the effect of DXR. Dramatic elevation in malondialdehyde (MDA), nitric oxide (NO), nitric oxide synthase (NOS) and significant reductions in the levels of reduced glutathione (GSH), glutathione peroxidase (GPx), superoxide dismutase (SOD) were seen after DXR treatment. These effects were effectively ameliorated by co-administration with valsartan. Conclusion: The findings of our study indicate that valsartan may play an important role in protecting DXR-induced renal toxicity, at least in part, through its antioxidant properties.
https://ijbms.mums.ac.ir/article_12203_3c0df9b265f5dcc1ffb9b99ed03e16e2.pdf
2019-03-01
251
254
10.22038/ijbms.2019.32871.7851
Antioxidants
Doxorubicin
Histopathology
Nephrotoxicity
Valsartan
Hai-Xia
Liu
251352054@qq.com
1
Department of Pharmacology, City College, Wuhan University of Science and Technology, Wuhan, China
AUTHOR
Jin
Li
pearli1980@126.com
2
Department of Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, China
AUTHOR
Qi-Xiong
Li
1015563065@qq.com
3
Department of Pharmacology, City College, Wuhan University of Science and Technology, Wuhan, China
LEAD_AUTHOR
1. Saad SY, Najjar TA, Al-Rýkabý AC, et al. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 2001; 43: 211–218.
1
2. Liu LL, Li QX, Lin Xia, Li J, Shao L. Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats. Toxicology 2007; 231:81–90.
2
3. Criscione L, Gasparo M, Bühlmayer P, Whitebread S, Ramjoué HP, Wood J. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 1993; 110:761–771.
3
4. Müller P, Cohen T, Gasparo M, Sioufi A, RacinePA, Howald H, et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47:231–245.
4
5. Wang Y, Wei RB, Yang Y, Su TY, Huang MJ, Li P, Chen XM, et al. Valsartan alleviates insulin resistance in skeletal muscle of chronic renal failure rats. Med Sci Monit 2018; 24:2413–2419.
5
6. Wu K, Zhou T, Sun G, Wang W, Zhang Y, et al. Valsartan inhibited the accumulation of dendritic cells
6
in rat fibrotic renal tissue. Cellular & Molecular Immunology 2006; 3:213–220.
7
7. Raeisi S, Ghorbanihaghjo A, Argani H, Dastmalchi S, Ghasemi B, et al. The effects of valsartan on renal glutathione peroxidase expression in alleviation of cyclosporine nephrotoxicity in rats. Bioimpacts Bi 2016; 6:119–124.
8
8. Gervasini G, Robles N R. Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug. Expert Opinion on Investigational Drugs 2017; 26:651–659.
9
9. Salant DJ, Ybulsky AV. Experimental glomerulonephritis. Meth Enzymol 1988; 162:421–461.
10
10. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95:351–358.
11
11. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autooxidation of pyrogallol and convenient assay for superoxide dismutase. Eur J Biochem 1974; 47:469–474.
12
12. Beutler E, Durom O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963; 61: 882–888.
13
13. Flohe L, Gunzler WA. Assays of glutathione peroxidase. Methods Enzymol 1984; 105:114–121.
14
14. Stuehr DJ, Know NS, Gross SS. Synthesis of nitrogen oxides from l-arginine by macrophage cytosol: requirement for inducible and constitutive components. Biochem Biophys Res Commun 1989; 161:420–426.
15
15. Lowry OH, Rosebrough NJ, Far AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193:265–275.
16
16. Luis MR, Jean CA, Claudio P, Pascale OS, Florence B, Johannes F M, et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J Hypertens 2000; 18:89–95.
17
17. Sun Y, Peng PA, Ma Y. Valsartan protects against contrast-induced acute kidney injury in rats by inhibiting endoplasmic reticulum stress-induced apoptosis. Curr Vasc Pharmacol 2017; 15:174–183.
18
18. Wu K, Zhou T, Sun G, Wang W, Zhang Y, et al. Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue. Cell Mol Immunol 2006; 3:213-220.
19
19. De BEL, Bottone AE, Voest, EE. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. Eur J Pharmacol 2001; 415:1–11.
20
20. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000; 207:77–86.
21
21. Fujihara CK, Sena CR, Malheiros DM, Mattar AL, Zatz R. Shortterm nitric oxide inhibition induces progressive nephropathy after regression of initial renal injury. Am J Physiol Renal Physiol 2006; 290:632–640.
22
22. Passauer J, Pistrosch F, Bussemaker E. Nitric oxide in chronic renal failure. Kidney Int 2005; 67:1665–1667.
23
23. Dobashi K, Ghosh B, Orak JK, Singh I, Singh AK. Kidney ischemia-reperfusion: modulation of antioxidant defenses. Mol Cell Biochem 2000; 205:1-11.
24
ORIGINAL_ARTICLE
The effect of alpha linolenic acid on tracheal responsiveness, lung inflammation and immune markers in sensitized rats
Objective(s): The effects of alpha linolenic acid (ALA) on tracheal responsiveness (TR), total protein (TP), phospholipase A2 (PLA2), immunoglobulin E (IgE), interleukin 4 (IL-4), interferon gamma (INF-γ) level and INF-γ/IL4 ratio in bronchoalveolar lavage fluid (BALF) of sensitized rats were examined.Materials and Methods: TR to methacholine and ovalbumin (OA), BALF levels of TP, PLA2 and IgE as well as IL-4, INF-γ and INF-γ/IL4 ratio were measured in control group (non-sensitized, group C), sensitized rats to OA (group S), S groups treated with two concentrations of ALA and dexamethasone group. Results: TR to methacholine and OA, BALF levels of TP, PLA2, IgE and IL-4 were significantly increased but BALF level of INF-γ and INF-γ/IL4 ratio decreased in group S compared to group C (PConclusion: Results showed an immune modulatory effect of the ALA that increased INF-γ, INF-γ/IL4 ratio (as an index of Th1/Th2) and decreased IL-4 in sensitized rats. ALA also showed preventive effect on inflammatory markers and tracheal responsiveness in sensitized animals comparable to the effect of dexamethasone.
https://ijbms.mums.ac.ir/article_12205_fde96d7a1b2cec3ffcffd688df151938.pdf
2019-03-01
255
261
10.22038/ijbms.2019.27381.6684
Asthma
Alpha linolenic acid
Inflammatory markers
Sensitized rats
Th1/Th2 balance
Tracheal responsiveness
Mahsa
Kaveh
kaveh-mahsa@yahoo.com
1
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Naeima
Eftekhar
naeimaeftekhar@yahoo.com
2
Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Iran
AUTHOR
Mohammad Hossein
Boskabady
boskabadymh@mums.ac.ir
3
Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1.Barbato A, Turato G, Baraldo S, Bazzan E, Calabrese F, Tura M, et al. Airway inflammation in childhood asthma. Am J Respir Crit Care Med 2003; 168:798–803.
1
2.Boulet LP. Physiopathology of airway hyperresponsiveness. Curr Allergy Asthma Rep 2003; 3:166–171.
2
3.Brannan JD, Lougheed MD. Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment. Front Physiol 2012; 3:1-11.
3
4.Vadas P, Pruzanski W. Role of secretory phospholipase A2 in the pathology of disease. Lab Invest 1986; 55:391-404.
4
5.Kashima N, Nakajima H, Katsura T, Sugihara S, Fukaura A, Takahashi T. Study of serum phosholipase A2 activity in bronchial asthmatic patients. Arerugi 1993; 42:723-727.
5
6.Qureshi S, Memon SA, Laghari AJ, Ghanghro AB. Metabolic total protein investigation in local industry workers exposed to acid anhydrids. Sindh Univ Res J 2009; 41:63-66.
6
7.Kelly C, Ward C, Stenton CS, Bird G, Hendrick DJ, Walters EH. Numbers and activity of cells obtained at bronchoalveolar lavage in asthma, and their relationship to airway responsiveness. Thorax 1998; 43:684–692.
7
8.Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004; 22:789–815.
8
9.Randolph DA, Stephens R, Carruthers CJLD. Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J Clin Invest 1999; 104:1021–1029.
9
10.Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641–648.
10
11.Busse WW, Coffman RL, Gelfand EW, Kay AB, Rosenwasser LJ. Mechanisms of persistent airway inflammation in asthma: a role for T cells and T-cell products. Am J Respir Crit Care Med 1995; 152:388–393.
11
12.Ren J, Chung SH. Anti-inflammatory effect of α-linolenic acid and its mode of action through the inhibition of nitric oxide production and inducible nitric oxide synthase gene expression via NF-κB and mitogen-activated protein kinase pathways. J Agric Food Chem 2007; 55:5073–5080.
12
13.Anand R, Kaithwas G. Anti-inflammatory potential of alpha-linolenic acid mediated through selective COX inhibition: computational and experimental data. Inflammation 2014; 37: 1297-1306.
13
14.Erdinest N, Shmueli O, Grossman Y, Ovadia H, Solomon A. Anti-inflammatory effects of alpha linolenic acid on human corneal epithelial cells. Invest Ophthalmol Vis Sci 2012; 53: 4396-4406.
14
15.Wendell SG, Baffi C, Holguin F. Fatty acids, inflammation and asthma. J Allergy Clin Immunol 2014; 133:1255–1264.
15
16.Kaithwas G, Mukherjee A, Chaurasia AK, Majumdar DK. Anti-inflammatory, analgesic and antipyretic activities of Linum usitatissimum L. (flaxseed/linseed) fixed oil. Indian J Exp Biol 2011; 49:932-938.
16
17.Francès H, Coudereau JP, Sandouk P, Clément M, Monier C, Bourre JM. Influence of a dietary alpha-linolenic acid deficiency on learning in the Morris water maze and on the effects of morphine. Eur J Pharmacol 1996; 18; 298:217-225.
17
18.Huang CB, Ebersole JL. A novel bioactivity of omega-3 polyunsaturated fatty acids and their ester derivatives. Mol Oral Microbiol 2010; 25:75-80.
18
19.Lee JY, Kim YS, Shin DH. Antimicrobial synergistic effect of linolenic acid and monoglyceride against Bacillus cereus and Staphylococcus aureus. J Agric Food Chem 2002; 50:2193-2199.
19
20.Dhar P, Chattopadhyay K, Bhattacharyya D, Roychoudhury A, Biswas A, Ghosh S. Antioxidative effect of conjugated linolenic acid in diabetic and non-diabetic blood: an in vitro study. J Oleo Sci 2006; 56:19-24.
20
21.Simopoulos AP. Omega-3 fatty acids and antioxidants in edible wild plants. Biol Res 2004; 37:263-277.
21
22.Blondeau N, Lipsky RH, Bourourou M, Duncan MW, Gorelick PB, Marini AM. Alpha-linolenic acid: an omega-3 fatty acid with neuroprotective properties—ready for use in the stroke clinic? Biomed Res Int 2015; 2015:1-8.
22
23.Pan H, Hu XZ, Jacobowitz DM, Chen C, McDonough J, Van Shura K, et al. Alpha-linolenic acid is a potent neuroprotective agent against soman-induced neuropathology. Neurotoxicology 2012; 33:1219-1229.
23
24.Pan H, Piermartiri TC, Chen J, McDonough J, Oppel C, Driwech W, et al. Repeated systemic administration of the nutraceutical alpha-linolenic acid exerts neuroprotective efficacy, an antidepressant effect and improves cognitive performance when given after soman exposure. Neurotoxicology 2015; 51:38-50.
24
25.Jeromson S, Gallagher IJ, Galloway SDR, Hamilton DL. Omega-3 fatty acids and skeletal muscle health. Mar Drugs 2015; 13:6977–7004.
25
26.Cornish SM, Chilibeck PD. Alpha-linolenic acid supplementation and resistance training in older adults. Appl Physiol Nutr Metab 2009; 34:49-59.
26
27.Mizota T, Fujita-Kambara C, Matsuya N, Hamasaki S, Fukudome T, Goto H, et al. Effect of dietary fatty acid composition on Th1/Th2 polarization in lymphocytes. JPEN J Parenter Enteral Nutr 2009; 33:390-396.
27
28.Kankaanpää P, Sütas Y, Salminen S, Lichtenstein A, Isolauri E. Dietary fatty acids and allergy. Ann Med 1999; 31:282-287.
28
29.Salmon M, Walsh D, Huang T, Barnes P, Leonard T, Hay D, et al. Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats. Br J Pharmacol 1999; 127:1151-1158.
29
30.Kaveh M, Akram E, Nemati A, Boskabady MH. The extract of Portulaca oleracea and its constituent, alpha linolenic acid affects serum oxidantlevels and inflammatory cells in sensitized rats. Iran J Allergy Asthma Immunol 2017; 16:256-270.
30
31.Kianmeher M, Ghorani V, Boskabady MH. Animal model of asthma, various methods and measured parameters: a methodological review. Iran J Allergy Asthma Immunol 2017; 15:445-65.
31
32.Shakeri F, Soukhtanloo M, Boskabady MH. The effect of hydro-ethanolic extract of Curcuma longa rhizome and curcumin on total and differential WBC and serum oxidant, antioxidant biomarkers in rat model of asthma. Iran J Basic Med Sci 2017; 20:155-165.
32
33.Boskabady MH, Bayrami G. The effect of safranal on tracheal responsiveness and white blood cells count in lung lavage of sensitized guinea-pigs. Pharmacol Rep 2014; 66: 56–61.
33
34.Shakeri F, Boskabady MH. Anti-inflammatory, antioxidant and immunomodulatory effects of curcumin in ovalbumin-sensitized rat. BioFactors, 217; 43:567-576.
34
35.Keyhanmanesh R, Boskabady MH, Khamneh S, Ebrahimi MA. The effect of thymoquinone, the main constituent of Nigella sativa on tracheal responsiveness and WBC count in lung lavage of sensitized guinea-pigs. Planta Med 2010; 76:218–222
35
36.Boskabady MH, Ziaei T. Effect of ascorbic acid on airway responsiveness in ovalbumin sensitized guinea pigs. Respirology 2003; 8:473-478.
36
37.Boskabady MH, Mehrjardi SS, Rezaee A, Rafatpanah H, jalali S. The impactof Zataria multiflora Boiss extracton in vitro and in vivo Th1/Th2 cytokine (IFN-γ/IL4) balance. J Ethnopharmacpol 2013; 150:1024-1031.
37
38.Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, Van Der Meer JW, et al. The effect of dietary supplementation with n—3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320:265-271.
38
39.Sun P, Wang J, Yang G, Khas-Erdene, Liu Q. Effects of different doses of free alpha-linolenic acid infused to the duodenum on the immune function of lactating dairy cows. Arch Anim Nutr 2010; 64:504-513.
39
40.Askari VR, Rezaei A, Boskabady MH, Sadeghnia H, Abnus K, Iranshahi M. The influence of hydro-ethanolic extract of Portulaca oleracea on Th1/Th2 balance in isolated human lymphocytes. J Ethnopharmacol 2016; 16:31626-31629.
40
41.Mickleborough TD, Rundell KW. Dietary polyunsaturated fatty acids in asthma-and exercise-induced bronchoconstriction. Eur J Clin Nutr 2005; 59:1335-1346.
41
42.Kelley DS, Branch LB, Love JE, Taylor PC, Rivera YM, Iacono JM. Dietary alpha-linolenic acid and immunocompetence in humans. Am J Clin Nutr 1991; 53:40-46.
42
43.Jeffery NM, Newsholme EA, Calder PC. Level of polyunsaturated fatty acids and the n-6 to n-3 polyunsaturated fatty acid ratio in the rat diet alter serum lipid levels and lymphocyte functions. Prostaglandins Leukot Essent Fatty Acids 1997; 57:149-160.
43
44.Stark AH, Crawford MA, Reifen R. Update on alpha‐linolenic acid. Nutr Rev 2008; 66:326-332.
44
45.Calder PC. Omega-3 polyunsaturated fatty acids, inflammation and immunity. World Rev Nutr Diet. 2001; 88:109-116.
45
46.Tang XY, Yu HP, Deng HJ, Chen X, Fan HZ, Gong YX, et al. Pathogenic mechanism of CD8(+) CD28(-) T cell and the effect of dexamethasone in asthmatic mouse. Zhonghua Yi Xue Za Zhi 2011; 91:1861-1865.
46
47.Boskabady MH, Boroushaki M, Aslani MR. Relaxant effect of Portulaca oleraceae on guinea pig tracheal chains and its possible mechanism (s) of action. Med Hypotheses Res 2004; 1:139-147.
47
48.Parry O, Okwuasaba F, Ejike C. Effect of an aqueous extract of Portulaca oleracea leaves on smooth muscle and rat blood pressure. J Ethnopharmacol 1988; 22:33-44.
48
49.Boroushaki MT, Boskabady MH, Maleka F. Antitussive effect of Portulaca oleracea L. in guinea pigs. Iran J Pharmac Res 2010; 3:187-190.
49
50.Malek F, Boskabady MH, Borushaki MT, Tohidi M. Bronchodilatory effect of Portulaca oleracea in airways of asthmatic patients. J Ethnopharmacol 2004; 93:57-62.
50
51.Boskabady MH, Hashemzehi M, Khazdair MR, Askari VR. Hydro-ethanolic extract of Portulaca oleracea affects beta-adrenoceptors of guinea pig tracheal smooth muscle. Iran J Pharm Res 2016; 15:867–874.
51
52.Hashemzehi M, Khazdair MR, Kiyanmehr M, Askari VR, Boskabady MH. Portulaca oleracea affects muscarinic receptors of guinea pig tracheal smooth muscle. Ind J Pharmac Scei 2016; 78:388-394.
52
ORIGINAL_ARTICLE
Anti-diabetic effect of loganin by inhibiting FOXO1 nuclear translocation via PI3K/Akt signaling pathway in INS-1 cell
Objective(s): JiangTangXiaoKe (JTXK) granule, a Chinese traditional herbal formula, has been clinically used and demonstrated to be beneficial in controlling high glucose and to relieve the symptoms of Type 2 diabetes mellitus patients for decades. In this study, we explored how loganin, one of the components in JTXK granule, mediated the anti-diabetic effect.Materials and Methods: We generate a cell model with the dysfunction of insulin secretion by over-expression FOXO1 in INS-1 cells. MTT method was used to detect cytotoxicity after treated with Loganin. ELISA analysis was used to examine insulin secretion. The expression levels of FOXO1 and Akt were evaluated by Western blot.Results: Treatment with Loganin did not change the expression level of FOXO1 in INS-1 cells, but increased phosphorylation of FOXO1 and inhibited the nuclear translocation and accumulation of FOXO1, which improved the insulin secretion of the cells. Mechanistically, we found PI3K/Akt signaling pathway involved in these effects, which were blocked by an Akt inhibitor, LY294002.Conclusion: Loganin mediated the subcellular distribution of FOXO1 via PI3K/Akt signaling pathway, which protected the function of insulin secretion in islet INS-1 cells.
https://ijbms.mums.ac.ir/article_12189_0aada324bcc5a71a6841ea2e8adec17b.pdf
2019-03-01
262
266
10.22038/ijbms.2019.30246.7294
Akt pathway
Factor forkhead box O1-(FOXO1)
INS-1 cells
Loganin
Pancreatic β-cell
Fang-Fang
Mo
xiaofang.tcm@163.com
1
Beijing University of Chinese Medicine, Beijing, 100029, China
AUTHOR
Hai-Xia
Liu
lhx8866_7@163.com
2
Beijing University of Chinese Medicine, Beijing, 100029, China
AUTHOR
Yi
Zhang
yicando@163.com
3
Beijing Open University, Beijing, 100081, China
AUTHOR
Jing
Hua
yesmacc@163.com
4
Beijing University of Chinese Medicine, Third Affiliated Hospital, Beijing, 100029, China
AUTHOR
Dan-Dan
Zhao
bucmzhaodandan@163.com
5
Beijing University of Chinese Medicine, Beijing, 100029, China
AUTHOR
Tian
An
antian0403@163.com
6
Beijing University of Chinese Medicine, Beijing, 100029, China
AUTHOR
Dong-Wei
Zhang
dongwei1006@gmail.com
7
Beijing University of Chinese Medicine, Beijing, 100029, China
AUTHOR
Tian
Tian
tt8324@163.com
8
Beijing University of Chinese Medicine, Beijing, 100029, China
AUTHOR
Sihua
Gao
xiaofangtcm@126.com
9
Beijing University of Chinese Medicine, Beijing, 100029, China
LEAD_AUTHOR
1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. Lancet 2016; 387:1513-1530.
1
2. Collaborators GRF. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386:2287-2323.
2
3. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Investig 1999; 104:787-794.
3
4. Sesti G, Federici M, Lauro D, Sbraccia P, Lauro R. Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes Metab Res Rev 2001; 17:363-373.
4
5. Singh KA, Devi RKB, Singh KL. B-cell failure and preservation in type 2 diabetes mellitus: a review. J Evolution Med Dent Sci 2016; 5:5315-5321.
5
6. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Investig 2006; 116:1802-1812.
6
7. Leibowitz G, Kaiser N, Cerasi E. beta-Cell failure in type 2 diabetes. J Diabetes Investig 2011; 2:82-91.
7
8. Tsuchiya K, Ogawa Y. Forkhead box class O family member proteins: The biology and pathophysiological roles in diabetes. J Diabetes Investig 2017; 8:726-734.
8
9. Yang Y, Xu H, Dai Q. Foxo regulates cell proliferation, differentiation and apoptosis. Prog Physiol Sci 2008; 39:362-365.
9
10. Lu Z, Gan L, Miao H, Wang Z, Zou Q. Foxo1 expression influence proliferation and apoptosis of pancreatic β cells. Chin J Biochem Mol Biol 2009; 25:50-56.
10
11. Kitamora T, Kitamura YI. Role of foxo proteins in pancreatic β cells. Endocr J 2007; 54:507-515.
11
12. Huang H, Xia N. Effect of FOXO1 on pancreatic beta cells in diabetes mellitus. Intel Med Chin 2009; 4:404-407.
12
13. Pajvani UB, Accili D. The new biology of diabetes. Diabetologia 2015; 58:2459-2468.
13
14. Rutter GA, Pullen TJ, Hodson DJ, Martinez-Sanchez A. Pancreatic β-cell identity, glucose sensing and the control of insulin secretion. Biochem J 2015; 466:203-218.
14
15. Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, McIntosh CH. Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 2005; 280:22297-22307.
15
16. Ma Y, Wang X, Peng Y, Ding X. Forkhead box O1 promotes INS1 cell apoptosis by reducing the expression of CD24. Mol Med Rep 2016; 13:2991-2998.
16
17. Gao S, Gong Y, Ni Q, Luo Z, Zhao J, Gao Y, et al. Clinical study on treatment of type 2 diabetes from aspects of liver, spleen and kidney. J Tradit Chin Med 2009; 24:1007-1010.
17
18. Zhao D, Li X, Yu N, Fang X, Mu Q, Qin P, et al. Effect of Jiangtang xiaoke granule on glucose and lipid metabolism in type 2 diabetic rats. Chin J Exp Trad Med Form 2013; 19:172-176.
18
19. Zhang Y, Yu N, Mu Q, Zhao D, Zuo J, An H, et al. Effect of Jiangtang xiaoke granule on hepatic lipid metabolism in type 2 diabetic KKAy mice. J Tradit Chin Med 2016; 34:2626-2629.
19
20. Guerra SD, Lupi R, Marselli L, Masini M, Bugliani M, Sbrana S, et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 2005; 54:727-735.
20
21. Kim HJ, Kobayashi M, Sasaki T, Kikuchi O, Amano K, Kitazumi T, et al. Overexpression of FoxO1 in the hypothalamus and pancreas causes obesity and glucose intolerance. Endocrinology 2012; 153:659-671.
21
22. Nakae J, Cao Y, Hakuno F, Takemori H, Kawano Y, Sekioka R, et al. Novel repressor regulates insulin sensitivity through interaction with foxo1. EMBO J 2012; 31:2275-2295.
22
23. Wu R, Zhao D, Fang X, Gao S. Effects of Jiangtang xiaoke granule-containing serum on apoptosis of INS-1 cells. J Tradit Chin Med 2016; 34:2090-2092.
23
24. Shu T, Zhu Y, Wang H, Lin Y, Ma Z, Han X. AGEs decrease insulin synthesis in pancreatic b-cell by repressing Pdx-1 protein expression at the post-ttranslational level. PLoS One 2011; 6:18782-18789.
24
25. Sathanoori R, Olde B, Erlinge D, Goransson O, Wierup N. Cocaine- and amphetamine-regulated transcript (CART) protects beta cells against glucotoxicity and increases cell proliferation. J Biol Chem 2013; 288:3208-3218.
25
26. Wang Y, Lin H, Hao N, Zhu Z, Wang D, Li Y, et al. Forkhead box O1 mediates defects in palmitate-induced insulin granule exocytosis by downregulation of calcium/calmodulin-dependent serine protein kinase expression in INS-1 cells. Diabetologia 2015; 58:1272-1281.
26
ORIGINAL_ARTICLE
Anticonvulsant and ameliorative effects of pioglitazone on cognitive deficits, inflammation and apoptosis in the hippocampus of rat pups exposed to febrile seizure
Objective(s): Pioglitazone (PGZ), a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, has significant neuroprotective effects and has been reported to regulate inflammatory processes.Materials and Methods: We evaluated the effects of PGZ on febrile seizure (FS) in rat pups. Three groups of male rat pups received intraperitoneal (IP) injections of PGZ (5, 10, and 20 mg/kg). Lipopolysaccharide (LPS) and kainic acid (KA) were injected to induce FS. The rat pups behaviors were recorded and analyzed. Seizure latency, duration, and severity were recorded to evaluate the effect of PGZ on FS. Novel object recognition task (NORT) was used to evaluate the effect of PGZ on cognitive deficits induced by FS. At the end of the experimental protocol, molecular and histological tests were done.Results: PGZ significantly increased seizure latency and decreased seizure duration and median of seizure scores (P<0.05, P<0.01, and P<0.001) after induction of FS. Rat pups exposed to FS had memory deficits both in short-term and long-term memories in the NORT that were reversed by PGZ-treatment (P<0.01 and P<0.001). PGZ significantly reduced interleukin-1β, tumor necrosis factor-α, and inducible nitric oxide synthase concentration in the hippocampus (P<0.05 and P<0.01). In addition, PGZ decreased the number of degenerating and TUNEL positive neurons in CA1, CA3, and DG subfields of the hippocampus (P< 0.05, P<0.01 and P<0.001).Conclusion: The present results indicated that PGZ had anticonvulsant, anti-inflammatory, and anti-apoptotic effects with ameliorative effects on cognitive deficits induced by FS in rat pups.
https://ijbms.mums.ac.ir/article_12195_0158855c3f687bdebb9ddaeb1c47e94a.pdf
2019-03-01
267
276
10.22038/ijbms.2019.35056.8339
Apoptosis
Febrile seizure
Hippocampus
Inflammation
Memory
Pioglitazone
Hussein
Hussein
hussein@mail.um.ac.ir
1
Rayan Center for Neuroscience & Behavior, Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Iran
AUTHOR
Ali
Moghimi
moghimi@um.ac.ir
2
Rayan Center for Neuroscience & Behavior, Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Iran
LEAD_AUTHOR
Ali
Roohbakhsh
roohbakhsha@mums.ac.ir
3
Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
1. van Gassen KL, Hessel EV, Ramakers GM, Notenboom RG, Wolterink-Donselaar IG, Brakkee JH, et al. Characterization of febrile seizures and febrile seizure susceptibility in mouse inbred strains. Genes Brain Behav 2008; 7:578-586.
1
2. Feng B, Chen Z. Generation of febrile seizures and subsequent epileptogenesis. Neurosci Bull 2016; 32:481-492.
2
3. Eun BL, Abraham J, Mlsna L, Kim MJ, Koh S. Lipopolysaccharide potentiates hyperthermia-induced seizures. Brain Behav 2015; 5:e00348.
3
4. Dey A, Kang X, Qiu J, Du Y, Jiang J. Anti-inflammatory small molecules to treat seizures and epilepsy: from bench to bedside. Trends Pharmacol Sci 2016; 37:463-484.
4
5. Yu N, Liu H, Di Q. Modulation of Immunity and the Inflammatory Response: A New Target for Treating Drug-resistant Epilepsy. Curr Neuropharmacol 2013; 11:114-127.
5
6. Choy M, Dube CM, Ehrengruber M, Baram TZ. Inflammatory processes, febrile seizures, and subsequent epileptogenesis. Epilepsy Curr 2014; 14:15-22.
6
7. Alheim K, Bartfai T. Interleukin‐1 System: Receptors, Ligands, and ICE in the Brain and Their Involvement in the Fever Response. Ann N Y Acad Sci 1998; 840:51-58.
7
8. Cartmell T, Luheshi GN, Rothwell NJ. Brain sites of action of endogenous interleukin-1 in the febrile response to localized inflammation in the rat. J Physiol 1999; 518 ( Pt 2):585-594.
8
9. Rao RS, Prakash A, Medhi B. Role of different cytokines and seizure susceptibility: a new dimension towards epilepsy research. Indian J Exp Biol 2009; 47:625-634.
9
10. Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens M, Bartfai T, et al. Interleukin-1β enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 2003; 23:8692-8700.
10
11. Patel DC, Wallis G, Dahle EJ, McElroy PB, Thomson KE, Tesi RJ, et al. Hippocampal TNFalpha signaling contributes to seizure generation in an infection-induced mouse model of limbic epilepsy. eNeuro 2017; 4.
11
12. Mollace V, Muscoli C, Masini E, Cuzzocrea S, Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 2005; 57:217-252.
12
13. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 2003; 27:325-355.
13
14. Lind M, Hayes A, Caprnda M, Petrovic D, Rodrigo L, Kruzliak P, et al. Inducible nitric oxide synthase: Good or bad? Biomed Pharmacother 2017; 93:370-375.
14
15. Chang YC, Kuo YM, Huang AM, Huang CC. Repetitive febrile seizures in rat pups cause long-lasting deficits in synaptic plasticity and NR2A tyrosine phosphorylation. Neurobiol Dis 2005; 18:466-475.
15
16. Heida JG, Boisse L, Pittman QJ. Lipopolysaccharide-induced febrile convulsions in the rat: short-term sequelae. Epilepsia 2004; 45:1317-1329.
16
17. Heida JG, Teskey GC, Pittman QJ. Febrile Convulsions Induced by the Combination of Lipopolysaccharide and Low‐dose Kainic Acid Enhance Seizure Susceptibility, Not Epileptogenesis, in Rats. Epilepsia 2005; 46:1898-1905.
17
18. Eriksson C, Tehranian R, Iverfeldt K, Winblad B, Schultzberg M. Increased expression of mRNA encoding interleukin-1beta and caspase-1, and the secreted isoform of interleukin-1 receptor antagonist in the rat brain following systemic kainic acid administration. J Neurosci Res 2000; 60:266-279.
18
19. Rosen ED, Spiegelman BM. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276:37731-37734.
19
20. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab 2012; 23:205-215.
20
21. Xing B, Xin T, Hunter RL, Bing G. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J Neuroinflammation 2008; 5:4.
21
22. Shafaroodi H, Hassanipour M, Mousavi Z, Rahimi N, Dehpour AR. The Effects of Sub-Chronic Treatment with Pioglitazone on the Septic Mice Mortality in the Model of Cecal Ligation and Puncture: Involvement of Nitric Oxide Pathway. Acta Med Iran 2015; 53:608-616.
22
23. Shafaroodi H, Moezi L, Ghorbani H, Zaeri M, Hassanpour S, Hassanipour M, et al. Sub-chronic treatment with pioglitazone exerts anti-convulsant effects in pentylenetetrazole-induced seizures of mice: The role of nitric oxide. Brain Res Bull 2012; 87:544-550.
23
24. Abdallah DM. Anticonvulsant potential of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in pentylenetetrazole-induced acute seizures and kindling in mice. Brain Res 2010; 1351:246-253.
24
25. Heida JG, Pittman QJ. Causal links between brain cytokines and experimental febrile convulsions in the rat. Epilepsia 2005; 46:1906-1913.
25
26. Drexel M, Preidt AP, Sperk G. Sequel of spontaneous seizures after kainic acid-induced status epilepticus and associated neuropathological changes in the subiculum and entorhinal cortex. Neuropharmacology 2012; 63:806-817.
26
27. Rezvani ME, Roohbakhsh A, Mosaddegh MH, Esmailidehaj M, Khaloobagheri F, Esmaeili H. Anticonvulsant and depressant effects of aqueous extracts of Carum copticum seeds in male rats. Epilepsy Behav 2011; 22:220-225.
27
28. Zhou J, Wang F, Zhang J, Gao H, Yang Y, Fu R. Repeated febrile convulsions impair hippocampal neurons and cause synaptic damage in immature rats: neuroprotective effect of fructose-1,6-diphosphate. Neural Regen Res 2014; 9:937-942.
28
29. Ghadimkhani M, Saboory E, Roshan-Milani S, Mohammdi S, Rasmi Y. Effect of magnesium sulfate on hyperthermia and pentylen-tetrazol-induced seizure in developing rats. Iran J Basic Med Sci 2016; 19:608-614.
29
30. Reger ML, Hovda DA, Giza CC. Ontogeny of rat recognition memory measured by the novel object recognition task. Dev Psychobiol 2009; 51:672-678.
30
31. Martins de Lima MN, Presti-Torres J, Dornelles A, Bromberg E, Schroder N. Differential effects of low and high doses of topiramate on consolidation and retrieval of novel object recognition memory in rats. Epilepsy Behav 2007; 10:32-37.
31
32. de Lima MN, Laranja DC, Caldana F, Bromberg E, Roesler R, Schroder N. Reversal of age-related deficits in object recognition memory in rats with l-deprenyl. Exp Gerontol 2005; 40:506-511.
32
33. Schroder N, O’Dell SJ, Marshall JF. Neurotoxic methamphetamine regimen severely impairs recognition memory in rats. Synapse 2003; 49:89-96.
33
34. Kolosowska K, Maciejak P, Szyndler J, Turzynska D, Sobolewska A, Plaznik A. The role of interleukin-1beta in the pentylenetetrazole-induced kindling of seizures, in the rat hippocampus. Eur J Pharmacol 2014; 731:31-37.
34
35. Hulse RE, Kunkler PE, Fedynyshyn JP, Kraig RP. Optimization of multiplexed bead-based cytokine immunoassays for rat serum and brain tissue. J Neurosci Methods 2004; 136:87-98.
35
36. Zhang X, Yan F, Feng J, Qian H, Cheng Z, Yang Q, et al. Dexmedetomidine inhibits inflammatory reaction in the hippocampus of septic rats by suppressing NF-kappaB pathway. PLoS One 2018; 13:e0196897.
36
37. Rossi O, Maggiore L, Necchi F, Koeberling O, MacLennan CA, Saul A, et al. Comparison of colorimetric assays with quantitative amino acid analysis for protein quantification of Generalized Modules for Membrane Antigens (GMMA). Mol Biotechnol 2015; 57:84-93.
37
38. Bagheri-Abassi F, Alavi H, Mohammadipour A, Motejaded F, Ebrahimzadeh-Bideskan A. The effect of silver nanoparticles on apoptosis and dark neuron production in rat hippocampus. Iran J Basic Med Sci 2015; 18:644-648.
38
39. Khazipov R, Zaynutdinova D, Ogievetsky E, Valeeva G, Mitrukhina O, Manent JB, et al. Atlas of the postnatal rat brain in stereotaxic coordinates. Front Neuroanat 2015; 9:161.
39
40. Pourzaki M, Homayoun M, Sadeghi S, Seghatoleslam M, Hosseini M, Ebrahimzadeh Bideskan A. Preventive effect of Coriandrum sativum on neuronal damages in pentylentetrazole-induced seizure in rats. Avicenna J Phytomed 2017; 7:116-128.
40
41. Zhao Y, Han Y, Bu DF, Zhang J, Li QR, Jin HF, et al. Reduced AKT phosphorylation contributes to endoplasmic reticulum stress-mediated hippocampal neuronal apoptosis in rat recurrent febrile seizure. Life Sci 2016; 153:153-162.
41
42. Haghir H, Hami J, Lotfi N, Peyvandi M, Ghasemi S, Hosseini M. Expression of apoptosis-regulatory genes in the hippocampus of rat neonates born to mothers with diabetes. Metab Brain Dis 2017; 32:617-628.
42
43. Homayoun M, Seghatoleslam M, Pourzaki M, Shafieian R, Hosseini M, Ebrahimzadeh Bideskan A. Anticonvulsant and neuroprotective effects of Rosa damascena hydro-alcoholic extract on rat hippocampus. Avicenna J Phytomed 2015; 5:260-270.
43
44. Wang CP, Shi YW, Tang M, Zhang XC, Gu Y, Liang XM, et al. Isoquercetin Ameliorates Cerebral Impairment in Focal Ischemia Through Anti-Oxidative, Anti-Inflammatory, and Anti-Apoptotic Effects in Primary Culture of Rat Hippocampal Neurons and Hippocampal CA1 Region of Rats. Mol Neurobiol 2017; 54:2126-2142.
44
45. Rajabzadeh AA, Bideskan AR, Haghir H, Fazel AR. Morphometrical study of polysialylated neural cell adhesion molecule positive cells in rat pups hippocampus following induction of seizure during pregnancy. Iran Biomed J 2011; 15:157-163.
45
46. Mohammadipour A, Fazel A, Haghir H, Motejaded F, Rafatpanah H, Zabihi H, et al. Maternal exposure to titanium dioxide nanoparticles during pregnancy; impaired memory and decreased hippocampal cell proliferation in rat offspring. Environ Toxicol Pharmacol 2014; 37:617-625.
46
47. Yagoubi N, Jomni Y, Sakly M. Hyperthermia-induced febrile seizures have moderate and transient effects on spatial learning in immature rats. Behav Neurol 2015; 2015:924303.
47
48. Weiss EF, Masur D, Shinnar S, Hesdorffer DC, Hinton VJ, Bonner M, et al. Cognitive functioning one month and one year following febrile status epilepticus. Epilepsy Behav 2016; 64:283-288.
48
49. Huang CC, Chang YC. The long-term effects of febrile seizures on the hippocampal neuronal plasticity - clinical and experimental evidence. Brain Dev 2009; 31:383-387.
49
50. Saeedi Borujeni MJ, Hami J, Haghir H, Rastin M, Sazegar G. Evaluation of Bax and Bcl-2 proteins expression in the rat hippocampus due to childhood febrile seizure. Iran J Child Neurol 2016; 10:53-60.
50
51. Reid AY, Riazi K, Campbell Teskey G, Pittman QJ. Increased excitability and molecular changes in adult rats after a febrile seizure. Epilepsia 2013; 54:e45-48.
51
52. Auvin S, Shin D, Mazarati A, Sankar R. Inflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA. Epilepsia 2010; 51 Suppl 3:34-38.
52
53. Vezzani A, Aronica E, Mazarati A, Pittman QJ. Epilepsy and brain inflammation. Exp Neurol 2013; 244:11-21.
53
54. Kenney-Jung DL, Vezzani A, Kahoud RJ, LaFrance-Corey RG, Ho ML, Muskardin TW, et al. Febrile infection-related epilepsy syndrome treated with anakinra. Ann Neurol 2016; 80:939-945.
54
55. Adabi Mohazab R, Javadi-Paydar M, Delfan B, Dehpour AR. Possible involvement of PPAR-gamma receptor and nitric oxide pathway in the anticonvulsant effect of acute pioglitazone on pentylenetetrazole-induced seizures in mice. Epilepsy Res 2012; 101:28-35.
55
56. Okada K, Yamashita U, Tsuji S. Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice. Brain Res 2006; 1102:175-178.
56
57. Simeone TA, Matthews SA, Simeone KA. Synergistic protection against acute flurothyl-induced seizures by adjuvant treatment of the ketogenic diet with the type 2 diabetes drug pioglitazone. Epilepsia 2017; 58:1440-1450.
57
58. Martinos MM, Yoong M, Patil S, Chin RF, Neville BG, Scott RC, et al. Recognition memory is impaired in children after prolonged febrile seizures. Brain 2012; 135:3153-3164.
58
59. Jiang LY, Tang SS, Wang XY, Liu LP, Long Y, Hu M, et al. PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus. CNS Neurosci Ther 2012; 18:659-666.
59
60. Yin QQ, Pei JJ, Xu S, Luo DZ, Dong SQ, Sun MH, et al. Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats. PLoS One 2013; 8:e59313.
60
61. Dube CM, Brewster AL, Richichi C, Zha Q, Baram TZ. Fever, febrile seizures and epilepsy. Trends Neurosci 2007; 30:490-496.
61
62. Saghazadeh A, Gharedaghi M, Meysamie A, Bauer S, Rezaei N. Proinflammatory and anti-inflammatory cytokines in febrile seizures and epilepsy: systematic review and meta-analysis. Rev Neurosci 2014; 25:281-305.
62
63. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 2004; 10:201-222.
63
64. Zou JN, Xiao J, Hu SS, Fu CS, Zhang XL, Zhang ZX, et al. Toll-like receptor 4 signaling pathway in the protective effect of pioglitazone on experimental immunoglobulin A nephropathy. Chin Med J (Engl) 2017; 130:906-913.
64
65. Xu J, Nie M, Li J, Xu Z, Zhang M, Yan Y, et al. Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An (18)F-FDG-PET/CT in vivo imaging study. Herz 2017.
65
66. Chedrawe MAJ, Holman SP, Lamport AC, Akay T, Robertson GS. Pioglitazone is superior to quetiapine, clozapine and tamoxifen at alleviating experimental autoimmune encephalomyelitis in mice. J Neuroimmunol 2018; 321:72-82.
66
67. Kim S, Dede AJ, Hopkins RO, Squire LR. Memory, scene construction, and the human hippocampus. Proc Natl Acad Sci U S A 2015; 112:4767-4772.
67
68. Lee CH, Yi MH, Chae DJ, Zhang E, Oh SH, Kim DW. Effect of pioglitazone on excitotoxic neuronal damage in the mouse hippocampus. Biomol Ther (Seoul) 2015; 23:261-267.
68
69. Sauerbeck A, Gao J, Readnower R, Liu M, Pauly JR, Bing G, et al. Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol 2011; 227:128-135.
69
70. El-Sahar AE, Safar MM, Zaki HF, Attia AS, Ain-Shoka AA. Neuroprotective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: Modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkers. Pharmacol Rep 2015; 67:901-906.
70
71. Chuang YC, Lin TK, Huang HY, Chang WN, Liou CW, Chen SD, et al. Peroxisome proliferator-activated receptors gamma/mitochondrial uncoupling protein 2 signaling protects against seizure-induced neuronal cell death in the hippocampus following experimental status epilepticus. J Neuroinflammation 2012; 9:184.
71
72. Offringa M, Newton R, Cozijnsen MA, Nevitt SJ. Prophylactic drug management for febrile seizures in children. Cochrane Database Syst Rev 2017; 2:CD003031.
72
73. Leonard CE, Han X, Brensinger CM, Bilker WB, Cardillo S, Flory JH, et al. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study. Pharmacoepidemiol Drug Saf 2018; 27:9-18.
73
ORIGINAL_ARTICLE
Effect of crocin on cardiac antioxidants, and hemodynamic parameters after injuries induced by hepatic ischemia-reperfusion in rats
Objective(s): This research aimed to test the impact of liver ischemia/reperfusion (IR) insult on the activity of antioxidant enzymes, functional enzymes, histological, and hemodynamic parameters of heart, as well as protective function of crocin on these variables in rats. Materials and Methods: Thirty two rats were randomly assigned into 4 experimental groups (8 rats in each). I: sham-operated, II: IR induction, III: Crocin alone, and IV: Crocin+IR induction. Groups I and III received normal saline at 2 ml per day and crocin at 200 mg per kg on a daily basis for a week via intraperitoneally injection. Afterwards, laparotomy was performed. Groups II and IV was also received normal saline and crocin and then experienced a 45 min ischemia followed by 1 hr reperfusion. Tissue samples of heart and blood were taken to use for further microscopic and laboratories analysis. Hemodynamic parameters were measured by tail cuff method. Results: Findings indicated that crocin dramatically elevated the activity of antioxidant enzymes, and attenuated serum concentrations of hepatic and cardiac enzymes. Crocin also inhibited histopathological disarrangements, and modulated hemodynamic parameters beyond IR-induced hepatic insult. Conclusion: Current experiment indicated that crocin has potential cardioprotective action following hepatic I/R-induced damage. Therefore, it can be administered before elective hepatic surgeries.
https://ijbms.mums.ac.ir/article_12165_bab763290401e0a9523978aca21297bf.pdf
2019-03-01
277
281
10.22038/ijbms.2019.29660.7159
Crocin
Heart
Hemodynamic parameters
Ischemia/Reperfusion
Liver
Ghaidafeh
Akbari
ghaidafehakbari@yahoo.com
1
Department of Physiology, Yasuj University of Medical Sciences, Yasuj, Iran
AUTHOR
Seyyed Ali
Mard
alimard77@gmail.com
2
Alimentary Tract Research Center, Physiology Research Center, Department of Physiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
LEAD_AUTHOR
Mahin
Dianat
dianatmah@yahoo.com
3
Physiology Research Center, Department of Physiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
1. Salomão LS, Young SB, Galhardo MA, Pereira LA, Pires ARC, Boaventura GT, et al. Evaluation of liver regeneration by modulation with ischemic preconditioning after ischemia and reperfusion and partial hepatectomy. Rev Col Bras Cir 2012; 39:211-215.
1
2. Hochhauser E, Alterman I, Weinbroum A, Barak Y, Harell D, Raz A, et al. Effects of vasoactive substances released from ischemic reperfused liver on the isolated rat heart. Exp Clin Cardiol 2001; 6:29-34.
2
3. Chen Y, Liu Z, Xie X. Hydrogen sulphide attenuates renal and cardiac injury after total hepatic ischemia and reperfusion. J Surg Res 2010; 164:e305-313.
3
4. Jin G, Prabhakaran MP, Kai D, Annamalai SK, Arunachalam KD, Ramakrishna S. Tissue engineered plant extracts as nanofibrous wound dressing. Biomaterials 2013; 34:724-734.
4
5. Ebrahimzadeh MA, Nabavi SM, Nabavi SF, Bahramian F, Bekhradnia AR. Antioxidant and free radical scavenging activity of H. officinalis L. var. angustifolius, V. odorata, B. hyrcana and C. speciosum. Pak J Pharm Sci 2010; 23:29-34.
5
6. Padma VV, Sowmya P, Felix TA, Baskaran R, Poornima P. Protective effect of gallic acid against lindane induced toxicity in experimental rats. Food Chem Toxicol 2011; 49:991-998.
6
7. Zahra Jahanbakhsh, Bahram Rasoulian MJ, Shahnaz Shekarforoush, Mansour Esmailidehaj, Mohammad taghi Mohammadi, Hasan Aghai, et al. Protective effect of crocin against reperfusion– induced cardiac arrhythmias in anaesthetized rats. EXCLI J 2012; 11:20-2 9.
7
8. Jalili C, Tabatabaei H, Kakaberiei S, Roshankhah S, Salahshoor MR. Protective role of crocin against nicotine-induced damages on male mice liver. Int J Prev Med 2015; 6:92.
8
9. Akbari G, Mard SA, Dianat M, Mansouri E. The hepatoprotective and microRNAs downregulatory effects of crocin following hepatic ischemia-reperfusion injury in rats. Oxid Med Cell Longev 2017;2017.
9
10. Najafi H, Yarijani ZM, Pourmotabed A, Madani SH. The effect of Crocin on the renal tissue damages and leukocyte infiltration induced by ischemia-reperfusion among rats. J Kermanshah Univ Med Sci 2013; 17:394-403.
10
11. Qi Y, Chen L, Zhang L, Liu W-B, Chen X-Y, Yang X-G. Crocin prevents retinal ischaemia/reperfusion injury-induced apoptosis in retinal ganglion cells through the PI3K/AKT signalling pathway. Exp Eye Res 2013; 107:44-51.
11
12. Naghizadeh B, Boroushaki MT, Vahdati Mashhadian N, Mansouri SMT. Protective effects of crocin against cisplatin-induced acute renal failure and oxidative stress in rats. Iran Biomed J 2008; 12:93-100.
12
13. Naghizadeh B, Mansouri SMT, Mashhadian NV. Crocin attenuates cisplatin-induced renal oxidative stress in rats. Food Chem Toxicol 2010; 48:2650-2655.
13
14. Askaripour M, Fatemi-Tabatabaei SR, Hosseini F, Rashno M, Ghaderi S. Effects of aqueous extract of purslane (Portulaca oleracea) on hepatic enzymes in two models of renal ischemia-reperfusion injury in rats. Zahedan J Res Med Sci 2015; X: XX-XX .
14
15. Sözen S, Kisakürek M, Yildiz F, Gönültas M, Dinçel A. The effects of glutamine on hepatic ischemia reperfusion injury in rats. Hippokratia 2011; 15:161-166.
15
16. Tüfek A, Tokgöz O, Aliosmanoglu İ, Alabalik U, Evliyaoglu O, Çiftçi T, et al. The protective effects of dexmedetomidine on the liver and remote organs against hepatic ischemia reperfusion injury in rats. Int J Surg 2013; 11:96-100.
16
17. Hochhauser E, Ben-Ari Z, Pappo O, Chepurko Y, Vidne B. TPEN attenuates hepatic apoptotic ischemia/reperfusion injury and remote early cardiac dysfunction. Apoptosis 2005; 10:53-62.
17
18. Suchalatha S, Devi C. Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol. Indian J Exp Biol 2004; 42:174-178.
18
19. Basbug M, Yildar M, Yaman I, Ozkan OF, Aksit H, Cavdar F, et al. EFfects of boric acid in an experimental rat model of hepatic ischemia-reperfu-sion injury. Acta Medica Mediterranea 2015; 31:1067.
19
20. Unsal C, Celik J, Toy H, Esen H, Otelcioglu S. Protective role of zinc pretreatment in hepatotoxicity induced by halothane. Eur J Anaesthesiol 2008; 25:810-815.
20
21. Goyal SN, Arora S, Sharma AK, Joshi S, Ray R, Bhatia J, et al. Preventive effect of crocin of Crocus sativus on hemodynamic, biochemical, histopathological and ultrastuctural alterations in isoproterenol-induced cardiotoxicity in rats. Phytomedicine 2010; 17:227-232.
21
22. Rasool MK, Sabina EP, Ramya SR, Preety P, Patel S, Mandal N, et al. Hepatoprotective and antioxidant effects of gallic acid in paracetamol-induced liver damage in mice. J Pharm Pharmacol 2010; 62:638-643.
22
23. Dianat M, Esmaeilizadeh M, Badavi M, Samarbaf-zadeh AR, Naghizadeh B. Protective effects of crocin on ischemia-reperfusion induced oxidative stress in comparison with vitamin E in isolated rat hearts. Jundishapur J Nat Pharm Prod 2014; 9:e17187.
23
24. Papoutsidakis N, Arkadopoulos N, Smyrniotis V, Tzanatos H, Kalimeris K, Nastos K, et al. Basic research Early myocardial injury is an integral component of experimental acute liver failure–a study in two porcine models. Arch Med Sci 2011; 7: 217–223.
24
25. Tanaka Y, Maher JM, Chen C, Klaassen CD. Hepatic ischemia-reperfusion induces renal heme oxygenase-1 via NF-E2-related factor 2 in rats and mice. Mol Pharmacol 2007; 71:817-825.
25
26. Rajaei Z, Hadjzadeh M-A-R, Nemati H, Hosseini M, Ahmadi M, Shafiee S. Antihyperglycemic and antioxidant activity of crocin in streptozotocin-induced diabetic rats. J Med Food 2013; 16:206-210.
26
27. Weinbroum AA, Hochhauser E, Rudick V, Kluger Y, Sorkine P, Karchevsky E, et al. Direct induction of acute lung and myocardial dysfunction by liver ischemia and reperfusion. J Trauma 1997; 43:627-635.
27
28. Dianat M, Esmaeilizadeh M, Badavi M, Samarbaf-Zadeh AR, Naghizadeh B. Protective effects of crocin on ischemia-reperfusion induced oxidative stress in comparison with vitamin E in isolated rat hearts. Jundishapur J Nat Pharm Prod 2014; 9:e17187.
28
29. Jahanbakhsh Z, Rasoulian B, Jafari M, Shekarforoush S, Esmailidehaj M, Taghi Mohammadi M, et al. Protective effect of crocin against reperfusion-induced cardiac arrhythmias in anaesthetized rats. EXCLI J 2012;11: 20-29.
29
ORIGINAL_ARTICLE
Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids
Objective(s): Curcuminoids, comprising curcumin, demethoxycurcumin (DMC) and bisdemethoxycurcumin (BDMC), are bioactive phytochemicals with numerous pharmacological effects. Oral biological availability of curcuminoids is low due to the low aqueous solubility and rapid metabolism. This study aimed at fabricating a nanomicellar curcuminoid formula with enhanced pharmacokinetic properties. Materials and Methods: Curcuminoids nanomicelles were prepared and characterized regarding particle properties, stability, release profile and pharmacokinetic parameters.Results: Encapsulation efficiency of curcuminoids in nanomicelles were 100%. Particle size analysis demonstrated a mean size of around 10 nm that remained stable for 24 months. Dissolution test showed the complete dissolution of encapsulated curcuminoids from nanomicelles within 20 min while the free curcuminoids were poorly dissolved (approximately 7% after 60 min). The results of long-term (24 months) and accelerated (6 months) stability studies showed no changes in the size and content of nanomicelles. The release studies in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) showed no release of curcuminoids for at least 4 hours. In vivo study in BALB/c mice showed improved pharmacokinetic parameters including maximum plasma concentration (Cmax) and time to reach the maximum concentration (Tmax) with nanomicelles as compared to free curcuminoids and two other commercial products. Tmax for all the three curcuminoid components was observed 30 min following oral administration. AUC of nanomicellar curcuminoids was 59.2 times more than free curcuminoids. Conclusion: These data indicated that nanomicelles could improve solubility, oral bioavailability and also the stability of curcuminoids. Thus, they merit further investigation for enhancing pharmacological effects of curcuminoids.
https://ijbms.mums.ac.ir/article_12252_d7c8c914cdd8434f0a317a16dc3bcb10.pdf
2019-03-01
282
289
10.22038/ijbms.2019.32873.7852
Biological availability
Curcuminoid
Drug stability
Micelle
Pharmacokinetics
Mahdi
Hatamipour
hatamipourm931@mums.ac.ir
1
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Amirhossein
Sahebkar
sahebkara@mums.ac.ir
2
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Seyedeh Hoda
Alavizadeh
alavizadehh@mums.ac.ir
3
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mahyar
Dorri
dorrim901@mums.ac.ir
4
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mahmoud Reza
Jaafari
jafarimr@mums.ac.ir
5
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Pulido-Moran M, Moreno-Fernandez J, Ramirez-Tortosa C, Ramirez-Tortosa M. Curcumin and health. Molecules 2016; 21:264.
1
2. Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 2013; 39:2-13.
2
3. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv 2014; 32:1053-1064.
3
4. Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 2014; 28:633-642.
4
5. Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 2012; 49:580-588.
5
6. Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. Clin Nutr 2015; 34:1101-1108.
6
7. Mirzaei H, Naseri G, Rezaee R, Mohammadi M, Banikazemi Z, Mirzaei HR, et al. Curcumin: A new candidate for melanoma therapy? Int J Cancer 2016; 139:1683-1695.
7
8. Momtazi AA, Shahabipour F, Khatibi S, Johnston TP, Pirro M, Sahebkar A. Curcumin as a microRNA regulator in cancer: A review. Rev Physiol Biochem Pharmacol 2016; 17:1-38.
8
9. Liu W, Zhai Y, Heng X, Che FY, Chen W, Sun D, et al. Oral bioavailability of curcumin: problems and advancements. J Drug Target 2016; 24:694-702.
9
10. Dawidczyk C, Kim C, Park J, Russell L, Lee K, Pomper M, et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release 2014; 187:133-144.
10
11. Mobasheri M, Attar H, Rezayat Sorkhabadi SM, Khamesipour A, Jaafari MR. Solubilization behavior of polyene antibiotics in nanomicellar system: Insights from molecular dynamics simulation of the amphotericin B and nystatin interactions with polysorbate 80. Molecules 2015; 21:E6.
11
12. Shakeri A, Sahebkar A. Opinion Paper: Nanotechnology: A Successful Approach to Improve Oral Bioavailability of Phytochemicals. Recent Pat Drug Deliv Formul 2016; 10:4-6.
12
13. Patent Cooperation Treaty: 2018 MRJ, curcumin nanomicelles for oral administration, International application No. PCT/IB2018/051370; International filing date: March 4, 2018.
13
14. Ahmadi M, Agah E, Nafissi S, Jaafari MR, Harirchian MH, Sarraf P, et al. Safety and efficacy of nanocurcumin as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A pilot randomized clinical trial. Neurotherapeutics 2018; 15:430-438.
14
15. Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Mobarhan MG, et al. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed 2016; 6:567-577.
15
16. Charbgoo F, Alibolandi M, Taghdisi S, Abnous K, Soltani F, Ramezani M. MUC1 aptamer-targeted DNA micelles for dual tumor therapy using doxorubicin and KLA peptide. Nanomedicine 2018; 14:685-697.
16
17. Khodaverdi E, Tekie FSM, Mohajeri SA, Ganji F, Zohuri G, Hadizadeh F. Preparation and investigation of sustained drug delivery systems using an injectable, thermosensitive, in situ forming hydrogel composed of PLGA–PEG–PLGA. AAPS Pharm Sci Tech 2012; 13:590-600.
17
18. Gao J, Sun J, Li H, Liu W, Zhang Y, Li B, et al. Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing. Biomaterials 2010; 31:2655-2664.
18
19. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release 2010; 145:182-195.
19
20. Letchford K, Liggins R, Burt H. Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations. J Pharm Sci 2008; 97:1179-1190.
20
21. Zhao L, Du J, Duan Y, Zang Y, Zhang H, Yang C, et al. Curcumin loaded mixed micelles composed of Pluronic P123 and F68: preparation, optimization and in vitro characterization. Colloids Surf B Biointerfaces 2012; 97:101-108.
21
22. Erfani-Moghadam V, Nomani A, Zamani M, Yazdani Y, Najafi F, Sadeghizadeh M. A novel diblock of copolymer of (monomethoxy poly [ethylene glycol]-oleate) with a small hydrophobic fraction to make stable micelles/polymersomes for curcumin delivery to cancer cells. Int J Nanomedicine 2014; 9:5541-5554.
22
23. Sahu A, Kasoju N, Goswami P, Bora U. Encapsulation of curcumin in pluronic block copolymer micelles for drug delivery applications. J Biomater Appl 2011; 25:619-639.
23
24. Hussain N, Jaitley V, Florence AT. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 2001; 50:107-142.
24
25. Bao Y, Guo Y, Zhuang X, Li D, Cheng B, Tan S, et al. D-α-tocopherol polyethylene glycol succinate-based redox-sensitive paclitaxel prodrug for overcoming multidrug resistance in cancer cells. Mol Pharm 2014; 11:3196-3209.
25
26. Yodkeeree S, Chaiwangyen W, Garbisa S, Limtrakul P. Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA. J Nutr Biochem 2009; 20:87-95.
26
ORIGINAL_ARTICLE
Ultra structural characteristics of methicillin resistant Staphylococcus aureus cell wall after affecting with lytic bacteriophages using atomic force microscopy
Objective(s): During the last years with increasing resistant bacteria to the most antibiotics bacteriophages are suggested as appropriate treatment option. To investigate lytic activity of bacteriophages there are indirect microbial procedures and direct methods. The present study to complement microbial procedures and investigate ultra-structural characteristics of infection bacterium-phage use atomic force microscopy technique.Materials and Methods: The Siphoviridae bacteriophages were isolated from sewage at the Tertiary Pediatric Hospital. Bacteriophages (10×108 PFU/ml) were diluted and were mixed with 100 μl of methicillin resistant Staphylococcus aureus (MRSA) ATCC 33591 (1.5×108 CFU/ml). The tubes were incubated for 20 min at 37 °C, at intervals 10 min, 10 μl samples were removed and directly were investigated MRSA ATCC morphology, roughness parameter, 3D topography, cell height, and fast Fourier transform (FFT) by atomic force microscopy (AFM) technique. Concurrently turbidity assay were performed.Results: Concentration of MRSA ATCC No. 33591 strain after 10 min in phage-treated MRSA S3 (1.5×106 CFU/ml), S4 (1.5×105 CFU/ml), S5 (1.5×104 CFU/ml), S6 (1.5×103 CFU/ml) decreased 2-log, 3-log, 4-log, and 5-log respectively. The results AFM micrographs shown the most changes in bacterial morphology and 3D topography, destruction of cell wall, decrease of cell height, and loss of their shape after 10 min at phage-treated MRSA S3 (1.5×106 CFU/ml), S4 (1.5×105 CFU/ml), S5 (1.5×104 CFU/ml), S6 (1.5×103 CFU/ml) respectively .Conclusion: In this study MRSA ATCC ultra-structural changes in phage-treated MRSA ATCC groups directly were detected using AFM technique.
https://ijbms.mums.ac.ir/article_12231_da5a3085dd020571468ce7298b684001.pdf
2019-03-01
290
295
10.22038/ijbms.2019.31226.7521
AFM
Bacteriophages
Lytic activity
MRSA
3D Topography
Golnar
Rahimzadeh
rahimzadehgolnar@yahoo.com
1
Pediatric Infectious Diseases Research Center, Mazandaran University of Medical Sciences, Sari, Iran
AUTHOR
Pooria
Gill
pooriagill@yahoo.com
2
Nanomedicine Group, Immunogenetics Research Center, Mazandaran University of Medical Sciences, Sari, Iran
AUTHOR
Mohammad Sadegh
Rezai
drmsrezaii@yahoo.com
3
Pediatric Infectious Diseases Research Center, Mazandaran University of Medical Sciences, Sari, Iran
LEAD_AUTHOR
1. Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003;36:281-285.
1
2. Lentino J, Baddour L, Wray M, Wong E, Yu V. Staphylococcus aureus and other bacteremias in hemodialyis patients: Antibiotic therapy and surgical removal of access site. Infection 2000;28:355-360.
2
3. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003;111:1265-1273.
3
4. Rezai MS, Pourmousa R, Dadashzadeh R, Ahangarkani F. Multidrug resistance pattern of bacterial agents isolated from patient with chronic sinusitis. Caspian J Intern Med 2016;7:114.
4
5. Inal JM. Phage therapy: a reappraisal of bacteriophages as antibiotics. Arch Immunol Ther Exp 2003;51:237-244.
5
6. Park SC, Shimamura I, Fukunaga M, Mori K-I, Nakai T. Isolation of bacteriophages specific to a fish pathogen, Pseudomonas plecoglossicida, as a candidate for disease control. Appl Environ Microbiol 2000;66:1416-1422.
6
7. Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol 1997;5:268-271.
7
8. Garcia-Doval C, Castón JR, Luque D, Granell M, Otero JM, Llamas-Saiz AL, et al. Structure of the receptor-binding carboxy-terminal domain of the bacteriophage T5 L-shaped tail fibre with and without its intra-molecular chaperone. Viruses 2015;7:6424-6240.
8
9. Miller ES, Kutter E, Mosig G, Arisaka F, Kunisawa T, Rüger W. Bacteriophage T4 genome. Microbiol Mol Biol Rev 2003; 67:86-156.
9
10. Simon LD, Randolph B. Bacteriophage T4 bypass31 mutations that make gene 31 nonessential for bacteriophage T4 replication: isolation and characterization. J Virol 1984;51:321-328.
10
11. Synnott AJ, Kuang Y, Kurimoto M, Yamamichi K, Iwano H, Tanji Y. Isolation from sewage influent and characterization of novel Staphylococcus aureus bacteriophages with wide host ranges and potent lytic capabilities. Appl Environ Microbiol 2009;75:4483-4490.
11
12. Awais R, Fukudomi H, Miyanaga K, Unno H, Tanji Y. A recombinant bacteriophage‐based assay for the discriminative detection of culturable and viable but nonculturable Escherichia coli O157: H7. Biotechnol Prog 2006;22:853-859.
12
13. Dupres V, Verbelen C, Dufrêne YF. Probing molecular recognition sites on biosurfaces using AFM. Biomaterials 2007;28:2393-2402.
13
14. Ackermann H-W, Ackermann H-W. The first phage electron micrographs. Bacteriophage 2011;1:225-227.
14
15. Fotiadis D, Scheuring S, Müller SA, Engel A, Müller DJ. Imaging and manipulation of biological structures with the AFM. Micron 2002;33:385-397.
15
16. Dufrene Y. Application of atomic force microscopy to microbial surfaces: from reconstituted cell surface layers to living cells. Micron 2001;32:153-165.
16
17. Meyer RL, Zhou X, Tang L, Arpanaei A, Kingshott P, Besenbacher F. Immobilisation of living bacteria for AFM imaging under physiological conditions. Ultramicroscopy 2010;110:1349-1357.
17
18. Bolshakova AV, Kiselyova OI, Yaminsky IV. Microbial surfaces investigated using atomic force microscopy. Biotechnol Prog 2004;20:1615-1622.
18
19. Brown DF, Edwards DI, Hawkey PM, Morrison D, Ridgway GL, Towner KJ, et al. Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother 2005;56:1000-1018.
19
20. Abdulamir AS, Jassim SA, Hafidh RR, Bakar FA. The potential of bacteriophage cocktail in eliminating Methicillin-resistant Staphylococcus aureus biofilms in terms of different extracellular matrices expressed by PIA, ciaA-D and FnBPA genes. Ann Clin Microbiol Antimicrob 2015;14:49.
20
21. Jandt KD. Atomic force microscopy of biomaterials surfaces and interfaces. Surf SCI 2001;491:303-32.
21
22. Rahimzadeh G, Gill P, Rezai MS. Characterization and lytic activity of methicillin-resistant Staphylococcus aureus (MRSA) phages isolated from NICU. Australasian Med J 2016;9:169-175.
22
23. Rahimzadeh G, Gill P, Rezai MS. Characterization of methicillin-resistant Staphylococcus aureus (MRSA) phages from sewage at a tertiary pediatric hospital. Arch Pediatr Infect Dis 2017; 5:e39615.
23
24. Rafati A, Gill P. Ultrastructural characterizations of DNA nanotubes using scanning tunneling and atomic force microscopes. J Microsc Ultrastruct 2016;4:1-5.
24
25. Dubrovin EV, Voloshin AG, Kraevsky SV, Ignatyuk TE, Abramchuk SS, Yaminsky IV, et al. Atomic force microscopy investigation of phage infection of bacteria. Langmuir 2008;24:13068-13074.
25
26. Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel antimicrobials. Future Microbiol 2012;7:1147-1171.
26
27. Dubrovin EV, Fedyukina GN, Kraevsky SV, Ignatyuk TE, Yaminsky IV, Ignatov SG. AFM specific identification of bacterial cell fragments on biofunctional surfaces. Open Microbiol J 2012;6:22.
27
28. Cao B, Xu H, Mao C. Transmission electron microscopy as a tool to image bioinorganic nanohybrids: The case of phage‐gold nanocomposites. Microsc Res Tech 2011;74:627-635.
28
29. Kourkoutis LF, Plitzko JM, Baumeister W. Electron microscopy of biological materials at the nanometer scale. Annu Rev Mater Res 2012;42:33-58.
29
ORIGINAL_ARTICLE
Evaluation of lentinan effects on cytochrome P450 activity in rats by a cocktail method
Objective(s): In this study, a cocktail of probe drugs was used to assess whether lentinan could influence the activities of rat enzymes CYP3A4, CYP2D6, CYP1A2, CYP2C19, and CYP2C9 in vivo. Materials and Methods: Fourteen days after intraperitoneal injection of lentinan, rats were given an oral dose of a cocktail solution containing phenacetin, tolbutamide, omeprazole, metoprolol, and midazolam. Then, we obtained blood in specific durations for the determination of plasma concentration of the probe drugs using UPLC-MS/MS. We also evaluated the pharmacokinetic parameters using the DAS 2.0 software. Results: We found that various concentrations of lentinan increased the activity of rat CYP1A2, CYP3A4, CYP2D6, and CYP2C19 but not CYP2C9. Conclusion: These findings suggest that clinical application of lentinan combination with CYP3A4, CYP1A2, CYP2C19, or CYP2D6 should be given careful consideration as this may lead to herb-drug interactions and hence treatment failure.
https://ijbms.mums.ac.ir/article_12194_e36ea5b976a2f89ce7525a89090adc1e.pdf
2019-03-01
296
301
10.22038/ijbms.2019.31611.7611
Cocktail
CYP
Herb-drug interaction
Lentinan
Probe drug
Yiping
Lin
2424514192@qq.com
1
Jinhua Polytechnic, Jinhua 321007, Zhejiang, China
AUTHOR
Yanli
Wei
57103009@qq.com
2
Jinhua Polytechnic, Jinhua 321007, Zhejiang, China
AUTHOR
Xiaoxia
Hu
85588581@qq.com
3
Jinhua Central Hospital, Jinhua 321000, Zhejiang, China
AUTHOR
Mei-Ling
Wu
550997006@qq.com
4
Jinhua Polytechnic, Jinhua 321007, Zhejiang, China
AUTHOR
Jingchan
Yao
1343381183@qq.com
5
Jinhua Polytechnic, Jinhua 321007, Zhejiang, China
AUTHOR
Xiaoqian
Ying
532793840@qq.com
6
Jinhua Polytechnic, Jinhua 321007, Zhejiang, China
AUTHOR
Xiaoyan
Fu
fxythd@qq.com
7
Jinhua Polytechnic, Jinhua 321007, Zhejiang, China
AUTHOR
Mingxing
Ding
1583893673@qq.com
8
Jinhua Polytechnic, Jinhua 321007, Zhejiang, China
AUTHOR
Liman
Qiao
qiaoliman163@163.com
9
The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China
LEAD_AUTHOR
1. Suga T, Shiio T, Maeda YY, and Chihara G. Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis. Cancer Res 1984; 44:5132-5137.
1
2. Zhang L, Ji Q, Ni ZH, and Sun J. Prohibitin induces apoptosis in BGC823 gastric cancer cells through the mitochondrial pathway. Asian Pac J Cancer Prev 2012; 13:3803-3807.
2
3. Fujimoto K, Tomonaga M, and Goto S. A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan. Anticancer Res 2006; 26:4015-4018.
3
4. Chen YW, Hu DJ, Cheong KL, Li J, Xie J, Zhao J, et al. Quality evaluation of lentinan injection produced in China. J Pharm Biomed Anal 2013; 78-79:176-182.
4
5. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002; 34:83-448.
5
6. Rendic S and Guengerich FP. Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 2010; 11:4-84.
6
7. Zhou SF, Liu JP, and Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41:89-295.
7
8. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, and Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008; 82:667-715.
8
9. Jiang K, Li K, Qin F, Lu X, and Li F. Assessment of a novel beta2-adrenoceptor agonist, trantinterol, for interference with human liver cytochrome P450 enzymes activities. Toxicol In Vitro 2011; 25:1033-1038.
9
10. Tanaka E, Kurata N, and Yasuhara H. How useful is the “cocktail approach” for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J Clin Pharm Ther 2003; 28:157-165.
10
11. Xu RA, Xu ZS, Lin GY, Hu LF, Wang XQ, and Ma JS. Effect of Repeated Wuniu Early Tea Administration on the CYP450 Activity Using a Cocktail Method. Indian J Pharm Sci 2013; 75:94-98.
11
12. Xu RA, Xu ZS, Hu LF, Zhang CH, Pan XF, Shi DW, et al. Effects of repeated allopurinol administration on rat cytochrome P450 activity. Pharmazie 2013; 68:365-368.
12
13. Wang S, Dong Y, Su K, Zhang J, Wang L, Han A, et al. Effect of codeine on CYP450 isoform activity of rats. Pharm Biol 2017; 55:1223-1227.
13
14. Wei YL, Du HJ, Lin YP, Wu ML, Ying XQ, Ding MX, et al. Simultaneous determination of five rat CYP450 probe drugs by UPLC-MS/MS method. Latin American Journal of Pharmacy 2016; 35:1810-1815.
14
15. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423.
15
16. Mustajoki P, Mustajoki S, Rautio A, Arvela P, and Pelkonen O. Effects of heme arginate on cytochrome P450-mediated metabolism of drugs in patients with variegate porphyria and in healthy men. Clin Pharmacol Ther 1994; 56:9-13.
16
17. Miners JO and Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45:525-538.
17
18. Goldstein JA and de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4:285-299.
18
19. Lu SK, Callahan SM, and Brunner LJ. Suppression of hepatic CYP3A1/2 and CYP2C11 by cyclosporine is not mediated by altering growth hormone levels. J Pharmacol Exp Ther 2003; 305:331-337.
19
20. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009; 48:689-723.
20
21. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009; 48:761-804.
21
ORIGINAL_ARTICLE
Effect of IL-2 co-expressed or co-inoculated with immuno-dominant epitopes from VP1 protein of FMD virus on immune responses in BALB/c mice
Objective(s): The results of studies on vaccine development for foot-and-mouth disease (FMD) virus show that the use of inactivated vaccines for FMD virus is not completely effective. Novel vaccinations based on immuno-dominant epitopes have been shown to induce immune responses. Furthermore, for safety of immunization, access to efficient adjuvants against FMD virus seems to be critical.Materials and Methods: In this study, we produced epitope recombinant vaccines from the VP1 protein of the FMD virus for serotype O of Iran. Constructs were included polytope (tandem-repeat multiple-epitope), polytope coupled with interleukin-2 (polytope-IL 2) as a molecular adjuvant and IL-2. Three expression vectors were constructed and expressed in Escherichia coli BL21 (DE3). To evaluate whether these recombinant vaccines induce immune responses, BALB/c mice were injected with the recombinant vaccines and their immune responses were compared with a negative control group. The humoral and cellular immune responses were measured by ELISA.Results: The results showed that IL-2 co-expressed or co-inoculated with Polytope protein enhances the immune effect of multiple epitope recombinant vaccine against FMD virus. The results of total immunoglobulin G (IgG), IgG1, and IgG2a levels and secretion of interferon gamma (IFN-γ), IL-4 and IL-10 revealed that there were significant differences between negative control group and other injected mice with the recombinant vaccines (P<0.05).Conclusion: Observations indicated that the epitope recombinant plasmid of the VP1 protein co-expressed or co-inoculated with IL-2 was effective in inducing an enhanced immune response. Therefore, IL-2 can be recommended as a potential adjuvant for epitope recombinant vaccine of the VP1 protein from FMD virus.
https://ijbms.mums.ac.ir/article_12230_8f93319238daad8d9839c71982feac76.pdf
2019-03-01
302
309
10.22038/ijbms.2019.31972.7683
Adjuvant
Foot-and-mouth disease-virus
Immune response Interleukin-2
VP1 protein
Mohammad
Doosti
doosti.m@gmail.com
1
Department of Animal Science, Ferdowsi University of Mashhad, Mashhad, Iran
AUTHOR
Mohammadreza
Nassiri
nassiryr@um.ac.ir
2
Department of Animal Science, Ferdowsi University of Mashhad, Mashhad, Iran
LEAD_AUTHOR
Khadijeh
Nasiri
kh.nasiri@umz.ac.ir
3
Department of Exercise Physiology, Faculty of Sport Science, University of Mazandaran, Babolsar, Iran 4 Razi Vaccine and Serum Research Institute, Mashhad, Iran
AUTHOR
Mojtaba
Tahmoorespur
tahmoorespur@um.ac.ir
4
Department of Animal Science, Ferdowsi University of Mashhad, Mashhad, Iran
AUTHOR
saeed
Zibaee
saeedzibaee@yahoo.co.uk
5
Razi Vaccine and Serum Research Institute, Mashhad, Iran
AUTHOR
1. Kim SA, Liang CM, Cheng IC, Cheng YC, Chiao MT, Tseng CJ, et al. DNA vaccination against foot-and-mouth disease via electroporation: study of molecular approaches for enhancing VP1 antigenicity. J Gene Med 2006;8:1182-1191.
1
2. Mason PW, Grubman MJ, Baxt B. Molecular basis of pathogenesis of FMDV. Virus Res 2003; 91: 9-32.
2
3. Kupper H, Keller W, Kurz C, Forss S, Schaller H, Franze R, et al. Cloning of cDNA of major antigen of foot-and-mouth disease virus and expression in E. coli. Nature 1981; 289: 555-559.
3
4. Saiz M, Nunez JI, Jimenez-Clavero MA, Baranowski E, Sobrino F. Foot-and-mouth disease virus: biology and prospects for disease control. Microbes Infect 2002; 4: 1183-1192.
4
5. Sutmoller P, Olascoaga RC. The risks posed by the importation of animals vaccinated against foot and mouth disease and products derived from vaccinated animals: a review. Rev Sci Tech 2003; 22: 823–835.
5
6. Barteling SJ, Vreeswijk J. Developments in foot-and-mouth disease vaccines. Vaccine 1991; 9: 75–88.
6
7. Doel TR. FMD vaccines. Virus Res 2003; 91:81–89.
7
8. Du Y, Dai J, Li Y, Li C, Qi J, Duan S, Jiang P. Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon alpha in mice and guinea pigs, Veterinary. Immunol. Immunopathol 2008;124: 274-283.
8
9. Chinsangaram J, Mason PW, Grubman MJ. Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus. Vaccine 1998; 16:1516-1622.
9
10. DiMarchi R, Brooke G, Gale C, Cracknell V, Doel T, Mowat N. Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science 1986; 232: 639-641.
10
11. Liu XS, Wang YL, Zhang YG, Fang YZ, Pan L, Lu JL, et al. Identification of H-2d restricted T cell epitope of foot-and-mouth disease virus structural protein VP1. Virol J 2011; 7:426.
11
12. Fang M, Li J, Wang H, Yang M, Zhang Y, Zhou L, et al. Correlation between efficacy and structure of recombinant epitope vaccines against bovine type O foot and mouth disease virus. Biotechnol Lett 2012;34: 839-847.
12
13. Morgan D, Moore D. Protection of cattle and swine against foot-and-mouth disease, using biosynthetic peptide vaccines. Am J Vet Res 1990;51: 40-45.
13
14. Zhang L, Zhang J, Chen HT, Zhou JH, Li NM, Ding YZ, et al. Research in advance for FMD Novel Vaccines.Virol J 2011; 8:268.
14
15. Zhang C, Wang B, Wang M. GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease. Virol J 2011;8: 7.
15
16. Doosti M, Nassiri MR, Tahmoorespur M, Haghparast A, Zibaei S. Design and construction of multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O. Research On Animal Production 2017; 8: 115-123.
16
17. Shao JJ, Wong C, Lin T, Lee SK, Cong GZ, Sin FW, et al. Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine. Clin Vaccine Immunol 2011;18: 143-149.
17
18. Bradford MM. A rapid and sensitive for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal Biochem1976; 72:248-254. 19. Masoudi S, Mohammadi AA, Mahboudi F, Roustai, MH, Khedmati K. Molecular Cloning of VP1 gene of Foot-and-Mouth Disease Virus Type Ol/lran. Arch. Razi ln 2001; 51.
18
20. Qiumei S , Guisheng G , Yanying Z , Hua X , Zengqiang Y, Hongxuan H. Cloning of structural protein VPI gene of foot and mouth disease virus and its expression in Escherichia coli. J Animal Veterinary Adv 2012; 11:426-430.
19
21. Bae JY, Moon SH, Choi JA, Park JS, Hahn BS, Kim KY, et al. Recombinant DNA and protein vaccines for foot-and-mouth disease induce humoral and cellular immune responses in mice. Immune Netw 2009;9: 265-273.
20
22. Gao SD, Du JZ, Chang HY, Cong GZ, Shao JJ, Lin T, et al. B cell epitopes within VP1 of type O foot-and-mouth disease virus for detection of viral antibodies. Virol Sin 2010;25: 18-26.
21
23. Zhang Z, Hutching G, Kitching P, Alexandersen S. The effects of gamma interferon on replication of foot-and-mouth disease virus in persistently infected bovine cells. Arch Virol 2002;147:2157-2167.
22
24. Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012; 4:1015-1028.
23
25. Shi XJ, Wang B, Zhang C, Wang M. Expressions of Bovine IFN-γ and Foot-and-Mouth Disease VP1 antigen in P. pastoris and their effects on mouse immune response to FMD antigens. Vaccine 2006;24: 82-89.
24
26. Yang CD, Liao JT, Lai CY, Jong MH, Liang CM, Lin YL, et al. Induction of protective immunity in swine by recombinant bamboo mosaic virus expressing foot-and-mouth disease virus epitopes. BMC Biotechnol 2007; 7: 62.
25
27. Du J, Chang H, Cong G, ShaoJ, Lin T, Shang Y, et al. Complete nucleotide sequence of a Chinese serotype Asia1 vaccine strain of foot-and-mouth disease virus. Virus Genes 2007; 35:635-642.
26
28. Gao F, Feng L, Zhang Q, Yan R, Li YG, Li XS. Immunogenicity of Two FMDV nonameric peptides encapsulated in liposomes in mice and the protective efficacy in guinea pigs. PLoS One 2013;8: e68658.
27
29. Park JH, Kim SJ, Oem JK, Lee KN, Kim YJ, Kye SJ, et al. Enhanced immune response with foot and mouth disease virus VP1 and interleukin-1 fusion genes. J Vet Sci 2006; 7: 257-262.
28
ORIGINAL_ARTICLE
Ketamine and its combinations with valproate and carbamazepine are ineffective against convulsions induced by atropine treatment and food intake in fasted mice
Objective(s): Fasted rodents treated with antimuscarinics develop convulsions after refeeding. Food deprivation for 48 hr produces changes in [3H]glutamate binding suggesting glutamatergic contribution to the underlying mechanism of the seizures that are somewhat unresponsive to antiepileptics. Studies in animals and epileptic patients yielded considerable information regarding the anticonvulsant effect of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine. Thus, this study evaluated the efficacy of ketamine and its combinations with valproate and carbamazepine on convulsions in fasted animals.Materials and Methods: Following 24 hr of fasting, mice were given saline, 5 or 10 mg/kg ketamine, 250 mg/kg sodium valproate, 24 mg/kg carbamazepine, 5 mg/kg ketamine+sodium valproate, or 5 mg/kg ketamine+carbamazepine and then were treated with saline or 2.4 mg/kg atropine (5-9 mice per group). The animals were observed for the occurrence of convulsions after being allowed to eat ad libitum.Results: Ketamine, valproate and carbamazepine pretreatments were ineffective in preventing the convulsions developed after atropine treatment and food intake in fasted animals. The incidence of convulsions was significantly higher in 5 and 10 mg/kg ketamine, carbamazepine, and carbamazepine+ketamine groups, but not in the valproate and valproate+ketamine treated animals. Conclusion: In contrast to previous findings obtained with the NMDA antagonist dizocilpine (MK-801), ketamine lacks activity against convulsions developed after fasting. The drug does not enhance the efficacy of valproate and carbamazepine either. Using different doses of ketamine or other NMDA antagonists, further studies may better clarify the anticonvulsant effect of ketamine and/or role of glutamate in these seizures.
https://ijbms.mums.ac.ir/article_12188_ea40902ea2fb1dd049405130beb8ec74.pdf
2019-03-01
310
314
10.22038/ijbms.2019.33890.8062
Atropine
Carbamazepine
Convulsion
fasting
Glutamate
Ketamine
Valproate
Neriman
Gözüaçık
nerimang@hotmail.com
1
Department of Medical Pharmacology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
AUTHOR
Aslı
Zengin Türkmen
aslizenginn@yahoo.com
2
Department of Physiology, Faculty of Medicine, Istanbul Yeni Yuzyil University, Istanbul, Turkey
AUTHOR
Asiye
Nurten
asiyenurten@gmail.com
3
Department of Physiology, Faculty of Medicine, Istanbul Yeni Yuzyil University, Istanbul, Turkey
AUTHOR
Nurhan
Enginar
engnur@istanbul.edu.tr
4
Department of Medical Pharmacology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
LEAD_AUTHOR
1. Enginar N, Nurten A. Seizures triggered by food intake in antimuscarinic-treated fasted animals: evaluation of the experimental findings in terms of similarities to eating-triggered epilepsy. Epilepsia 2010; 51(Suppl 3):80-84.
1
2. Saygı Bacanak M, Aydın B, Cabadak H, Nurten A, Gören MZ, Enginar N. Contribution of M1 and M2 muscarinic receptor subtypes to convulsions in fasted mice treated with scopolamine and given food. Behav Brain Res 2017; doi: 10.1016/j.bbr.2017.11.018.
2
3. Enginar N, Yamantürk P, Nurten A, Nurten R, Koyuncuoğlu H. Scopolamine-induced convulsions in fasted mice after food intake: determination of blood glucose levels, (3H)glutamate binding kinetics and antidopaminergic drug effects. Neuropharmacology 2003; 44:199-205.
3
4. Nurten A, Ozerman B, Ozen I, Kara I. The role of solid fluid intake in antimuscarinic-induced convulsions in fasted mice. Epilepsy Behav 2009; 15:142-145.
4
5. Enginar N, Nurten A, Yamantürk Çelik P, Açıkmeşe B. Scopolamine-induced convulsions in fasted mice after food intake: effects of glucose intake, antimuscarinic activity and anticonvulsant drugs. Neuropharmacology 2005; 49:293-299.
5
6. Büget B, Türkmen AZ, Allahverdiyev O, Enginar N. Antimuscarinic-induced convulsions in fasted animals after food intake: evaluation of the effects of levetiracetam, topiramate and different doses of atropine. Naunyn-Schmiedebergs Arch Pharmacol 2016; 389:57-62.
6
7. Ahuja GK, Pauranik A, Behari M, Prasad K. Eating epilepsy. J Neurol 1988; 235:444-447.
7
8. Senanayake N. Reflex epilepsies: experience in Sri Lanka. Ceylon Med J 1994; 39:67-74.
8
9. Striano S, Coppola A, del Gaudio L, Striano P. Reflex seizures and reflex epilepsies: old models for understanding mechanisms of epileptogenesis. Epilepsy Res 2012; 100:1-11.
9
10. Mason KP, Michna E, DiNardo JA, Zurakowski D, Karian VE, Connor L, et al. Evolution of a protocol for ketamine-induced sedation as an alternative to general anesthesia for interventional radiologic procedures in pediatric patients. Radiology 2002; 225:457-465.
10
11. Ghasemi M, Schachter SC. The NMDA receptor complex as a therapeutic target in epilepsy: a review. Epilepsy Behav 2011; 22:637-642.
11
12. Borowicz KK, Czuczwar SJ. Effects of etomidate, ketamine or propofol, and their combinations with conventional antiepileptic drugs on amygdala-kindled convulsions in rats. Neuropharmacology 2003; 45:315–324.
12
13. Prüss H, Holtkamp M. Ketamine successfully terminated malignant status epilepticus. Epilepsy Res 2008; 82:219-222.
13
14. Ferrer-Allado T, Brechner VL, Dymond A, Cozen H, Crandall P. Ketamine-induced electroconvulsive phenomena in the human limbic and thalamic regions. Anesthesiology 1973; 38:333-344.
14
15. Modica PA, Tempelhoff R, White PF. Pro- and anticonvulsant effects of anesthetics (Part II). Anesth Analg 1990; 70:433-444.
15
16. Lee W, Wolfe BB. Regulation of muscarinic receptor subtypes and their responsiveness in rat brain following chronic atropine administration. Mol Pharmacol 1989; 36:749-757.
16
17. Racine RJ. Modification of seizure activity by electrical modification. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972; 32: 281-294.
17
18. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995; 34:1239-1258.
18
19. McDonald JF, Bartlett MC, Mody I, Pahapill P, Reynolds JN, Salter MW, et al. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultered mouse hippocampal neurons. J Physiol 1991; 432:483-508.
19
20. Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 1996; 8:446-454.
20
21. Tricklebank MD, Singh L, Oles RJ, Preston J, Iversen SD. The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 1989; 167:127-135.
21
22. Szakacz R, Weiczner R, Mihály A, Krisztin-Péva B, Zádor Z, Zádor E. Non-competitive NMDA antagonists moderate seizure-induced c-fos expression in the rat cerebral cortex. Brain Res Bull 2003; 59:485-493.
22
23. Durieux ME. Inhibition by ketamine of muscarinic acetylcholine receptor function. Anesth Analg 1995; 81:57-62.
23
24. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the prefrontal cortex: modulation by a group of II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003; 117:697-706.
24
25. Manocha A, Sharma KK, Mediratta PK. Possible mechanism of anticonvulsant effect of ketamine in mice. Indian J Exp Biol 2001; 39:1002-1008.
25
26. Sharma AC, Thorat SN, Nayar U, Kulkarni SK. Dizocilpine, ketamine and ethanol reverse NMDA-induced EEG changes and convulsions in rats and mice. Indian J Physiol Pharmacol 1991; 35:111-116.
26
27. Freitas RM, Sousa FC, Viana GS, Fonteless MM. Effect of gabaergic, glutamatergic, antipsychotic and antidepressant drugs on pilocarpine-induced seizures and status epilepticus. Neuroscience Lett 2006; 408:79-83.
27
28. Guler G, Erdogan G, Golgeli A, Akin A, Boyaci A. Ketamine reduces lidocaine-induced seizures in mice. Int J Neurosci 2005; 115:1239-1244.
28
29. Schneider PG, Rodrigues de Lorez Arnaiz G. Ketamine prevents seizures and reverses changes in muscarinic receptor induced by bicucilline in rats. Neurochem Inter 2013; 62:258-264.
29
30. Ghasemi M, Shafaroodi H, Nazarbeiki S, Meskar H, Heydarpour P, Ghasemi A, et al. Voltage-dependent calcium channel and NMDA receptor antagonists augment anticonvulsant effects of lithium chloride on pentylenetetrazole-induced clonic seizures in mice. Epilepsy Behav 2010; 18:171-178.
30
31. Twele F, Bankstahl M, Klein S, Römermann K, Löscher W. The AMPA receptor antagonist NBQX exerts antiseizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy. Neuropharmacology 2015; 95:234-242.
31
32. Kurdi MS, Sushma KS, Ranjana R, Kiran PB. Ketamine: a convulsant? Anesth Essays Res 2017; 11:272-273.
32
33. DeVore GR, McQueen JK, Woodburry DM. Ketamine hydrochloride and its effect on a chronic cobalt epileptic cortical focus. Epilepsia 1976; 17:111-117.
33
34. Dashputra AV, Borkar AS, Hemnani TJ, Badwaik RT. Effect of ketamine on seizure activity and its interactions with antiepileptic drugs in rats. Int J Med Pharm Sci 2012; 3:1-8.
34
35. Bourn WM, Yang DJ, Davisson JN. Effect of ketamine enantiomers on sound-induced convulsions in epilepsy prone rats. Pharmacol Res Commun 1983; 15:815-824.
35
36. Gasior M, Kaminski R, Brudniak T, Kleinrok Z, Czuczwar SJ. Influence of nicardipine, nimodipine and flunarizine on the anticonvulsant efficacy of antiepileptics against pentylenetetrazol in mice. J Neural Transm 1996; 103:819-831.
36
37. Borowicz KK, Piskorska B, Stepniak B, Czuczwar SJ. Effects of fluoxetine on the anticonvulsant action of valproate and ethosuximide in mouse model of myoclonic convulsions. Ann Agric Environ Med 2012: 19:487-490.
37
38. Sarro GD, Paola ED, Gratteri S, Gareri P, Rispoli V, Siniscalchi A, et al. Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. Pharmacol Res 2012; 65:285-296.
38
39. Borowicz KK, Luszczki J, Czuczwar SJ. Interactions between non-barbiturate injectable anesthetics and conventional antiepileptic drugs in the maximal electroshock test in mice-an isobolographic analysis. Eur Neuropsychopharmacol 2004; 14:163-172.
39
40. Nurten A, Enginar N. The evaluation of antimuscarinic-induced convulsions in fasted rats after food intake. Epilepsy Res 2006; 72:171-177.
40
41. Enginar N, Nurten A, Karamürsel Y, Zengin A, Baran E. Scopolamine-induced convulsions in fasted mice after food intake: evaluation of the sedative effect in the suppression of convulsions. Epilepsy Res 2010; 89:2-6.
41
ORIGINAL_ARTICLE
Efficiency of naringin against reproductive toxicity and testicular damages induced by bisphenol A in rats
Objective(s): Bisphenol A (BPA) as a synthetic compound is applied in many plastic industries. BPA has been reported to have endocrine-disrupting feature with cytotoxic effects. The study aimed to evaluate the efficiency of Naringin against testicular toxicity induced by BPA in adult rats.Materials and Methods: The animals were assigned into six groups of control, BPA-treated (50 mg/kg), BPA+Naringin-administrated (40, 80, 160 mg/kg) and Naringin-treated (160 mg/kg) for 30 days. At the end of experiments, testicular weight, total testicular protein, epididymal sperm count, testicular enzymes, serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone and estradiol, testicular enzymatic and non-enzymatic antioxidants and histopathology of testis tissue were evaluated by their own methods. Results: The results showed a reduction in testicular weight, total testicular protein, epididymal sperm count, testicular enzymes (alkaline phosphatase and lactate dehydrogenase) and decrease in the serum TSH, LH, testosterone and estradiol in BPA-administrated rats. Furthermore, BPA reduced the enzyme activities of glutathione peroxidase, superoxide dismutase, and catalase in testis tissue. Also, BPA caused an induction in lipid peroxidation and increase in reactive oxygen species levels, whereas it decreased the glutathione content of testis tissue. Histological findings exhibited seminiferous tubules vacuoles, atrophy and separation of the germinal epithelium in BPA-administrated rats. Oral administration of Naringin along with BPA normalized the biochemical, morphological and histological changes and reduced the testicular toxic condition. Conclusion: These results demonstrated that Naringin significantly managed male reproductive toxicity by antioxidant capabilities, preventing morphological modifications and escalating defense mechanism, thereby reducing oxidative stress from BPA-induced damage.
https://ijbms.mums.ac.ir/article_12179_e60d094bd3ed220aea360cae542db6f8.pdf
2019-03-01
315
323
10.22038/ijbms.2019.29757.7184
Bisphenol A
Endocrine-disrupting chemicals
Naringin
Oxidative stress
Testicular toxicity
Soheila
Alboghobeish
alboghobeish.s@ajums.ac.ir
1
Department of Pharmacology, School of Medicine, Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Masoud
Mahdavinia
mahdavimasoud@yahoo.com
2
Department of Toxicology, School of Pharmacy, Jundishapur University of Medical Sciences, Ahvaz, Iran
LEAD_AUTHOR
Leila
Zeidooni
leilazeidooni@gmail.com
3
Department of Toxicology, School of Pharmacy, Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Azin
Samimi
azin.samimi831@gmail.com
4
Department of Toxicology, School of Pharmacy, Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Ali Akbar
Oroojan
aliakbar_oroojan@yahoo.com
5
Department of Physiology, Student Research Committee of Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran
AUTHOR
Saeid
Alizadeh
alizadeh.s@ajums.ac.ir
6
Department of Toxicology, School of Pharmacy, Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Mohammad Amin
Dehghani
mohammaddeh83@yahoo.com
7
Department of Toxicology, School of Pharmacy, Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Akram
Ahangarpour
akramahangarpour@gmail.com
8
Health Research Institute, Diabetes Research Center, Department of Physiology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Layasadat
Khorsandi
khorsandi_cmrc@yahoo.com
9
Department of Histology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
1. Gurunath S, Pandian Z, Anderson RA, Bhattacharya S. Defining infertility a systematic review of prevalence studies. Hum Reprod Update 2011;17:575-588.
1
2. Meeker JD. Exposure to environmental endocrine disrupting compounds and men’s health. Maturitas 2010;66:236-241.
2
3. Mohapatra D, Brar S, Tyagi R, Surampalli R. Physico-chemical pre-treatment and biotransformation of wastewater and wastewater sludge fate of bisphenol A. Chemosphere 2010;78:923-941.
3
4. Vandenberg L, Hauser R, Marcus M, Olea N, Welshons W. Human exposure to bisphenol A (BPA). Reprod Toxicol 2007; 24: 139–177.
4
5. Geens T, Aerts D, Berthot C, Bourguignon J-P, Goeyens L, Lecomte P, et al. A review of dietary and non-dietary exposure to bisphenol-A. Food Chem Toxicol 2012;50:3725-3740.
5
6. Dobrzyńska MM, Jankowska‐Steifer EA, Tyrkiel EJ, Gajowik A, Radzikowska J, Pachocki KA. Comparison of the effects of bisphenol a alone and in a combination with X‐irradiation on sperm count and quality in male adult and pubescent mice. Environ Toxicol 2014;29:1301-1313.
6
7. Dobrzyńska MM, Radzikowska J. Genotoxicity and reproductive toxicity of bisphenol A and X-ray/bisphenol A combination in male mice. Drug Cheml Toxicol 2013;36:19-26.
7
8. Tamilselvan P, Langeswaran K, Vijayaprakash S, Revathy R, Balasubramanian MP. Efficiency of lycopene against reproductive and developmental toxicity of bisphenol A in male Sprague Dawley rats. Biomed Prevent Nutrit. 2014;4:491-498.
8
9. Muñoz-de-Toro M, Markey CM, Wadia PR, Luque EH, Rubin BS, Sonnenschein C, et al. Perinatal exposure to bisphenol-A alters peripubertal mammary gland development in mice. Endocrinology. 2005;146:4138-4147.
9
10. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, Van Der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 1998;139:4252-3263.
10
11. Richter CA, Birnbaum LS, Farabollini F, Newbold RR, Rubin BS, Talsness CE, et al. In vivo effects of bisphenol A in laboratory rodent studies. Reprod Toxicol. 2007;24:199-224.
11
12. Tainaka H, Takahashi H, Umezawa M, Tanaka H, Nishimune Y, Oshio S, et al. Evaluation of the testicular toxicity of prenatal exposure to bisphenol A based on microarray analysis combined with MeSH annotation. J Toxicol Sci 2012;37:539-548.
12
13. Tiwari D, Vanage G. Mutagenic effect of Bisphenol A on adult rat male germ cells and their fertility. Reprod Toxicol 2013;40:60-68.
13
14. Salian S, Doshi T, Vanage G. Neonatal exposure of male rats to Bisphenol A impairs fertility and expression of sertoli cell junctional proteins in the testis. Toxicology 2009;265:56-67.
14
15. D’Cruz SC, Jubendradass R, Jayakanthan M, Rani SJA, Mathur PP. Bisphenol A impairs insulin signaling and glucose homeostasis and decreases steroidogenesis in rat testis: an in vivo and in silico study. Food Chem Toxicol 2012;50:1124-1133.
15
16. Kabuto H, Hasuike S, Minagawa N, Shishibori T. Effects of bisphenol A on the metabolisms of active oxygen species in mouse tissues. Environ Res 2003;93:31-35.
16
17. Fang Y, Zhou Y, Zhong Y, Gao X, Tan T. Effect of vitamin E on reproductive functions and anti-oxidant activity of adolescent male mice exposed to bisphenol A. J Hygiene Res. 2013;42:18-22.
17
18. El-Beshbishy HA, Aly HA, El-Shafey M. Lipoic acid mitigates bisphenol A-induced testicular mitochondrial toxicity in rats. Toxicol Ind Health 2013;29:875-887.
18
19. Xi W, Lee C, Yeung W, Giesy JP, Wong M, Zhang X, et al. Effect of perinatal and postnatal bisphenol A exposure to the regulatory circuits at the hypothalamus–pituitary–gonadal axis of CD-1 mice. Reprod Toxicol. 2011;31:409-417.
19
20. Ho Y-S, Magnenat J-L, Gargano M, Cao J. The nature of antioxidant defense mechanisms: a lesson from transgenic studies. Environ Health Perspect 1998;106:1219-1225.
20
21. Hales DB, Allen JA, Shankara T, Janus P, Buck S, Diemer T, et al. Mitochondrial function in Leydig cell steroidogenesi: Ann N Y Acad Sci 2005;1061:120-134.
21
22. Abdel-Monaim M, Abo-Elyousr K, Morsy K. Effectiveness of plant extracts on suppression of damping-off and wilt diseases of lupine (Lupinus termis Forsik. Crop Protect 2011;30:185-191.
22
23. Podder B, Song H-Y, Kim Y-S. Naringenin exerts cytoprotective effect against paraquat-induced toxicity in human bronchial epithelial BEAS-2B cells through NRF2 activatio. J Microbiol Biotechnol. 2014;24:605-613.
23
24. Jain A, Yadav A, Bozhkov A, Padalko V, Flora S. Therapeutic efficacy of silymarin and naringenin in reducing arsenic-induced hepatic damage in young rats. Ecotoxicol Environ Safet. 2011;74:607-614.
24
25. Kannappan S, Palanisamy N, Anuradha CV. Suppression of hepatic oxidative events and regulation of eNOS expression in the liver by naringenin in fructose-administered rats. Europ J Pharmacol 2010;645:177-184.
25
26. Fang F, Tang Y, Gao Z, Xu Q. A novel regulatory mechanism of naringenin through inhibition of T lymphocyte function in contact hypersensitivity suppression. Biochem Biophys Res Commun. 2010;397:163-169.
26
27. Renugadevi J, Prabu SM. Naringenin protects against cadmium-induced oxidative renal dysfunction in rats. Toxicology 2009;256:128-134.
27
28. Renugadevi J, Prabu SM. Cadmium-induced hepatotoxicity in rats and the protective effect of naringenin. Exp Toxicol Pathol 2010;62:171-181.
28
29. Akondi RB, Kumar P, Annapurna A, Pujari M. Protective effect of rutin and naringin on sperm quality in streptozotocin (STZ) induced type 1 diabetic rats. Iran J Pharm res 2011;10:585-393.
29
30. Ahangarpour A, Oroojan AA, Khorsandi L, Arzani G, Afshari G. Effects of betulinic acid on the male reproductive system of a streptozotocin-nicotinamide-induced diabetic mouse model. World J Men’s Health 2016;34:209-216.
30
31. Ahangarpour A, Oroojan AA, Heidari H. Effects of exendin-4 on male reproductive parameters of d-galactose induced aging mouse model. World J Men’s Health 2014;32:176-183.
31
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
32
33. Ahangarpour A, Zeidooni L, Rezaei M, Alboghobeish S, Samimi A, Oroojan AA. Protective effect of metformin on toxicity of butyric acid and arsenic in isolated liver mitochondria and langerhans islets in male mice: an in vitro study. Iran J Basic Med Sci 2017;20:1297-1303.
33
34. Ahangarpour A, Alboghobeish S, Oroojan AA, Zeidooni L, Samimi A, Afshari G. Effects of combined exposure to chronic high-fat diet and arsenic on thyroid function and lipid profile in male mouse. Biol Trace Elem Res 2017:1-12.
34
35. Ahangarpour A, Alboghobeish S, Rezaei M, Khodayar MJ, Oroojan AA, Zainvand M. Evaluation of diabetogenic mechanism of high fat diet in combination with Arsenic exposure in male mice. Iran J Pharm Res 2017;3:184-193.
35
36. Ahangarpour A, Zeidooni L, Samimi A, Alboghobeish S, Khorsandi LS, Moradi M. Chronic exposure to arsenic and high fat diet additively induced cardiotoxicity in male mice. Res Pharm Sci 2018;13:47-53.
36
37. Ahangarpour A, Oroojan AA, Rezaei M, Khodayar MJ, Alboghobeish S, Zeinvand M. Effects of butyric acid and arsenic on isolated liver mitochondria and pancreatic islets of male mouse. Gastroenterol Hepatol Bed Bench. 2017:134-139.
37
38. Lawrence RA. Reprint of “glutathione peroxidase activity in selenium-deficient rat liver”. Biochem Biophysic Res Com 2012;425:503-509.
38
39. Talebi AR, Khorsandi L, Moridian M. The effect of zinc oxide nanoparticles on mouse spermatogenesis. J Assist Reprod Genet 2013;30:1203-1209.
39
40. Shalaby KA, Saleh EM. Ameliorative effect of honey bee propolis on the nonylphenol induced-reproductive toxicity in male Albino rats. Aust J Basic Applied Sci 2011;5:918-927.
40
41. Agarwal A, Gupta S, Sikka S. The role of free radicals and antioxidants in reproduction. Curren Opin Obstet Gynecol 2006;18:325-332.
41
42. Anjum S, Rahman S, Kaur M, Ahmad F, Rashid H, Ansari RA, et al. Melatonin ameliorates bisphenol A-induced biochemical toxicity in testicular mitochondria of mouse. Food Chem Toxicol 2011;49:2849-2854.
42
43. Revathy R, Langeswaran K, Ponnulakshmi R, Balasubramanian MP, Selvaraj J. Ipomoea batatas tuber efficiency on bisphenol A-induced male reproductive toxicity in sprague dawley rats. J Biol Active Prod Nature 2017;7:118-130.
43
44. Working P, Chellman G. The testis, spermatogenesis and the excurrent duct system. Reprod Toxicol Infertil 1993:55-76.
44
45. Mantovani A. Hazard identification and risk assessment of endocrine disrupting chemicals with regard to developmental effects. Toxicology 2002;181:367-370.
45
46. Chauhan A, Agarwal M, Kushwaha S, Mutreja A. Suppression of fertility in male albino rats following the administration of 50% ethanolic extract of Aegle marmelos. Contraception 2007;76:474-481.
46
47. Jin P, Wang X, Chang F, Bai Y, Li Y, Zhou R, et al. Low dose bisphenol A impairs spermatogenesis by suppressing reproductive hormone production and promoting germ cell apoptosis in adult rats. J Biomed Res 2013;27:135-139.
47
48. Nanjappa MK, Simon L, Akingbemi BT. The industrial chemical bisphenol A (BPA) interferes with proliferative activity and development of steroidogenic capacity in rat Leydig cells. Biol Reprod 2012;86:135, 1-12.
48
49. Akingbemi BT, Sottas CM, Koulova AI, Klinefelter GR, Hardy MP. Inhibition of testicular steroidogenesis by the xenoestrogen bisphenol A is associated with reduced pituitary luteinizing hormone secretion and decreased steroidogenic enzyme gene expression in rat Leydig cells. Endocrinology 2004;145:592-603.
49
50. Kim JY, Han EH, Kim HG, Oh KN, Kim SK, Lee KY, et al. Bisphenol A-induced aromatase activation is mediated by cyclooxygenase-2 up-regulation in rat testicular Leydig cells. Toxicol Lett 2010;193:200-208.
50
51. Jahan S, Ain QU, Ullah H. Therapeutic effects of quercetin against bisphenol A induced testicular damage in male Sprague Dawley rats. Syst Biol Reprod Med 2016;62:114-124.
51
52. Sinha N, Narayan R, Saxena D. Effect of endosulfan on the testis of growing rats. Bull Environ Contam Toxicol 1997;58:79-86.
52
53. Turner R, McDonnell S. Alkaline phosphatase in stallion semen. Characterization and clinical applications: Theriogenology 2003;60:1-10.
53
54. Agarwal A, Prabakaran SA, Said TM. Prevention of oxidative stress injury to sperm. J Androl 2005;26:654-660.
54
55. Merker H, Günther T, Höllriegl V, Vormann J, Schümann K. Lipid peroxidation and morphology of rat testis in magnesium deficiency. Andrologia 1996;28:43-51.
55
56. Thiele J, Freisleben H, Fuchs J, Ochsendorf F. Ascorbic acid and urate in human seminal plasma: determination and interrelationships with chemiluminescence in washed semen. Hum Reprod 1995;10:110-115.
56
57. Kao S-H, Chao H-T, Chen H-W, Hwang TI, Liao T-L, Wei Y-H. Increase of oxidative stress in human sperm with lower motility. Fertil Steril 2008;89:1183-1190.
57
58. Chitra K, Latchoumycandane C, Mathur P. Induction of oxidative stress by bisphenol A in the epididymal sperm of rats. Toxicology 2003;185:119-127.
58
59. Mershiba SD, Dassprakash MV, Saraswathy SD. Protective effect of naringenin on hepatic and renal dysfunction and oxidative stress in arsenic intoxicated rats. Mol Biol Rep 2013;40:3681-1391.
59
60. Hermenean A, Ardelean A, Stan M, Herman H, Mihali C-V, Costache M, et al. Protective effects of naringenin on carbon tetrachloride-induced acute nephrotoxicity in mouse kidney. Chem Biol Interact 2013;205:138-147.
60
61. Wang J, Yang Z, Lin L, Zhao Z, Liu Z, Liu X. Protective effect of naringenin against lead-induced oxidative stress in rats. Biol Trace Elem Res 2012;146:354-359.
61
62. Prabu SM, Shagirtha K, Renugadevi J. Reno-protective effect of naringenin in combination with vitamins C and E on cadmium induced oxidative nephrotoxicity in rats. J Pharm Res 2011;4:1921-1926.
62
63. Badary OA, Abdel-Maksoud S, Ahmed WA, Owieda GH. Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci 2005;76:2125-2135.
63
64. Mostafa HES, Abd El‐Baset SA, Kattaia AA, Zidan RA, Sadek A, Mona M. Efficacy of naringenin against permethrin‐induced testicular toxicity in rats. Int J Exp Pathol 2016;97:37-49.
64
65. Ciz M, Denev P, Kratchanova M, Vasicek O, Ambrozova G, Lojek A. Flavonoids inhibit the respiratory burst of neutrophils in mammals. Oxid Med Cell Longev 2012:43-49.
65
66. Comporti M. Three models of free radical-induced cell injury. Chemi Biol Interact 1989;72:1-56.
66
67. Mínguez-Alarcón L, Hauser R, Gaskins AJ. Effects of bisphenol A on male and couple reproductive health. Fertil Steril 2016;106:864-870.
67
68. Sanja S, Sheth N, Joshi D, Golwala D, Patel Dhaval RM. Anti inflammatory activity of Ipomoea reniformis methanolic extract. Inter J Pharm Sci Drug Res 2009;1:34-39.
68
69. Qu J-H, Hong X, Chen J-F, Wang Y-B, Sun H, Xu X-L, et al. Fenvalerate inhibits progesterone production through cAMP-dependent signal pathway. Toxicol lett 2008;176:31-39.
69
70. Kono Y, Fridovich I. Superoxide radical inhibits catalase. J Biol Chem 1982;257:5751-5754.
70
71. Aitken RJ, Roman SD. Antioxidant systems and oxidative stress in the testes. Oxid Med Cell Longev 2008;1:15-24.
71
72. Mukherjee S, Mukhopadhyay P. Studies on arsenic toxicity in male rat gonads and its protection by high dietary protein supplementation. Al Ameen J Med Sci 2009;2:73-77.
72
73. Peltola V, Huhtaniemi I, Ahotupa M. Antioxidant enzyme activity in the maturing rat testis. J Androl 1992;13:450-455.
73
74. Chitra K, Latchoumycandane C, Mathur P. Effect of nonylphenol on the antioxidant system in epididymal sperm of rats. Arch Toxicol 2002;76:545-551.
74
75. Kaneko T, Iuchi Y, Kobayashi T, Fujii T, Saito H, Kurachi H, et al. The expression of glutathione reductase in the male reproductive system of rats supports the enzymatic basis of glutathione function in spermatogenesis: Eur J Biochem 2002;269:1570-1578.
75
ORIGINAL_ARTICLE
Association of rs712 polymorphism in a let-7 microRNA-binding site of KRAS gene with colorectal cancer in a Mexican population
Objective(s): The rs712 polymorphism in a let-7 microRNA-binding site at KRAS gene has been associated with cancer. To examine its association with rs712 polymorphism, we analyzed Mexican individuals with colorectal cancer (CRC) and healthy subjects. Materials and Methods: Genotyping of the rs712 polymorphism was performed by polymerase chain reaction in 281 controls and 336 CRC patients. Results: The observed frequencies of rs712 polymorphism indicated an associated protective factor for CRC (P=0.032). An association between genotype and the disease was evident in: colon localization (allele T, odds ratio (OR) 3.82, 95% confidence Intervals (CI) 2.77-5.28, P=0.0001), node metastasis (genotype TT, OR 2.49, 95% CI 1.45-4.28, P=0.0009), poor differentiation (genotype GT, OR 2.35, 95% CI 1.35-4.1, P=0.0033), and poor chemotherapy response (genotype GT, OR 2.6, 95% CI 1.7-4.24, P=0.0001). Conclusion: Comparison of the data from patients with control group showed that polymorphism of rs712 in KRAS gene was protective factor, which was associated with susceptibility for CRC. However, the genotypes TT and GT of rs712 polymorphism in KRAS could contribute significantly to colon localization, node metastasis, poor differentiation and poor chemotherapy response in CRC patients in this sample population.
https://ijbms.mums.ac.ir/article_12147_eb65049ef21eb3b73b9f24d8721061d8.pdf
2019-03-01
324
327
10.22038/ijbms.2019.26564.6507
Colorectal cancer
KRAS
let-7
Mexican population
Polymorphism
Gallegos
Martha Patricia
marthapatriciagallegos08@gmail.com
1
División de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México
LEAD_AUTHOR
Guillermo Moisés
Zúñiga-González
mutagenesis95@hotmail.com
2
Medicina Molecular, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico
AUTHOR
Karen
Gómez-Mariscal
karen910_mariscal@hotmail.com
3
Medicina Molecular, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico
AUTHOR
Mónica Alejandra
Rosales-Reynoso
mareynoso@hotmail.com
4
Medicina Molecular, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico
AUTHOR
Luis E
Figuera
luisfiguera@yahoo.com
5
División de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México
AUTHOR
Ana María
Puebla-Pérez
ampueblap@yahoo.com.mx
6
Laboratorio de Inmunofarmacología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
AUTHOR
Tomas
Pineda-Razo
tmspnd@gmail.com
7
Servicio de Oncología, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico
AUTHOR
1. Alberts SR, Citrin D, Schwartz D, Rodriguez M. Colon, Rectal, and Anal Cancers. Cancer Management. 2016; http://www.cancernetwork.com/cancer-management/colon-rectal-and-anal-cancers.
1
2. Pourhoseingholi MA. Epidemiology and burden of colorectal cancer in asia-pacific region: what shall we do now?. Transl Gastrointest Cancer 2014; 3:169-173.
2
3. Gutiérrez IA, Puebla AM, Delgado JI, Figuera LE, Zúñiga GM, Gómez K, et al. Association between TNF-α-308G>A and -238G>A gene polymorphisms and TNF-α serum levels in mexican colorectal cancer patients. Genet Mol Res 2016; 15:1-11.
3
4. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64:104-117.
4
5. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer 2015; 136:359-386.
5
6. García S, Téllez FI, Méndez N, Uribe M. Results of the first program of colorectal cancer screening in mexico. Endoscopia 2015; 27:59-63.
6
7. OMIM entry 190070. V-KI-RAS2 Kirsten rat sarcoma viral
7
oncogene homolog; KRAS. https://www.omim.org/entry/190070.
8
8. Jancík S, Drábek J, Radzioch D, Hajdúch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010; 2010:150960-150973.
9
9. Liu X, Jakubowski M, Hunt JL. KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am J Clin Pathol 2011; 135: 245-252.
10
10. Jiang QH, Peng HX, Zhang Y, Tian P, Xi ZL, Chen H. rs712 polymorphism within let-7 microRNA-binding site might be involved in the initiation and progression of colorectal cancer in chinese population. Onco Targets Ther 2015; 8:3041-3045.
11
11. Du XY, Hu YY, Xie C, Deng CY, Liu CY, Luo ZG, et al. Significant association between Let-7-KRAS rs712 G > T polymorphism and cancer risk in the chinese population: a meta-analysis. Oncotarget 2017; 8:13863-13871.
12
12. Chan SH, Wang LH. Regulation of cancer metastasis by microRNAs. J Biomed Sci 2015; 22:9-21.
13
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215-1216.
14
14. Li ZH, Pan XM, Han BW, Guo XM, Zhang Z, Jia J, et al. A let-7 binding site polymorphism rs712 in the KRAS 3’ UTR is associated with an increased risk of gastric cancer. Tumour Biol 2013; 34:3159-3163.
15
15. Sanguinetti CJ, Dias E, Simpson AJ. Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. Biotechniques 1994; 17:914-921.
16
16. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, et al. A let-7 microRNA-binding site polymorphism in 3’-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 2011; 22:104-109.
17
17. Schulte PA, Whittaker C, Curran CP. Considerations for using genetic and epigenetic information in occupational health risk assessment and standard setting. J Occup Environ Hyg 2015; 12:69-81.
18
18. Sanaei S, Hashemi M, Eskandari E, Hashemi SM, Bahari G. KRAS gene polymorphisms and their impact on breast cancer risk in an iranian population. Asian Pac J Cancer Prev 2017; 18:1301-1305.
19
19. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131:1109-1123.
20
20. Cong T, Xiang D. KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol 2012; 18:5171-5180.
21
21. Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 2010; 15:699-731.
22
22. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006; 29:903-906.
23
23. Dong Y, Yu J, Ng SS. MicroRNA dysregulation as a prognostic biomarker in colorectal cancer. Cancer Manag Res 2014; 6:405-422.
24
24. Singh R, Mo YY. Role of microRNAs in breast cancer. Cancer Biol Ther 2013; 14:201-212.
25
25. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6:1653-1664.
26
26. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005; 47:141-146.
27
ORIGINAL_ARTICLE
Reno-protective effect of Rheum turkestanicum against gentamicin-induced nephrotoxicity
Objective(s): Gentamicin belongs to the family of aminoglycoside antibiotics and is a preferred drug in developing countries because of its low cost, availability, and potent effects against bacterial. However, gentamicin can induce nephrotoxicity. In this research, hydroalcoholic extract of Rheum turkestanicum was used against gentamicin- induced nephrotoxicity. Rheum turkestanicum is used against gentamicin-induced nephrotoxicity and in this study its effect against gentamicin-induced nephrotoxicity in rats has been investigated.Materials and Methods: The rats were placed into one of these groups: saline group, gentamicin group that received gentamicin 80 mg/kg/day for six days, and two treatment groups that received R. turkestanicum intraperitoneally at doses of 100 and 200 mg/kg body weight, respectively, 1 hr before gentamicin injections. Urine samples were collected at 24 hr to measure glucose and protein concentration. Blood samples were collected to determine serum urea and creatinine. One kidney was homogenized to measure malondialdehyde and thiol, and the other kidney was kept for pathological studies. Results: Gentamicin increased the level of urinary glucose and protein, and increased malondialdehyde while it decreased thiol in kidney tissue, and increased the concentration of urea and creatinine in the serum. Histopathological pathology revealed renal damage following gentamicin usage; however, the extract was able to improve gentamicin toxicity. Conclusion: R. turkestanicum has positive effects in the attenuation of gentamicin-induced nephrotoxicity.
https://ijbms.mums.ac.ir/article_12169_9ac1edae917673c860127b8afafcec9b.pdf
2019-03-01
328
333
10.22038/ijbms.2019.31552.7597
Rheum turkestanicum
Gentamicin
Reactive Oxygen Species
Malondialdehyde
Oxidative stress
Mohammad Taher
Boroushaki
boroushakimt@mums.ac.ir
1
Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Sahar
Fanoudi
fanoudis921@mums.ac.ir
2
Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Hamid
Mollazadeh
mollazadeh.h@nkums.ac.ir
3
Department of Physiology and Pharmacology, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
AUTHOR
Samaneh
Boroumand-Noughabi
boroumans@mums.ac.ir
4
Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Azar
Hosseini
hoseiniaz@mums.ac.ir
5
Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Martinez-Salgado C, López-Hernández FJ, López-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol 2007;223:86-98.
1
2. Balakumar P, Rohilla A, Thangathirupathi A. Gentamicin-induced nephrotoxicity: do we have a promising therapeutic approach to blunt it? Pharmacol Res 2010; 62:179-186.
2
3. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2011; 79:33-45.
3
4. Ehsani V, Amirteimoury M, Taghipour Z, Shamsizadeh A, Bazmandegan G, Rahnama A, et al. Protective effect of hydroalcoholic extract of Pistacia vera against gentamicin-induced nephrotoxicity in rats. Ren Fail 2017; 39:519-525.
4
5. Lakshmi B, Neelima N, Kasthuri N, Umarani V, Sudhakar M. Protective effect of Bauhinia purpurea on gentamicin-induced nephrotoxicity in rats. Indian J Pharm Sci 2009; 71:551-554.
5
6.Valipour P, Heidarian E, Khoshdel A, Gholami-Arjenaki M. Protective effects of hydroalcoholic extract of Ferulago angulata against gentamicin-induced nephrotoxicity in rats. Iran J Kidney Dis 2016;10:189-196.
6
7. Safa J, Argani H, Bastani B, Nezami N, Ardebili BR, Ghorbanihaghjo A, et al. Protective effect of grape seed extract on gentamicin-induced acute kidney injury. Iran J Kidney Dis 2010; 4:285-291.
7
8. Lakshmi B, Sudhakar M. Protective effect of Zingiber officinale on gentamicin-induced nephrotoxicity in rats. Int J Pharmacol 2010; 6:58-62.
8
9. Ajami M, Eghtesadi S, Pazoki-Toroudi H, Habibey R, Ebrahimi SA. Effect of Crocus sativus on gentamicin induced nephrotoxicity. Biol Res 2010; 43:83-90.
9
10. Khan SA, Priyamvada S, Farooq N, Khan S, Khan MW, Yusufi AN. Protective effect of green tea extract on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney. Pharmacol Res 2009; 59:254-262.
10
11. Yarijani ZM, Najafi H, Madani SH. Protective effect of crocin on gentamicin-induced nephrotoxicity in rats. Iran J Basic Med Sci 2016; 19:337-343.
11
12. Boroushaki MT, Sadeghnia HR. Protective effect of safranal against gentamicin-induced nephrotoxicity in rat. Iran J Basic Med Sci 2015; 34:285-288.
12
13. Boroushaki MT, Asadpour E, Sadeghnia HR, Dolati K. Effect of pomegranate seed oil against gentamicin-induced nephrotoxicity in rat. J Food Sci Technol 2014; 51:3510-3514.
13
14. Dorsey JF, Kao GD. Aloe (-emodin) for cancer? More than just a comforting salve. Cancer Biol Ther 2007; 6:89-90.
14
15. Hosseini A, Mollazadeh H, Amiri MS, Sadeghnia HR, Ghorbani A. Effects of a standardized extract of Rheum turkestanicum Janischew root on diabetic changes in the kidney, liver and heart of streptozotocin-induced diabetic rats. Biomed Pharmacother 2017; 86:605-611.
15
16. Hosseini A, Rajabian A. Protective effect of Rheum turkestanikum root against doxorubicin-induced toxicity in H9c2 cells. Revista Brasileira de Farmacognosia 2016; 26:347-351.
16
17. Alam MA, Javed K, Jafri M. Effect of Rheum emodi (Revand Hindi) on renal functions in rats. J Ethnopharmacol 2005; 96:121-125.
17
18. Masson P, Ohlsson P, Björkhem I. Combined enzymic-Jaffé method for determination of creatinine in serum. Clin Chem 1981; 27:18-21.
18
19. Lott JA, Turner K. Evaluation of Trinder’s glucose oxidase method for measuring glucose in serum and urine. Clin Chem 1975; 21:1754-60.
19
20. McElderry L, Tarbit I, Cassells-Smith A. Six methods for urinary protein compared. Clin Chem 1982; 28:356-60.
20
21. Fernández J, Pérez-Álvarez JA, Fernández-López JA. Thiobarbituric acid test for monitoring lipid oxidation in meat. Food Chem 1997; 59:345-53.
21
22. Hosseinzadeh H, Sadeghnia HR, Ziaee T, Danaee A. Protective effect of aqueous saffron extract (Crocus sativus L.) and crocin, its active constituent, on renal ischemia-reperfusion-induced oxidative damage in rats. J Pharm Pharm Sci 2005; 8:387-393.
22
23. Oda SS, El-Ashmawy IM. Protective effect of silymarin on mercury-induced acute nephro-hepatotoxicity in rats. Global Veterinaria 2012; 9:376-383.
23
24. Banday AA, Farooq N, Priyamvada S, Yusufi AN, Khan F. Time dependent effects of gentamicin on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in rat kidney tissues. Life Sci 2008; 82:450-459.
24
25. Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity. Hear Res 2011; 281:28-37.
25
26. Riff LJ, Jackson GG. Pharmacology of gentamicin in man. J Infect Dis 1971; 124:S98-S105.
26
27. Sahu BD, Tatireddy S, Koneru M, Borkar RM, Kumar JM, Kuncha M, et al. Naringin ameliorates gentamicin-induced nephrotoxicity and associated mitochondrial dysfunction, apoptosis and inflammation in rats: possible mechanism of nephroprotection. Toxicol Appl Pharmacol 2014; 277:8-20.
27
28. Alarifi S, Al-Doaiss A, Alkahtani S, Al-Farraj S, Al-Eissa MS, Al-Dahmash B, et al. Blood chemical changes and renal histological alterations induced by gentamicin in rats. Saudi J Biol Sci 2012; 19:103-110.
28
29. Sahu BD, Kuncha M, Putcha UK, Sistla R. Effect of metformin against cisplatin induced acute renal injury in rats: a biochemical and histoarchitectural evaluation. Exp Toxicol Pathol 2013; 65:933-940.
29
30. Biswas D, Rathod NS, Halagali K, Nidavani R, Shalavadi M, Biradar B, et al. Protective effect of Punica granatum l. on gentamicin-induced acute renal failure in adult rats. Res J Pharmacol Pharmacodyn 2016; 8:161-167.
30
31. Dehghan H, Salehi P, Amiri MS. Bioassay-guided purification of α-amylase, α-glucosidase inhibitors and DPPH radical scavengers from roots of Rheum turkestanicum. Ind Crops Prod 2018; 117: 303-309.
31
32. Mishra SK, Tiwari S, Shrivastava A, Srivastava S, Boudh GK, Chourasia SK, et al. Antidyslipidemic effect and antioxidant activity of anthraquinone derivatives from Rheum emodi rhizomes in dyslipidemic rats. J Nat Med 2014; 68:363-371.
32
33. Chai YY, Wang F, Li YL, Liu K, Xu H. Antioxidant activities of stilbenoids from Rheum emodi Wall. Evid Based Complement Alternat Med 2012; 2012:603678.
33
34. Yokozawa T, Fujioka K, Oura H, Nonaka G-i, Nishioka I. Effects of rhubarb tannins on uremic toxins. Nephron 1991; 58:155-160.
34
35. Yokozawa T, Nakagawa T, Lee Ki, Cho Ej, Terasawa K, Takeuchi S. Effects of green tea tannin on cisplatin‐induced nephropathy in LLC‐PK1 cells and rats. J Pharm Pharmacol 1999; 51:1325-1331.
35
36. Boroushaki MT, Mollazadeh H, Rajabian A, Dolati K, Hosseini A, Paseban M, et al. Protective effect of pomegranate seed oil against mercuric chloride-induced nephrotoxicity in rat. Ren Fail 2014; 36: 1581–1586
36